Final Programme Final

Unravelling hidden diseases. Unravelling Neurogenetics

ean congress lisbon 2018 4th Congress of the European Academy of Neurology ean congress lisbon 2018 4th Congress of the European Academy of Neurology FINAL PROGRAMME PAGE 1

General Information

Welcome Message ...... 03 About EAN...... 04 Board and Committees...... 05 EAN Membership Information...... 06 Educational grants Information ...... 07 Resident and Research Fellow Section (EAN-RRFS)...... 09 Congress Grants ...... 10 Appreciation and thanks ...... 12 Continuing Medical Education, Accreditation ...... 13 Instructions for Speakers and Presenters ...... 14 Information from A-Z...... 14 Floor plans ...... 24 EAN Business meeting overview...... 28 ePoster and ePresentation Overview ...... 31 Networking Programme and Other Activities ...... 36 Timetable/Session Overview ...... 42

Scientific Programme

Saturday, 16 June 2018 Monday, 18 June 2018

Educational Sessions ...... 50, 56, 58, 61, 62 Educational Sessions ...... 86, 91, 92, 94 Focused Workshops...... 51, 52 Focused Workshops...... 87, 88 Special Sessions ...... 52, 58, 61 Special Sessions ...... 89 Symposia...... 53, 54 Symposia...... 90 Teaching Courses ...... 59, 60, 61 Teaching Courses ...... 92 Oral Sessions ...... 64 Oral Sessions ...... 96

Sunday, 17 June 2018 Tuesday, 19 June 2018

Educational Sessions ...... 70, 71, 76, 79 Educational Sessions ...... 106, 107, 108, 109 Focused Workshops...... 71, 72 Highlight + Breaking News ...... 108 Presidential Symposium ...... 75 Special Sessions ...... 107 Special Sessions ...... 73, 76, 77 Symposia...... 106 Teaching Courses ...... 77 Teaching Courses ...... 109 Oral Sessions ...... 80 Oral Sessions ...... 112

Industry Sponsored Programme

Acknowledgements...... 119 Exhibitors and Exhibition Floor Plan...... 120 Satellite Symposia Programmes ...... 126 3-Days Satellite Sessions ...... 153 Forum Talk Programmes ...... 157

Index ...... 161

FINAL PROGRAMME PAGE 2 / 3

Welcome

On behalf of the European Academy of Neurology and the Portuguese Society of Neurology, we are pleased to you to the 4th Congress of the European Academy of Neurology (EAN) taking place in Lisbon, Portugal from June 16-19, 2018 .

The overarching theme for the Lisbon congress is ‘Neurogenetics – Unravelling hidden diseases’ . Diagnosis and treatment are increasingly using genetic methods and one purpose of the congress is to highlight clinically useful aspects of genetic medicine in Neurology . But as always, progress in all fields of neurology will be presented and participants will be updated about recent developments and news in clinical neurology . The selection of the educational programme is meanwhile organised within a newly adapted 5-year EAN educational curriculum . This curriculum is covering all important aspects a neurologist should learn and update in this period .

Lisbon is a modern town, easily accessible from almost everywhere, where you can enjoy the hospitality of its people, walking around town exploring culture, arts and food . The charming capital of Portugal is located by the wide estuary of Tagus River where you will find scenic views from almost every corner . Here, you can absorb the unique scent of the near Mediterranean, mild and pleasant climate of early summer and the peculiar luminosity of a blue sky reflected on its white ancient houses in historic areas. Lisbon is dominated by its castle, more than one thousand years old, with a unique view . This is a city full of history where you may feel the ambiance of the old Arab neighborhood of Alfama and Mouraria, where Fado, the national sentimental song, was born . Needless to say, that it was from Lisbon, that the navigators left to discover the world and you can meet history at several museums and monuments .

EAN and the Portuguese Society of Neurology cordially welcome the European neurological community to celebrate the strength and beauty of our field and to get inspired by meeting with colleagues and friends .

Paul Boon Günther Deuschl Joaquim Ferreira Chair President Chair Programme Committee European Academy Local Organising of the European of Neurology Committee Academy of Neurology FINAL PROGRAMME

Join us to promote excellence in neurology! About EAN The European Academy of Neurology (EAN) has been founded in 2014 on the initiative of the European Neu- rological Society (ENS) and the European Federation of Neurological Societies (EFNS), who both considered it essential to have one joint professional and scientific Neurology organisation in Europe. EAN shall provide the essential infrastructure together with the organisational framework for the support and development of neurological education and research in Europe .

The Aim of EAN is Excellence in Neurology in Europe

EAN is a non-profit organisation and identifies itself with EAN is an organisation of: the following five values: • 47 European national neurological societies • Professionalism . EAN will strive to reach the highest sci- • 900 individual members entific standards and to deliver unbiased information in its • 10 corresponding member societies research and educational activities . • High ethical standards . EAN will apply high ethical standards in all its activities within science, education, commu- EAN consists of: nication, and administration, complying with applicable regulations and codes of ethics . • an Assembly of Delegates of institutional and individual • Involvement . EAN will strive to involve its members and delegates collaborators in the organisation of research, education and • elected officers liaison activities . • 4 committees (+ 3 sub-committees) • Independence . EAN will operate as a professional and sci- • 31 Scientific Panels entific organisation, independent from the political or com- mercial interests of external companies or organisations . • Transparency . EAN will provide transparency in the organisation of all its scientific and administrative activities. FINAL PROGRAMME PAGE 4 / 5

Committees

EAN Board Programme Committee

Günther Deuschl, Germany Paul A .J M. . Boon, Belgium, (Chair) President Joaquim Ferreira, Portugal, (Co-Chair)

Franz Fazekas, Austria Valeria Caso, Italy President elect Hannah Cock, UK (Chair Education Committee) Marianne Dieterich, Germany Didier Leys, France Antonio Federico, Italy (Chair Scientific Committee) Secretary General Ivan Rektor, Czech Republic Philip Scheltens, The Netherlands Marianne de Visser, The Netherlands Aksel Siva, Turkey Treasurer Riccardo Soffietti, Italy Claudia Sommer, Germany (Chair Teaching Course sub-Committee) Antonio Federico, Italy Guido Stoll, Germany Chair Scientific Committee Pille Taba, Estonia (MDS-ES representative)

David B . Vodušek, Slovenia Chair Communication Committee Local Organising Committee Hannah Cock, UK Chair Education Committee Joaquim Ferreira, (Chair)

Paul A .J M. . Boon, Belgium Mamede de Carvalho, Manuel Correia, Rui Costa, José Ferro, Chair Programme Committee Victor Oliveira, Ana Amélia Nogueira Pinto, Isabel Pavão Martins

Per Soelberg Sørensen, Denmark Member at Large Teaching Course sub-Committee

Claudia Sommer, Germany, (Chair) Anish Bahra, United Kingdom Theodor Landis, Switzerland Elena R . Lebedeva, Russian Federation Milija Mijajlovic, Serbia Viktoria Papp, Denmark (RRFS Representative) Erich Schmutzhard, Austria Pille Taba, Estonia (MDS-ES representative) GENERAL INFORMATION

Membership Information

EAN Membership Information Corresponding Individual Member: • Neurologists who are nationals of and practice in countries other than EAN member countries Become an EAN individual member and benefit • Health Professionals and/or Scientists of other specialities from the following: or professions related to Neurology

• reduced membership fee at the annual congresses Undergraduate Student: • active and passive voting rights at the Assembly of Undergraduate medical students can become individual Delegates of the EAN members . They need to explain their special interest in • possibility to participate in EAN Committees and Scientific neurology and the purpose why they Panels request membership . • free online access to the online learning platform eBrain • free online access to the European Journal of Neurology • free online access to the guidelines Fellow of EAN (FEAN) • access to educational grants (if applicable) • right to purchase the European Journal of Neurology The title ‘Fellow of the EAN’ acknowledges a limited number (EJN) at a reduced rate of neurologists who are full individual members and who • a membership certificate deserve a special recognition of the EAN because of • monthly mailshots of the EAN electronic newsletter • one free Teaching Course at EAN annual congresses • a scientific achievement that places them within the • free access to VIP area at EAN annual congresses European leaders in their field, or • free professional photo taken at Congress • significant and continuing service in a leadership position • free access to selected congress webcasts on the website for of a European or World society for neurology or after the congress neurological subspecialty society, or • AAN shared Membership: • a service for neurological patients that is considered exceptional If you are an AAN Member, you are eligible of a 10% discount off your EAN Individual Membership fee . In reverse, EAN Fellow of the EAN is a title honouring special service to Individual members receive a 10% discount when applying neurology and the Society . for AAN membership . Please apply by sending your application form and CV (in English) to the EAN Head Office: [email protected] Forms can be downloaded online or be sent to upon request . Individual Membership Categories:

Full Individual Member: Neurologists who are nationals of Honorary Members and Service Award 2018 any EAN member country; and/or neurologists practicing in any EAN member country including neurologists in training . Mark Hallett, Bethesda, USA and Alistar Compston, Cambridge, UK will be awarded the EAN Honorary Resident and Research Fellow (RRF): Physicians in train- Membership during the Opening . ing can become individual members of EAN via the EAN Resident and Research Fellow Section at a reduced fee . Amadou Gallo Diop, Dakar, Senegal and Riad Gouider, Tunis, Residency has to be proven annually by a signed confirmation Tunisia will be receive the EAN Service Award during the of the physician in charge of the residency EAN Assembly of Delegates programme

GENERAL INFORMATION PAGE 6 / 7

Educational Grants Information

Clinical Fellowship 2019 Research training fellowship: Expected to be of typically 12 months and no less than 6 months, to lead either to comple- Application Deadline: October 31, 2018 tion of a higher degree, a grant application or peer-reviewed publication . The purpose of this award is to provide a well-defined observational clinical Research experience fellowship: Expected to be of typically practice, service structure or technical and no more than 6 months duration for individuals who experience to support training . The might otherwise not have the opportunity to gain high quality grant is to support a visit of six weeks research experience; more experienced clinicians/research- duration . ers requiring training in a specific research methodology or technique not currently available in their own country and of clear value to home department will also be considered . Each grant is amounting to € 1,500 .-/month (plus travel expenses of up to € 300 -). Candidates from EAN member countries and affiliated to a European academic neurological department with a mini- A list of approved hosting departments (and details for mum of 2 years neurology training, up to a maximum of 5 interested hosts of how to apply) is available on www .ean .org years beyond their final degree (PhD, MD, or equivalent) at the time of application are eligible to apply . Candidates from all EAN member (and corresponding member) countries are eligible to apply . Applicants must All applicants must be Full member or RRFS be current residents with a minimum of 2 years training in member at time of application. neurology, or have obtained their board certificate/completed training within the last 3 years at the time of application; be Applicants and hosts are expected to have consulted and fluent in English or the local language (host department). worked together on any application to maximise the likelihood of success . Awardees from previous years are no more qualified. All application documents must be submitted All applicants must be Full member or RRFS by August 31, 2018 by email to member at time of application. Ms . Julia Mayer: [email protected]

All application documents must be submitted Application Deadline: August 31, 2018 by October 31, 2018 by email to Ms . Magda Dohnalová: [email protected] EAN Spring School 2019 Application is open between 1 August and 31 October May 2019 2018 Application deadline: January 31, 2019

EAN Research Fellowship 2019 Dedicated to clinical neurologists in training who did not yet complete their Application deadline: August 31, 2018 residency/ clinical speciality training who wish to boost their knowledge and The purpose is to support training and to get the chance to enable personal experience for European Neurolo- contacts among participants and gists in any area of basic or clinical faculty members or applied research in neuroscience . The research work must be carried out at a European academic neurologi- Preliminary Programme: cal department outside the country 1 . Stroke of residence . All applications should 2 . Higher cortical functions demonstrate experience/ training of clear value to the home 3 . Neurorehabilitation department/individual beyond that available in their own countries/ institutions . Structure: morning plenary sessions and case-based workshops in the afternoons . Successful applicants will be awarded € 2,000 .- per month . GENERAL INFORMATION

Educational Grants Information

All applicants must be neurologists in training (not yet completed residency/ clinical speciality training) who will have Accommodation, tuition, board and programme are had at least 2 years of clinical experience by the time of the sponsored by the EAN . Participants pay for their travel only . course, and who are able to attend the full course . Partici- pants nominated for attendance by their national neurolog- All application documents must be submitted ical societies will be prioritised, but individual applications by July 31, 2018 by email to are also welcome up to the full capacity . Ms . Magda Dohnalová: [email protected] Awardees from previous years are no more qualified. Application open between 1 June and 31 July 2018 All applicants must be Full member or RRFS member at time of application. EAN Regional Teaching Courses (RTC) and EAN-Day Accommodation, tuition, board and programme are sponsored by the EAN . Participants pay for their travel only . EAN-RTCs are specially designed for the purpose to bring neurological standards directly to the countries in the East or All application documents must be submitted by Sub-Saharan Africa to avoid that our colleagues in training January 31, 2019 by email to have to travel to distant congresses . RTCs provide basic Ms . Magda Dohnalová: [email protected] teaching in neurology and thus also establish friendly relations with all colleagues . Application open between 1 October 2018 These courses are held in English language and have a and 31 January 2019 duration of 3 days . 4 plenary session will be held each morning and will deal with each of the three main topics of the RTC, i .e . focus on one EAN Autumn School 2018 main topic per day . Small tuitional groups in the afternoon November 8-11, 2018 are set up to enhance the hand-on learning (case-based vide- oclips, Hands-on course, Workshops) . Organisers are either Application deadline: July 31, 2018 National Neurological Societies or Neurological University departments . Increase your knowledge of clinical neurology! Experienced neurologists The next EAN RTC will be in Struga, Macedonia, September and sub-specialists will illustrate 14-16, 2018 how they approach specific clinical presentations, including an update The EAN-Day aims at bringing excellent teaching and spe- on relevant diagnostic and treatment cial recognition by EAN to our National Neurological Mem- approaches for key conditions in the ber Societies (and Corresponding Member Societies) . This relevant areas . day takes place directly prior or after a National Neurological Society meeting . Preliminary Programme: 1 . Episodic Loss of consciousness Three plenary sessions will take place in the morning 2 .Gait Disorders addressing 3 different topics . 3 .Tremor (jointly organised with MDS-ES) After a lunch break, there will be rotating workshops on the same 3 topics, case-based video clips or hands-on courses for Structure: morning plenary sessions and hands-on/case- participants to work and learn in smaller groups . based clinical workshops (video and patient presentations) The language is English . for 20 persons each in the afternoons . All Guidance documents and application forms can be found Location: Loutraki, Greece (1,5h from Athens airport) online: www .ean .org- LEARN- Educational events

All applicants must be neurologists in training (not yet completed residency/ clinical speciality training) who will have had at least 2 years of clinical experience by the time of the course, and who are able to attend the full course .

All applicants must be Full member or RRFS member at time of application. GENERAL INFORMATION PAGE 8 / 9

Education & RRFS

CME Articles Resident and Research Fellow Section

Each month a CME article is published RRFS represents the junior generation of neurologists within in the European Journal of Neurology EAN . Our members are physicians currently working as a res- and on the EAN website . Answer 5 ident in Neurology, research fellow, PhD student or neurol- article-related questions correctly and ogist with not more than 3 years of practice after completion receive a certificate recommending of the residence training . Application for membership can be one hour of CME . done directly at the EAN booth or be sent to rrfs@ean .org, further information is provided on the EAN homepage . Please log-in on the EAN website for free-of-charge access to all e-learning The aims of RRFS are to support neurology trainees in their features and the online version of the European Journal of clinical training or research, to promote network between Neurology . European junior neurologists and different generations of neurologists .

eBrain Activities of the Resident and Research Fellow Section during the Congress ebrain represents the world’s largest, most comprehensive web-based training Join us at the RRFS booth resource in clinical neuroscience designed During the congress, RRFS members are available at the to support training and continuous professional development LEARN and HOME area of the EAN booth in order to provide for clinical neuroscience trainees, consultants and up-to-date information about membership, education and non-specialists . It is free-of-charge for EAN members . Please travel/EBN grants and other congress activities . log-in on www .ean .org to have direct access . If you need help, please come to the EAN booth/LEARN, or contact RRFS special session [email protected] Sunday, June 17, 8 .00 - 9 .30h, room Oslo The multimedia-rich, engaging materials are designed to Resident and Research Fellow Section Round Table enhance traditional learning, support existing teaching meth- Discussion ods and provide a valuable reference point that is accessible anytime, anywhere . This is the ideal opportunity to - Learn about academic career and research opportunities The online training content comprises approximately 20 around Europe modules of e-learning, with each of the 550+ individual les- - Get expert advices on laboratory and clinical research sons taking around 20 minutes to complete . - Meet experts from different parts of Europe and improve the professional European network - Get to know opinion leaders‘ careers and how they got Guideline papers there

Included in the EJoN, the Handbook as well as FREE OF Participants will meet worldwide renowned professors CHARGE for EAN members via the Guideline Reference around Europe covering different field of interests as well as Center on the EAN website . basic and clinical neuroscience .

Table 1 - José M Ferro, Lisbon, Portugal (Main interest: stroke) Table 2 - Klaus Viktor Toyka, Würzburg, Germany (Main interest: Disease models of neuro-immuno logical and degenerative disorders of the nervous system) Table 3 - Hannah Cock, London, United Kingdom (Main interest: epilepsy) Table 4 - Eva Kubala Havrdová, Prague, Czech Republic (Main interest: multiple sclerosis) GENERAL INFORMATION

RRFS & Congress Grants

Following the successful session last year, the special session Congress Grants of RRFS is held as a round table discussion . As participants found it most helpful and interesting to have direct discussions with the speaker, participants and speakers will directly Bursaries sit down at four round tables with each Professor from different parts of Europe and with different fields of interest and The 4th EAN Congress offered 240 bursaries consisting of the participants will then circulate between the round tables . free registration and up to four nights of hotel accommodation . RRFS General Assembly Eligible were PhD (neurology) students, residents of neu- Monday, June 18, 14 .15 - 15 .15h, room 0 01. rology or certified clinical neurologists (with no more than 3 All RRFS members are invited to join the RRFS General years practice since completing training) who are working in Assembly . Europe and whose abstract had been accepted .

RRFS annual hospital visit It was also possible for colleagues in training from Algeria, Egypt, Jordan, Lebanon, Libya, Mauretania, Morocco, Monday, June 18, 18:15h Palestine, Syria and Tunisia as well as from sub-Saharan countries belonging to the HINARI Group A list of countries This year, the traditional hospital visit is organised on Mon- as established by WHO (www .who .int/hinari/eligibility/en/) day, June 18 . Participants will be introduced to the local neu- to apply for bursaries . rology education while visiting the Neurology Department of the Centro Hospitalar Lisboa Norte - Hospital de Santa Maria Applications were accompanied by a letter from the chairper- (Santa Maria University Hospital/North Lisbon Hospitalary son of the applicant’s department confirming that they are in Center) . training . Only one bursary per abstract was awarded . Afterwards, transfer will be organised to the EAN “Meet your neurology network” event that will take place in the Museu Bursary recipients were selected by the Programme Commit- Nacional de Arte Antiga (reduced entrance fee for all hospital tee based on abstract evaluation . visit participants) . Registration is necessary due to limited places . If you would Bursaries will be available for EAN RRFS and full members like to join us, send an email to [email protected] . only . The bursaries were co-sponsored by an educational grant from MDS-ES .

Applications for the 5th EAN congress Oslo 2019 can be submitted by the time of the abstract submission deadline: 23 January 2019.

Investigator Award

All free presentations (oral presentations, posters) selected for presentation at the 4th EAN Congress 2018 will auto matically take part in the selection of an Investigator Award . The award for the 20 best presentations will be a registration to the 5th EAN Congress in Oslo, Norway, a diploma and the winners will be announced in EAN Pages . The award will be given to the first author who needs to be the person to present the work at the congress. The EAN Scientific Panels together with the Scientific Committee and the Programme Committee will be responsible for the evaluation process before as well as during the congress . GENERAL INFORMATION PAGE 10 / 11

Congress Grants

Tournament for Neurologists in Training Presentation: Each selected candidate is allotted 10 minutes for presentation of his/her paper plus five minutes for discus- A tournament for neurologists in training will take place . The sion with the jury . tournament will be carried out in two groups . One on basic neurological science, Sunday, June 17, 2018 (see page 80) Jury: Members of the Programme, the Scientific and the and one on clinical related research on Monday, June 18, Teaching Course Committees . 2018 (see page 96) . Evaluation: Candidates will be judged not only on the scien- Eligible were PhD (neurology) students, residents of neu- tific value of the work presented, but also on the quality of the rology or certified clinical neurologists (with no more than 3 oral presentation and the way the candidate responds to the years practice since completing training) working in Europe questions of the jury . and whose abstract has been accepted . Prize: The winner of each group will receive a prize consisting Selection of candidates: The EAN Programme Committee has of: Free registration at the 5th EAN Congress in Oslo 2019, selected 6 candidates for each tournament group based on up to four nights hotel accommodation as well as a travel the contents of the abstracts submitted . The clinical subjects grant . The prize is not transferable and will not be paid off in had to be received from authors who work in Europe and cash . thus carry out their projects in Europe . For the basic science Two runner-up prizes in each, the clinical and basic tourna- session, clinical relevance was weighted . ment will be awarded. They will consist of a certificate and a free registration to the 5th EAN Congress in Oslo 2019 . Financial support: Candidates selected for the tournament have received a bursary consisting of free registration to the Congress, up to four nights hotel accommodation, and a travel grant .

GENERAL INFORMATION

Appreciation and thanks

We would like to thank the reviewers of the submitted abstracts for their invaluable help and assistance:

A F P Federica Agosta, Italy Franz Fazekas, Austria Eleftherios Papathanasiou, Cyprus Diana Aguiar de Sousa, Portugal Antonio Federico, Italy Viktoria Papp, Denmark Yuri Alekseenko, Belarus Luigi Ferini-Strambi, Italy Simon Podnar, Slovenia Pasquale Annunziata, Italy José Ferro, Portugal Werner Poewe, Austria Fabio Antonaci, Italy Massimo Filippi, Italy Maura Pugliatti, Italy Angelo Antonini, Italy Alessandro Filla, Italy Zohar Argov, Israel R Nadine Attal, France G Olivier Rascol, France Thomas Gattringer, Austria Radu Razvan, Romania B Raquel Gil-Gouveia, Portugal Heinz Reichmann, Germany Shakya Bhattacharjee, UK Raquel Gutiérrez Zúñiga, Spain Ivan Rektor, Czech Republic Paul Boon, Belgium Roberta Rudá, Italy Thomas Brandt, Germany H Marina Ruiz Piñero, Spain Geir Brathen, Norway Mario Habek, Hungary Filipe Brogueira Rodrigues, UK Hans-Peter Hartung, Germany S Wallace Brownlee, UK Wolfgang Heide, Germany Maria José Sá, Portugal Jean Marc Burgunder, Switzerland Raimund Helbok, Austria Simona Sacco, Italy Max J . Hilz, Germany Anna Sauerbier, UK C Philip Scheltens, The Netherlands Pasquale Calabrese, Switzerland K Erich Schmutzhard, Austria Stefano Cappa, Italy Ulf Kallweit, Germany Stefan Schwab, Germany Valeria Caso, Italy Reetta Kälviäinen, Finland Alessandro Simonati, Italy Declan Chard, UK Vincent Keereman, Belgium Aksel Siva, Turkey Hannah Cock, UK Michael Khalil, Austria Riccardo Soffietti, Italy Carlo Colosimo, Italy Nina Khizanishvili, Germany Aleksandra Sokołowska, Poland Giancarlo Comi, Italy Thomas Klopstock, Germany Claudia Sommer, Germany Pamela Correia, Switzerland Christian Krarup, Denmark Israel Steiner, Israel Ana Cristina Duque Santos, Portugal Jera Kruja, Albania Guido Stoll, Germany Laszlo Csiba, Hungary Jan Kuks, The Netherlands Walter Struhal, Austria Anna Czlonkowska, Poland L T D Lieven Lagae, Belgium Pille Taba, Estonia Maxwell Damian, UK Maurizio Leone, Italy Miguel Tábuas-Pereira, Portugal Marianne de Visser, The Netherlands Vitalie Lisnic, Moldova Radu Tanasescu, Romania Vida Demarin, Hungary Maarten Titulaer, The Netherlands Günther Deuschl, Germany M Antonio Toscano, Italy Giovanni Di Liberto, Switzerland Monica Margoni, Italy Klaus Toyka, Germany Marianne Dieterich, Germany Hugh Markus, UK Marie Trad, France Karin Diserens, Switzerland Geert Mayer, Germany João Luís Oliveira Durães, Portugal Patrik Michel, Switzerland U Raffaele Dubbioso, Italy Iris Unterberger, Austria Andreij Dubenko, Ukraine O Francois Ducray, France Stefan Oberndorfer, Austria V Oana Maria Obrisca, Romania José Valdueza, Germany E David Oliver, UK Josep Valls-Solé, Spain Edvard Ehler, Czech Rpublic Irina Orban, Romania Domizia Vecchio, Italy Stefan Evers, Germany Serefnur Öztürk, Turkey David B . Vodušek, Slovenia Tim von Oertzen, Austria Pieter Vos, The Netherlands GENERAL INFORMATION PAGE 12 / 13

Continuing Medical Education

Continuing Medical Education EACCME Accreditation statement (CME Information) EACCME EVENT CODE: LEE17-00902 The 4th Congress of the European Academy of Neurology is Purpose accredited by the European Accreditation Council for Contin- uing Medical Education (EACCME) to provide the following The purpose of the 4th EAN Congress is to offer a forum for CME activity for medical specialists . The EACCME is an insti- clinical and basic discussion on a variety of neurological top- tution of the European Union of Medical Specialists (UEMS): ics including presentations of current research and available http://www .uems .net . treatments . The Congress of the European Academy of Neurology (Satur- day, Sunday, Monday, Tuesday) is designated for a maximum of 24 hours of European external CME credits . Each medical Learning Objectives specialist should claim only those hours of credit that he/she actually spent in the educational activity . Through Plenary Symposia, Symposia, Focused Workshops, These points are accepted by several national societies, and Teaching Courses, Case-based workshops, Hands-on Courses, thus they be claimed in these countries . controversy sessions, Career development Sessions, Interac- Through an agreement between the Union Européenne des tive sessions and special sessions, participants will be better Médecins Spécialistes and the American Medical Association, able to: physicians may convert EACCME® credits to an equivalent 1 . Describe the pathophysiology and neurobiology of neuro- number of AMA PRA Category 1 CreditsTM . Information on logical diseases the process to convert EACCME® credit to AMA credit can 2 . Discuss the diagnostic approaches and tools available for be found at www .ama-assn org/education/earn-credit-. neurological diseases participation-international-activities . 3 . Discuss the pharmacological and non-pharmacological Live educational activities, occurring outside of Canada, treatment options available for neurological diseases recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program Target Audience of the Royal College of Physicians and Surgeons of Canada .

The target audience includes clinicians, researchers, post-doc Ethical MedTech has endorsed the congress fellows, medical residents, students and other healthcare professionals with an interest in the current research and diagnosis and treatment of neurological diseases . Kindly note CME Certificates and Attendance Tracking Report that in the description of some courses the target audience is separately disclosed . If you need a report of your attendance in sessions, please use the EAN website and app and evaluate all sessions that you have attended . From Thursday, 21 June, onwards you will Financial disclosure information receive a certificate including a report of all sessions you have attended and evaluated . It is the policy of the European Academy of Neurology to ensure objectivity, independence and balance in all congress CME Certificates will only be provided to activities . All participants are required to disclose any real or participants who have evaluated the sessions apparent conflict(s) of interest that can have a direct bearing attended during the congress. Evaluation is on the subject matter of the activity . Financial disclosure possible until Wednesday, 20 June 2018, information will be provided on the presentations and/or 23.59 CET. abstracts . Please see page 18, “Evaluation” for further information . GENERAL INFORMATION

Instructions for Speakers and Presenters | Information from A to Z

Instructions for Speakers and Presenters Information from A to Z

Speakers’ Service Centre Abstracts All speakers are requested to hand in their presentations (PowerPoint only) via a USB compatible memory stick at the All accepted abstracts will be published as a supplement Speakers’ Service Centre (SSC) at least three hours before to the European Journal of Neurology . There will be no the beginning of the session . The SSC is located on the press printed book available, but a USB drive can be picked up in gallery next to the entrance of Auditorium II and the EAN the Exhibition Area at the Sanofi Genzyme booth. You will Members’ Lounge on the first floor (Foyer D). receive a voucher together with your bag . You can create your personal abstract book by using the Speakers will have the opportunity to check their presenta- Interactive Programme Planner (IPP) . tions on PCs available in the SSC . The abstracts can also be found online on www.ean.org/Lisbon2018 The speakers’ service centre (SSC) is supported by www.europeanjournalofneurology.com.

ePresentations and ePosters App

All posters will be presented electronically only . The congress app “EAN Congress” is available for download Within the ePoster area (located in Hall 4 and Hall 5) there free of charge on Google Play and iTunes . are 22 poster screens (and 25 computer stations next to Hall 4) available throughout the whole congress, where presenters It includes the interactive programme planner (IPP), all and audience are invited to interact with each other . You will session evaluations as well as the voting system for the Inter- be able to contact all presenters and meet with them at any active sessions . Please download the app and login with your time at one of the poster screens to discuss his/her work . EAN user information . You can then go ahead and create In addition, there will be scheduled sessions, taking place your personal congress programme . You will also be able to Saturday to Monday from 12 .30 - 13 15. and 13 30. - 14 .15 . access the favourites you made on the EAN Congress website .

All ePoster and ePresentation sessions will be discussed with Seize all benefits of the EAN Congress app to connect and a chairperson . The chairperson will be present and discuss meet with colleagues, prepare your meeting schedule, be able each presentation with the presenter and the audience . to actively participate in the Interactive Sessions and have In ePoster sessions (45 minutes) up to 15 presentations are additional and up-to-date information on the congress . scheduled at the dedicated poster screens . Each presenter will have 2 minutes of presentation time and approximately 1 The congress app is supported by minute of discussion . ePresentation sessions will be 45 minutes long as well and accommodate up to 10 presentations . Each presenter ATM/Cash Machine will have 3 minutes of presentation time and 2 minutes of discussion . An ATM/cash machine is located in the registration area .

Please make sure that you are present at your screen at the beginning of your session . Please see page 31 or the Interactive Attendance tracking report Programme Planner (IPP) for details and exact session times . For better audio quality, please pick up a receiver and ear- See page 13 phones from the ePoster desk before the session . Different sessions will have different channels, indicated next to each poster screen . Badges

Access to all scientific and networking events will only be pos- Poster Desk sible with your personal badge . All participants are requested to wear their name badge throughout the congress . Technicians and hosts will be available throughout the con- If you forget your badge, we can reprint it for a deposit of gress in the ePoster area (Hall 4) . GENERAL INFORMATION PAGE 14 / 15

Information from A to Z

Evaluation is possible until Wednesday, 20 June 2018, 23:59 CET . 30€ . The deposit will be returned once you show that you From Thursday, 21 June, onwards, you can download your CME still have both badges, of which we will keep one . If you lost certificate including a report of all sessions you have attended and your badge or do not show both badges anymore, 30€ will be evaluated. The certificate lists all sessions that were evaluated and charged . includes all CME points . The 4th Congress of the European Academy of Neurology (EAN) Scanning of badges has been accredited by EACCME and is designated for a maximum Participants are not obliged to allow exhibitors to scan their of, or up to 24 European CME credits (ECMEC). Please find a list of badge in the exhibition area or when entering an industry countries that accept EACCME accreditation on the UEMS Website . symposium . Participants must show their badge for proof of The UEMS-EACCME® has mutual recognition agreements with the access rights, but do not need to let someone scan it . With American Medical Association (AMA) and with the Royal College of allowing a company to scan, you acknowledge that your regis- Physicians and Surgeons of Canada for live Events . tration details will be forwarded to the exhibitor .

Children at EAN Congress 2018 Caring for the environment There is no childcare facility available at the congress . Accompanying Bag recycling – You can leave your congress bag at the regis- children over the age of 1 year are not allowed to access the exhibition tration desk when leaving the congress . area due to the pharma codex . Thank you for your understanding .

Green print - The print materials of this congress have been printed on paper that is PEFC approved . PEFC is an Cloakroom organisation that certifies paper manufacturers who keep to sustainable forest management criteria . A cloakroom is located in front of the CCL in a separate tent and is open during the secretariat opening hours . The cloakroom service is Reducing print - The printed programme is available only for free of charge . participants who order it in advance at registration . The complete programme can also be found online in the Interactive Programme Planner (IPP) and on our congress app and you Congress secretariat and registration helpdesk can create your individual schedule & abstract book . The registration helpdesk, located in the entrance area of the Recycling - As part of our efforts we try to produce less waste, congress venue is open during the following hours: and recycle plastic, glass, cans and paper . Friday, 15 06. 2018:. 16 00. – 19 00. h (badge/congress bag Offset your Carbon Footprint - You can contribute to our pick-up for pre-registered delegates only) ecological efforts by offsetting the Carbon Footprint of your Saturday, 16 06. 2018:. 7 30. – 20 00. h travels to Lisbon . A Carbon Offset represents a reduction in Sunday, 17 .06 2018:. 7 30. – 19 00. h emissions somewhere else . You can learn more and offset Monday, 18 06. 2018:. 7 30. – 19 .00 h your carbon foot print at: www .carbonfund .org . Tuesday, 19 06. 2018:. 7 30. – 16 45. h

We are doing our best and there is still much to learn . We will All documents included in the registration package (congress bag, be happy to hear your ideas; please do not hesitate to write to personal name badge) will be handed over to the registered partici- us at [email protected] . pants . Onsite registration will be accepted, but receipt of all congress documents cannot be guaranteed . The registration helpdesk can be reached at +351 96 2799370 Certificates including CME Accreditation:

If you wish to receive individual reports of your attendance in sessions, please use the EAN website and congress app and evaluate all sessions that you have attended. You can also find a designated “evaluation station” in the congress entrance area in Foyer B .

CME Certificates will only be provided to participants who have evaluated the sessions attended during the congress. GENERAL INFORMATION

Information from A to Z

CONGRESS VENUE Visit the EAN Booth and its different areas (HOME, MEET, LEARN and RESEARCH) and find out more about the Lisbon Congress Centre CCL European Academy of Neurology, your home of neurology, Praça das Indústrias and its aims and missions: 1300-307 Lisbon Portugal HOME & MEET area www .lisboacc .pt Visit this area already in the morning for a cup of coffee and The 4th Congress of the European Academy of Neurology a chat among colleagues from all over Europe and the world takes place at the Lisbon Congress Centre (CCL) which is and seize the opportunity for quick casual business meetings . located only a few minutes away from the city centre and only Relax on our sofas and feel at HOME . Learn everything about 20 minutes away from the airport . EAN and the benefits of being a valuable part of Europe’s largest community of neurologists . Get all information on our Best way to go from the airport to the congress centre is by different membership programmes, meet the people behind taxi - the average cost is around 10 to 15 € . By public trans- EAN, the EAN Board as well as the EAN Head Office. portation, you need to take the bus: the fast way is take bus Get information on MyEAN and our activities in social nº 783 and then change at Campo Pequeno to bus nº 756 (no networks . direct connection) Latest information on the 2019 EAN Congress in Oslo will also be made available . • For bus & tram, please check: EAN Congress Postcards can be mailed - just drop them in http://carris .transporteslisboa .pt/en/home/ the EAN mailbox, EAN will provide the stamp and mail it for • For train connection, please check: you! https://www .cp .pt/passageiros/en • Local cab-companies: Join us and become a member of our community! AUTOCOOP Tel . (+351) 217 932 756; RETALIS Tel . (+351) 218 119 000; LEARN TELETAXIS Tel . (+351) 218 111 100 When visiting the LEARN area, you can find all educational aspects that underpin the EAN vision to promote excellence Currency in Neurology in Europe . From study programmes outside the EAN congress or grants to support projects in other Europe- The official currency of the 4th EAN Congress in Lisbon is an Neurological Departments or online learning possibilities . Euro (€) . The easiest way to get Euros is to withdraw cash from a Multibanco ATM (“Caixa automático”), which are During coffee and lunch breaks, challenge yourself with the everywhere in Lisbon . Most ATMs work with credit cards of tricky EAN “hot wire” game – special prizes will be offered for the Visa and MasterCard type, and debit cards that use the the lucky winners . Maestro or Cirrus systems . Most banks and post offices are open from Monday to Friday Need one-of-a-kind memorabilia? Come by and purchase one between 8 .30h and 15 .00h . Exchange bureaus are usually of the unique EAN bags – strictly limited to only 150 pieces open from 9 .00-13 .00h and from 14 .00-19 00h. . maximum per congress year, made of the poster background tarps of the 2015, 2016 and 2017 EAN congresses in Berlin, Copenhagen and Amsterdam . EAN decided to re-use nearly EAN Booth – Your Home of neurology all printed tarps and cloths of the poster booths and design its very own limited collector item . Be sure to get your one-of- “700 .000 .000 brains - 45 000. members - 47 countries - one a-kind limited bag for only €20 (discount possibilities: 2 for community!” €35 and 3 for €45 only) Location: first floor, between Auditorium I and II.

Opening hours: Saturday, 16 .06 2018:. 08 .00 – 18 .00 h Sunday, 17 .06 2018:. 07 30. – 18 .00 h Monday, 18 06. 2018:. 07 30. – 18 .00 h Tuesday, 19 .06 2018:. 07 30. – 15 .00 h GENERAL INFORMATION PAGE 16 / 17

Information from A to Z

The EAN bags are produced locally in Vienna, Austria by RESEARCH WienWork, an organisation that enables people with disa- bilities, chronic illnesses or long-term unemployed people to Get all the information on Scientific Panels - not only on pan- participate in economic and social life . With every purchase el membership but also what these panels do . Grab your copy of a bag you support this project . of the European Journal of Neurology and make yourself familiar with other great publications . Learn more about EAN Guideline Production, related cross- word puzzles are available . Come by and pick a paper printout of your #ean2018 picture posted on social media .

SCIENTIFIC THEATRE

In Lisbon, the scientific theatre is an extension of the EAN booth, where EAN committees, working-groups and task forces as well as partner organisations and related sub- specialties societies can use short timeslots to talk about their work, inform about their missions and encourage people to The EAN Photo-wall is also be located here… come by and have a seat and listen-in . have your photo taken – while waiting for your turn, just The Programme overview can be found on page 20 . solve one of the funny brain puzzles . During lunch and coffee breaks, the scientific theater is made available for forum talks by our industry partners . The detailed programme can be found on page 157 . Capacity is for 40 people, please bring your earphones (available at the Poster help desk) EAN Booth GENERAL INFORMATION

Information from A to Z

Evaluation/Quality control Hotel and travel

In order to guarantee the quality of the upcoming congresses, Official Housing Agency we are carrying out congress evaluations . Congrex Switzerland Ltd ,. Email: hotel .ean@congrex .com General Evaluation Congrex Switzerland is present at the Congress registration The general evaluation of the congress will be sent to all con- help desk . Staff can assist you with your hotel bookings . gress participants after the congress .

Session Evaluation/CME Certificate Insurance & Liability If you wish to receive individual reports of your attendance in sessions, please use the EAN website and congress app and The Congress organisers and PCO cannot accept liability for evaluate all sessions that you have attended. You can also find personal accidents or loss of or damage to private property of a designated “evaluation station” in the congress entrance participants, either during or indirectly arising from the 4th area in Foyer B . Evaluation is possible until Wednesday, Congress of the European Academy of Neurology . 20 June 2018, 23:59 CET . You can choose your individual cancellation and travel insur- CME Certificates will only be provided to ance package when registering to the congress at extra costs . participants who have evaluated the sessions attended during the congress. It is recommended that all participants take advantage of this . From Thursday, 21 June, onwards you can download your CME certificate including a report of all sessions you have attended and evaluated. The certificate lists all sessions that Internet Corner were evaluated and includes all CME points . An Internet Corner is located in the exhibition area (Hall 3) Please take time to complete the electronic evaluation forms and is available to all congress participants during the provided for each session you attend . Your input is essential opening hours of the exhibition . for planning future EAN congresses and for receiving your Wi-Fi information on page 22 . certificate.

Interactive Programme Planner (IPP) Exhibition Please use the IPP in order to create your personal An extensive exhibition will be held concurrently with the programme and abstract book . congress . All invited lectures, oral sessions and poster presentations Exhibition opening hours are: will be available in the IPP . By logging in with your EAN user Saturday, 16 June 2018: 09 .30 – 17 00h. information, you will be able to save and edit your personal Sunday, 17 June 2018: 09 .30 – 17 .00h programme . It is available for desktop, laptop and in our Monday, 18 June 2018: 09 .30 – 17 .00h congress app . Tuesday, 19 June 2018: 09 .30 – 13 30h. Contents are sorted by topic and can be searched through Accompanying children over the age of 1 year are not allowed standard web search functions . Once you have created your to access the exhibition area due to the Pharma Codex . Thank personal programme, you can export it to different calendar you for your understanding . formats, or download it as a book of abstracts .

The exhibition floor plan can be found on page 121. The IPP will be available before and during the congress .

Film and photos

Please be advised that photographs and video recordings may be taken at the 4th EAN Congress . By participating in the congress, you consent to the publication, release, exhibition and/or reproduction of such photos to be used for the EAN website, EAN newsblog “EAN pages”, and on social media . GENERAL INFORMATION PAGE 18 / 19

Information from A to Z

Language Mini-Programme

The official language of the congress is English. No simulta- The mini-programme gives you an overview of the scientific neous translation will be provided . programme at a glance .

Lost & Found Mobile charging stations

Please apply to the congress registration helpdesk . Mobile charging stations will be placed all over the venue available to all congress participants . The mobile charging stations are supported by Lunch and Coffee breaks

Light lunch and coffee is included in the registration fee and will be served in the exhibition area as per the times indicated in the timetable . Coffee will be served in Halls 1, 2 and 3 . Lunch will only be served in Hall 2 . Mobile phones

Please note that mobile phones must be switched off during Mail/Messages all sessions .

ePoster and ePresentation presenters can be contacted via the online poster system . Networking If you wish to leave a message for somebody, please apply to the information desk . Opening and Welcome Reception (See page 37) Challenges for women in neurology (see page 38) Musical Recital (see page 39) Media Contact History of Neuroscience visit (see page 40) Networking event “Meet your Neurology Network” (see page 40) B&K Resident and Research Fellow Section Activities (see page 9) Dr Birgit Kofler Members’ Lounge (see page 19) Phone: +43-1-319 43 78 EAN booth (see page 16) Mobile: +43-676-63 68 930 E-Mail: [email protected] Skype: bkk_Birgit.Kofler Poster Sessions /Poster Overview PRESS OFFICE Please see page 14 and 31

Medical assistance Press room Please apply to the congress registration helpdesk . A media room with wireless internet access is available to registered journalists . The Press Room is located in Foyer A Members’ lounge on the ground floor.

EAN Full and Corresponding individual members, FEANs and Faculty Members have the possibility to network and enjoy their lunch in a separated Members’ Lounge . The Members’ Lounge is located next to the EAN Booth area and is open during the exhibition opening hours . A separate “Members working Lounge” can be found above the staircase to Hall 4 (ePoster area) .

A photographer, to take a portrait picture of you for your EAN profile, is located in Foyer E during on-site announced hours . GENERAL INFORMATION

Information from A to Z

Scientific Replay lounge Sunday, June 17

The Scientific Replay Lounge is located in the exhibition area 9:30-10:00 (Hall 3) and will be available for the comfort of participants, Forum talks by industry (page 157) providing a place to see webcasts of selected previous sessions, relax and meet with colleagues . 10:00-10:30 News from European Union of Medical Specialists – European Board of Neurology Scientific Theatre Patrick Cras – UEMS – SN

Located on the ground floor, in Exhibition Hall 2, the Scien- 10:30-11:00 tific Theatre is a forum for EAN committees, working groups, European Board Exam for Neurology task forces and other EAN partner organisations to inform Jan Kuks – UEMS the audience in short about their latest achievements and future ambitions . 11:30-12:00 IFCN European Chapter – Training and education in Europe Set-up for 40 participants with their own ear phones . in Clinical Neurophysiology Johnathan Cole – IFCN

Scientific Theatre Programme 12:00-12:30 Mind the Treatment Gap! Saturday, June 16 Wolfgang Oertel – EAN Joke Jaarsma – EFNA 10:00-10:30 Forum talks by industry (page 157) 12:30-13:00 How to build a successful health policy campaign? 10:30-11:00 Lesson learnt from the Societal Impact of Pain campaign How political action can improve the lives of neuropathic Sam Kynman – EFIC pain patients? An introduction to the Societal Impact of Pain campaign 14:00-14:30 Marc Marlion – EFIC EBC – VoT Project – Improved patient journey in neurology Joke Jaarsma – EFNA 11:30-12:00 Maura Pugliatti – EAN EAN grants and other possibilities G. di Liberto, L. Klingelhoefer, V. Papp 15:00-15:30 EAN Guideline task force – Palliative Care in MS 12:30-13:00 Allesandra Solari Presentation: eBook on neurological examination Klaus V. Tokya 16:15-16:45 Forum talks by industry (page 157) 14:00-14:30 EAN Guideline Production Monday, June 18 Maurizio Leone – EAN 9:30-10:00 15:30-16:00 Forum talks by industry (page 157) How to prepare a scientific paper for publication Pertti Saloheimo - European Journal of Neurology 10:00-10:30 Palliative Care and Neurology 16:15-16:45 David Oliver – EAPC Forum talks by industry (page 157) 10:30-11:00 News from the International Neuro-Urology Society Jalesh Panicker – INUS GENERAL INFORMATION PAGE 20 / 21

Information from A to Z

11:30-12:00 Special Sessions: EAN grants and other possibilities Special Sessions (SPS) cover topics of special interest . G. di Liberto, L. Klingelhoefer, V. Papp Educational Sessions: 12:30-13:00 EAN Scientific Panels – how to get involved Teaching Courses: Celia Oreja-Guevara – EAN If you wish to participate, tickets can still be purchased at the Registration for a fee of € 50/ €30, availability permitting . 13:30-14:00 Health, wealth and workability: young people with MS TCs are held on each congress day in the afternoon and last Helen Chandler – EMSP for 3 hours (plus 1/2 hour coffee break) . They are interactive with ample opportunity for participants to ask questions . All 14:00-14:30 TCs are aimed primarily at a post-graduate audience . Presentation: eBook on neurological examination Klaus V. Tokya There are 3 levels of TCs: Level 1 (Introductory): Aimed primarily at neurologists 15:30-16:00 in training, or those wishing to refresh/update their basic Action Plan for Stroke in Europe in Cooperation with SAFE knowledge in the field. Level 1 can also be suitable for under- – Stroke Alliance for Europe graduates or general trainees with a particular interest . Valeria Caso – ESO Level 2 (standard): Assumes familiarity with basic clinical knowledge and practice, aimed at specialist trainees or practitioners wishing to update and further develop their Tuesday, June 19 knowledge in the field. Level 3 (advanced): Aimed at specialist trainees or practition- 12:00-12:30 ers with a particular interest in that field, covering the latest EAN grants and other possibilities advances of particular interest to a specialist audience . G. di Liberto, L. Klingelhoefer, V. Papp Participation is not included in the registration fee . Partici- pants will receive a manuscript of the lectures .

Session descriptions and Buttons Hands-on Courses: If you wish to participate, tickets can still be purchased at the Please make sure to be in session halls on time as all sessions Registration for a fee of € 50/ €30, availability permitting . will begin as per schedule . These Hands-on Courses (HoC) are for a small number of If you wish to receive individual reports of your attendance in participants only, with some built-in work in smaller groups sessions, please use the EAN website and congress app and evaluate who attend parallel by rotating to each presenter of the all sessions that you have attended. You can also find a designated course . Live demonstrations with screening machines are the “evaluation station” in the congress entrance area in Foyer B . core of these courses .

CME Certificates will only be provided to Participation is not included in the registration fee . For a participants who have evaluated the sessions limited number of participants only (first come-first-served attended during the congress. basis) . Participants will receive a manuscript of the presentations . Scientific Sessions: Case-based Workshops: Symposia: If you wish to participate, tickets can still be purchased at the Symposia are scheduled on each congress day and will last Secretariat for a fee of € 50/ €30, availability permitting . 2 hours each . Lecturers will give general information on the main topics of the congress . The case-based workshops are to support knowledge and practice in clinical diagnosis and management in a format, Focused Workshops: which requires the attendees to actively participate, with op- Focused workshops (FWs) will be held in the morning and portunities for direct discussion/contact with leading experts last for 1 .5 hours . They cover narrow topics and aim to to discuss pre-prepared cases . promote discussion around new ideas, evidence or theories . Ample time for discussion will be provided . GENERAL INFORMATION

Information from A to Z

Participation is not included in the registration fee . For a limited number of participants only (first come-first-served Smoking policy basis) . Smoking is prohibited at all times in the meeting halls, exhib- Interactive Sessions: it halls and restrooms . Your compliance is appreciated . These sessions are open for all participants . Through an interactive voting system via the congress app, the opinions of colleagues will be collected . Please download the congress Speakers’ Service Centre (SSC) app to actively participate in the Q&A . See page 14 . Controversy Sessions: Allow to give a critical overview of the current and most recent advances on key topics, share knowledge, stimulate WI-FI debate and forge opinions on controversial issues of clinical care, research, educational practice and therapy . Wi-Fi will be available free of charge in the registration and exhibition area as well as in the session rooms . Career development Sessions: This format shall allow to share and improve knowledge on: Network name: EAN-2018_supportedbyRoche “how to best write an academic paper”; “how to plan and Username: ROCHEatEAN organize a clinical or scientific study”; “how to apply for a Password: StartNOW grant”, “how to get a paper accepted” etc… These sessions are open for all participants and primarily aim The Wi-Fi is supported by . at a post-graduate audience .

Buttons @ scientific Programme

The Overarching Theme for the 2018 Congress is “Neurogenetics” . Sessions with this button are dedicated to the Overarching theme and were created by the Programme committee together with Local OVERACHING Organising committee . THEME

EFNA (European Federation of Neurological Associations), the federation uniting European Patients’ Associations, has selected these sessions as high priority . PATIENTS’ CHOICE

These are the highlights of the congress and/or innovative sessions .

HIGHLIGHT

These sessions were selected by the EAN Rare Neurological Disease Task Force . RARE DISEASES GENERAL INFORMATION GENERAL INFORMATION

Ground Floor

GROUND FLOOR

Case-based Foyer E Workshop Room To/From st Auditorium VI 0 R 0.08 1 Floor

EAN Info Area Over- R 0.07 flow Session Rooms Area 2 R 0.06 Meeting Rooms

Exhibition

Booth

Overflow Area

Toilets

Scientific LIFT Lift Theatre Coffee

Lunch

Cloakroom

Internet Corner

R 0.05

Exhibition Hall 2 Exhibition Hall 1 R 0.04

Auditorium V R 0.03

Overflow

Helpdesk Area 1

R 0.01 R 0.02 LIFT

To/From Material Congress Room Room 1st Floor Berlin Copen- hagen LIFT

Exhibition Hall 3 Foyer B Foyer C Badges Room Press Foyer A

Evaluation Entrance Exit New Registration Scientific Corner Course Bookings Replay Evaluation Lounge GENERAL INFORMATION PAGE 24 / 25

First Floor

FIRST FIRST To/From To/From Ground Floor Ground Floor FLOOR FLOOR

Scientific RScientific 1.17 R 1.17 Business Business Suite Suite R 1.16 R 1.16 1 1

EAN Info AreaEAN Info Area Foyer F Foyer F ePoster AreaePoster Area

Auditorium Auditorium Session RoomsSession Rooms VIII VIII R 1.15 R 1.15 To/From ExhibitionTo/From Exhibition Meeting RoomsMeeting Rooms Scientific BusinessScientific Business Suite Suite Toilets Toilets EAN Photo WallEAN Photo Wall LIFT Lift LIFT Lift

Auditorium AuditoriumIII III

Foyer D Foyer D

EAN EAN

Audi- Audi-Research Research

Booth Learn Booth Learn torium II torium IIArea Area Auditorium AuditoriumI I

To/From To/From 2nd 2nd Speakers’ Speakers’ Floor Meet Floor Meet Service Service Home Home Centre Centre

EAN EAN Members’ Members’ To/From Exhibition LoungeTo/From Exhibition Lounge LIFT LIFT

Room RoomRoom RoomRoom Room R 1.11 R 1.12 R 1.11R 1.13R 1.12 R 1.13 Amster- LisbonAmster- OsloLisbon Oslo

Desk ePoster Desk ePoster dam dam LIFT LIFT iMac Stations iMac Stations R 1.09 R 1.09 Hall 4 Hall 4 Hall 5 Hall 5 ePoster AreaePoster AreaePoster AreaePoster Area ePoster AreaePoster Area Screens A Screens A Screens B Screens B Screens C ScreensHoC C HoC Room Room R 1.02 R 1.03 R 1.04 R 1.02 R 1.03 R 1.04 R 1.05 R 1.06 R 1.07 R 1.05 R 1.08 R 1.06 R 1.07 R 1.08

EAN Members’EAN Members’ Working LoungeWorking Lounge FIRST FLOOR

SECOND FLOOR 1

GENERAL INFORMATION 2 EAN Info Area

Meeting Rooms ePoster Area Toilets

LIFT Lift Second Floor

SECOND FLOOR 2

Meeting Rooms

To/From Toilets 2nd Floor

LIFT Lift

LIFT

R2.01 R2.02 R2.03 R2.04 R2.05

ePoster Area To/From 2nd Floor

FIRST FLOOR LIFT 1 Hall 4 R2.01 R2.02 R2.03 R2.04 R2.05 EAN Info Area ePoster Area ePoster Area

Desk Desk ePosterePoster Hall 5 B9 B10 B11 B12 ePoster Area A1 Screens B A4 A6 B2 B4 B6 B8 Screens C C4 A2 A3 A5 B1 B3 B5 B7 C1 C2 C3 Screens A

Hall 4 ePoster Area

Desk Desk ePosterePoster Hall 5 B9 B10 B11 B12 ePoster Area A1 Screens B A4 A6 B2 B4 B6 B8 Screens C C4 A2 A3 A5 B1 B3 B5 B7 C1 C2 C3 Screens A GENERAL INFORMATION GENERAL INFORMATION

Overview of business meetings

(in chronological order, as per date of printing) Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area and can be found in the IPP (App) .

Group/Committee Day Time Room

European Affairs sub-Committee Saturday, 16 June 08:30 – 10:00 Room 1 .15

EBN/UEMS Board Meeting Saturday, 16 June 09:00 – 17:00 Room 1 .08

Assembly of Delegates Saturday, 16 June 13:00 – 15:00 Auditorium II

RRFS National representatives Saturday, 16 June 14:15 – 15:15 Room 1 .17

Quality Assurance sub-Committee Sunday, 17 June 08:30 – 10:00 Room 1 .15

TF Neurology – SSA + Corresponding Societies Sunday, 17 June 10:00 – 12:00 Room 1 .17

European Journal of Neurology Editorial Board Sunday, 17 June 13:30 – 14:30 Room 1 .15

EAN / Wiley Meeting Sunday, 17 June 15:00 – 16:00 Room 1 .17

eCommunication Board Sunday, 17 June 16:00 – 17:30 Room 1 .15

Teaching Course sub-Committee Monday, 18 June 08:00 – 09:30 Room 1 .15

Scientific Panel Chairs Meeting Monday, 18 June 12:00 – 14:00 Auditorium III

Communication Committee Monday, 18 June 12:30 – 14:00 Room 1 .17

Local Organising Committee Oslo Monday, 18 June 12:30 – 14:00 Room 1 .15

RRFS General Assembly Monday, 18 June 14:15 – 15:15 Room 0 .01

Scientific Committee Monday, 18 June 14:30 – 16:30 Room 1 .15

Industrial Relations Board (IRB) Monday, 18 June 15:00 – 16:30 Auditorium III

Guideline Production Group Monday, 18 June 17:00 – 18:30 Room 1 .15

Education Committee Tuesday, 19 June 08:30 – 10:00 Room 1 .15

Programme Committee Tuesday, 19 June 14:00 – 15:30 Room 1 .15

Board debriefing Tuesday, 19 June 16:00 – 17:00 Room 1 .15

Rare disease Taskforce please see IPP (App)

eCommunication Board and Scientific Panel please see IPP (App) Website representatives GENERAL INFORMATION PAGE 28 / 29

Overview of business meetings of Scientific Panels, Task Forces

(in chronological order, as per date of printing) Additional meetings reserved after the date of printing will be announced on the Message sceen in the registration area and can be found in the IPP (App) .

Group/Committee Day Time Room

Scientific Panel Autonomic nervous system disorders Saturday, 16 June 13:00 – 14:30 Room 1 .16

Scientific Panel Neuroepidemiology Saturday, 16 June 14:30 – 16:00 Room 1 .15

Scientific Panel Translational neurology Saturday, 16 June 15:00 – 16:00 Room 1 .11

Scientific Panel Multiple sclerosis Saturday, 16 June 15:15 – 16:15 Room 1 .13

Scientific Panel Neuroimaging Saturday, 16 June 17:00 – 18:00 Room 1 .15

Scientific Panel Muscle & NMJ disorders Sunday, 17 June 09:00 – 10:30 Room 1 .11

Scientific Panel Higher cortical functions Sunday, 17 June 10:00 – 11:00 Room 1 .13

Scientific Panel Neurorehabilitation Sunday, 17 June 11:00 – 12:00 Room 1 .12

Scientific Panel Neuro-oncology Sunday, 17 June 12:00 – 13:00 Room 1 .12

Scientific Panel Clinical neurophysiology Sunday, 17 June 12:30 – 14:00 Room 1 .16

Scientific Panel Neurotraumatology Sunday, 17 June 13:00 – 14:00 Room 1 .13

Task Force "Coma and chronic disorders of Sunday, 17 June 13:00 – 15:00 Room 1 .11 consciousness" Guideline

Scientific Panel Pain Sunday, 17 June 14:00 – 15:00 Room 1 .12

Scientific Panel Neurosonology Sunday, 17 June 14:00 – 15:00 Room 1 .16

Scientific Panel Neurotoxicology Sunday, 17 June 14:15 – 15:15 Room 1 .13

Scientific Panel Neurocritical care Sunday, 17 June 15:00 – 16:30 Room 1 .16

Scientific Panel Sleep-wake disorders Sunday, 17 June 16:00 – 17:00 Room 1 .13

Scientific Panel Palliative care Sunday, 17 June 16:00 – 17:00 Room 1 .12

Task Force "Narcolepsy" Guideline Sunday, 17 June 17:00 – 18:30 Room 1 .13

Scientific Panel Neuro-ophthalmology and -otology Sunday, 17 June 16:45 – 18:00 Room 1 .17

Task Force "Palliative care in MS" Guideline Sunday, 17 June 17:00 – 19:00 Room 1 .12

Task Force "Parkinson's diseases" Guideline Sunday, 17 June 17:00 – 18:00 Room 1 .16 GENERAL INFORMATION

Overview of business meetings of Scientific Panels, Task Forces

Group/Committee Day Time Room

Scientific Panel Epilepsy Monday, 18 June 09:00 – 11:00 Room 1 .16

Scientific Panel Headache Monday, 18 June 09:30 – 10:30 Room 1 .13

Scientific Panel Dementia and cognitive disorders Monday, 18 June 10:00 – 11:00 Room 1 .15

Scientific Panel Stroke Monday, 18 June 11:00 – 12:00 Room 1 .15

Scientific Panel Neuropathies Monday, 18 June 14:15 – 15:45 Room 1 .17

Scientific Panel Neurogenetics Monday, 18 June 15:00 – 16:00 Room 1 .16

Scientific Panel Infectious diseases Monday, 18 June 17:00 – 18:00 Room 1 .11

Scientific Panel Child neurology Tuesday, 19 June 10:00 – 11:00 Room 1 .12

Scientific Panel Coma and chronic disease of Tuesday, 19 June 10:00 – 12:00 Room 1 .13 consciousness GENERAL INFORMATION PAGE 30 / 31

ePoster overview

ePoster presenters are requested to be at their poster screen at the beginning of the session . Pick up your audio equipment at the poster desk!

Saturday, 16 June 2018 12:30–13:15

Topic Screen Nr Poster Numbers Chairs

Ageing and dementia Screen A1 EPO1001 – EPO1011 Miguel Tábuas-Pereira, Portugal

Cerebrovascular diseases 1 Screen A3 EPO1012 – EPO1022 Diana Aguiar de Sousa, Portugal

Cognitive neurology/neuropsychology Screen A6 EPO1023 – EPO1033 Alexandre Mendonça, Portugal

Epilepsy 1 Screen B1 EPO1034 – EPO1043 Ettore Beghi, Italy

Headache and pain 1 Screen B3 EPO1044 – EPO1052 Isabel Pavão, Portugal

Miscellaneous 1 Screen B9 EPO1053 – EPO1064 Bartosz Karaszewski, Poland

Movement disorders 1 Screen B6 EPO1065 – EPO1075 Aleksandra Herrera-Sokołowska, Poland

MS and related disorders 1 Screen B11 EPO1076 – EPO1089 Giovanni Di Liberto, Switzerland

MS and related disorders 2 Screen B7 EPO1090 – EPO1095 João Sá, Portugal

Muscle and neuromuscular junction disease 1 Screen C1 EPO1096 – EPO1105 Mamede de Carvalho, Portugal

Neurological manifestations of systemic diseases Screen C4 EPO1106 – EPO1115 Irina Alexandra Orban, Romania

Sonday, 17 June 2018 12:30–13:15

Topic Screen Nr Poster Numbers Chairs

Cerebrovascular diseases 2 Screen A3 EPO2001 – EPO2012 Natan Bornstein, Israel

Child neurology/developmental neurology Screen A6 EPO2013 – EPO2020 Teresa Temudo, Portugal

Clinical neurophysiology Screen B3 EPO2021 – EPO2027 Simon Podnar, Slovenia

Epilepsy 2 Screen B1 EPO2029 – EPO2037 Andreij Dubenko, Ukraine

Infectious diseases; Sleep disorders Screen B9 EPO2038 – EPO2048 Stefan Golaszewski, Austria

Movement disorders 2 Screen B6 EPO2049 – EPO2059 Angelo Antonini, Italy

Movement disorders 3 Screen B11 EPO2060 – EPO2070 Panagiotis Zis, United Kingdom

MS and related disorders 3 Screen B7 EPO2071 – EPO2080 Patrick Vermersch, France

Neurogenetics 1 Screen C1 EPO2081 – EPO2091 Isabelle Le Ber, France

Neuro-oncology Screen C4 EPO2092 – EPO2100 Francois Ducray, France

Neurorehabilitation Screen C2 EPO2101 – EPO2111 Fior Dafin Muresanu, Romania

Peripheral nerve disorders Screen A1 EPO2112 – EPO2124 Vitalie Lisnic, Moldova

All posters will be available throughout the congress on the poster screens and computer stations in the exhibition area . You can contact ePoster and ePresentation presenters via the poster system . For this, please use one of the poster screens in the ePoster area and navigate to the poster you would like to contact the author of. You can find a contact link on the bottom of that page. You can do the same via the link on the congress website GENERAL INFORMATION

ePoster overview

ePoster presenters are requested to be at their poster screen at the beginning of the session . Pick up your audio equipment at the poster desk!

Monday, 18 June 2018 12:30–13:15

Topic Screen Nr Poster Numbers Chairs

Cerebrovascular diseases 3 Screen A3 EPO3001 – EPO3012 Kristaps Jurjans, Latvia

Epilepsy 3 Screen B1 EPO3013 – EPO3022 Jera Kruja, Albania

Headache and pain 2 Screen B3 EPO3023 – EPO3031 Raquel Gil-Gouveia, Portugal

Miscellaneous 2 Screen A1 EPO3032 – EPO3043 Vida Demarin, Croatia

Motor neurone diseases; Cognitive neurology/ Screen A6 EPO3044 – EPO3055 Riadh Gouider, Tunisia neuropsychology

Movement disorders 4 Screen B6 EPO3056 – EPO3066 K Ray Chaudhuri, United Kingdom

MS and related disorders 4 Screen B11 EPO3067 – EPO3076 Celia Oreja-Guevara, Spain

Muscle and neuromuscular junction disease 2 Screen C1 EPO3077 – EPO3086 Josef Finsterer, Austria

Neurogenetics 2 Screen C4 EPO3087 – EPO3097 Jean Marc Burgunder, Switzerland

Neuro-ophthalmology/ neuro-otology Screen C2 EPO3098 – EPO3105 Neşe Celebisoy, Turkey

Sleep disorders Screen B7 EPO3106 – EPO3116 Teresa Paiva, Portugal

ePresentation overview

ePresentation presenters are requested to be at their poster screen at the beginning of the session . Pick up your audio equipment at the poster desk!

Saturday, 16 June 2018 13:30–14:15

Topic Screen Nr Presentation Numbers Chairs

Ageing and dementia 1 Screen A1 EPR1001 – EPR1008 Federica Agosta, Italy

Cerebrovascular diseases 1 Screen A3 EPR1009 – EPR1017 Hugh Markus, United Kingdom

Cerebrovascular diseases 2 Screen A2 EPR1018 – EPR1026 Serefnur Öztürk, Turkey

Cognitive neurology/neuropsychology 1 Screen A6 EPR1027 – EPR1032 Elisa Canu, Italy

Epilepsy 1 Screen B1 EPR1033 – EPR1040 Kristl Vonck, Belgium

Headache and pain 1 Screen B3 EPR1041 – EPR1049 Radu Razvan, Romania

Motor neurone diseases 1 Screen A4 EPR1050 – EPR1057 Thomas M . Jenkins, United Kingdom

Movement disorders 1 Screen B6 EPR1058 – EPR1065 Miguel Coelho, Portugal

Movement disorders 2 Screen B8 EPR1066 – EPR1073 Jean-Philippe Azulay, France

Movement disorders 3 Screen B10 EPR1074 – EPR1081 Anna Czlonkowska, Poland

MS and related disorders 1 Screen B11 EPR1082 – EPR1090 Declan Chard, United Kingdom

MS and related disorders 2 Screen B7 EPR1091 – EPR1098 Maria José Sá, Portugal

MS and related disorders 3 Screen B5 EPR1099 – EPR1106 Gavin Giovannoni, United Kingdom

Muscle and neuromuscular junction disease 1 Screen C1 EPR1107 – EPR1114 Zohar Argov, Israel

Neurogenetics 1 Screen C3 EPR1115 – EPR1121 Corrado Angelini, Italy

Neuroimaging 1 Screen A5 EPR1122 – EPR1128 Sofia Reimão,Portugal

Neuroimmunology 1 Screen B9 EPR1129 – EPR1136 Alvaro Cobo-Calvo, France

Neurological manifestations of systemic diseases Screen C4 EPR1137 – EPR1143 Markus Weber, Switzerland

Neuro-ophthalmology/neuro-otology; Spinal Screen B2 EPR1144 – EPR1151 Eleftherios Papathanasiou, Cyprus cord and root disorders

Neurorehabilitation 1 Screen C2 EPR1152 – EPR1159 Anabela Pinto, Portugal

Peripheral nerve disorders 1 Screen B4 EPR1160 – EPR1168 Geir Julius Braathen, Norway

Peripheral nerve disorders 2 Screen B12 EPR1170 – EPR1177 Teresa Paiva, Portugal

ePresentation overview

ePresentation presenters are requested to be at their poster screen at the beginning of the session . Pick up your audio equipment at the poster desk!

Sunday, 17 June 2018 13:30–14:15

Topic Screen Nr Presentation Numbers Chairs

Ageing and dementia 2 Screen A1 EPR2001 – EPR2008 Alla Guekht, Russia

Autonomic nervous system; Sleep disorders Screen C4 EPR2009 – EPR2017 Mario Habek, Croatia

Cerebrovascular diseases 3 Screen A3 EPR2018 – EPR2024 Patrik Michel, Switzerland

Cerebrovascular diseases 4 Screen A2 EPR2025 – EPR2033 Raquel Gutiérrez Zúñiga, Portugal

Child neurology/developmental neurology Screen A6 EPR2034 – EPR2040 Urs Fisch, Switzerland

Clinical neurophysiology Screen B3 EPR2041 – EPR2049 Letizia Leocani, Italy

Epilepsy 2 Screen B1 EPR2050 – EPR2057 Mar Carreño, Spain

Headache and pain 2 Screen B2 EPR2058 – EPR2065 Delphine Magis, Belgium

Infectious diseases Screen B9 EPR2066 – EPR2072 Erich Schmutzhard, Austria

Movement disorders 4 Screen B6 EPR2073 – EPR2080 Carlo Colosimo, Italy

Movement disorders 5 Screen B11 EPR2081 – EPR2088 Philippe Damier, France

Movement disorders 6 Screen B8 EPR2089 – EPR2096 Olivier Rascol, France

MS and related disorders 4 Screen B7 EPR2097 – EPR2104 Ludwig Kappos, Switzerland

MS and related disorders 5 Screen B10 EPR2105 – EPR2112 Michael Khalil, Austria

MS and related disorders 6 Screen B5 EPR2113 – EPR2120 Abhijit Chaudhuri, United Kingdom

Neurogenetics 2 Screen C3 EPR2121 – EPR2127 Max Hilz, Germany

Neurogenetics 3 Screen C1 EPR2128 – EPR2133 Christine Van Broeckhoven, Belgium

Neuroimaging 2 Screen A5 EPR2134 – EPR2140 Laszlo Csiba, Hungary

Neurological manifestations of systemic disea- Screen B12 EPR2141 – EPR2146 Riccardo Soffietti, Italy ses; Neuro-oncology

Neurorehabilitation 2 Screen C2 EPR2147 – EPR2154 Andreas Bender, Germany

Peripheral nerve disorders 3 Screen B4 EPR2155 – EPR2163 Ingemar SJ Merkies, The Netherlands

Peripheral nerve disorders; Muscle and neuro- Screen A4 EPR2164 – EPR2171 Yuri Alekseenko, Belarus muscular junction diseases

ePresentation overview

ePresentation presenters are requested to be at their poster screen at the beginning of the session . Pick up your audio equipment at the poster desk!

Monday, 18 June 2018 13:30–14:15

Topic Screen Nr Presentation Numbers Chairs

Ageing and dementia 3 Screen A1 EPR3001 – EPR3007 Pasquale Calabrese, Switzerland

Autonomic nervous system Screen B2 EPR3008 – EPR3015 Walter Struhal, Austria

Cerebrovascular diseases 5 Screen A3 EPR3016 – EPR3023 Stefan Schwab, Germany

Cognitive neurology/neuropsychology 2 Screen A6 EPR3024 – EPR3030 Maria Assunta Rocca, Italy

Epilepsy 3 Screen B1 EPR3031 – EPR3039 Reetta Kälviäinen, Finland

Headache and pain 3 Screen B3 EPR3040 – EPR3048 Simona Sacco, Italy

Miscellaneous Screen B9 EPR3049 – EPR3055 Patrick Cras, Belgium

Motor neurone diseases 2 Screen A4 EPR3056 – EPR3062 Christian Krarup, Denmark

Movement disorders 7 Screen B6 EPR3063 – EPR3070 Mário M . Rosa, Portugal

Movement disorders 8 Screen B8 EPR3071 – EPR3078 Leonor Correia Guedes, Portugal

Movement disorders 9 Screen A2 EPR3079 – EPR3086 Andreas Zwergal, Germany

MS and related disorders 7 Screen B11 EPR3087 – EPR3094 Per Soelberg Sörensen, Denmark

MS and related disorders 8 Screen B10 EPR3095 – EPR3102 Heinz Wiendl, Germany

MS and related disorders 9 Screen B5 EPR3103 – EPR3110 Tjalf Ziemssen, Germany

Muscle and neuromuscular junction disease 2 Screen C1 EPR3111 – EPR3117 Antonio Toscano, Italy

Neuroepidemiology Screen B12 EPR3118 – EPR3126 Maura Pugliatti, Italy

Neurogenetics 4 Screen C4 EPR3127 – EPR3133 Michelangelo Mancuso, Italy

Neuroimmunology 2 Screen A5 EPR3134 – EPR3141 Luca Massacesi, Italy

Neuro-ophthalmology/ neuro-otology Screen C2 EPR3142 – EPR3150 Michael Leo Strupp, Germany

Neurorehabilitation 3 Screen C3 EPR3151 – EPR3157 Volker Dietz, Germany

Peripheral nerve disorders 5 Screen B4 EPR3158 – EPR3164 Jean Marc Leger, France

Sleep disorders Screen B7 EPR3165 – EPR3173 Luigi Ferini-Strambi, Italy

Saturday 16 June

12:00 – 15:00h 13:40h Room 0 .01 CCL - Lisbon Congress Centre Clinical Trials in Huntington’s Disease „Huntington’s Disease - Scientific Updates G. Bernhard Landwehrmeyer (Ulm, Germany) for the HD Community (EHA and APDH)“ G . Bernhard Landwehrmeyer, MD, FRCP is Professor of Neu- 12:00h rology at Ulm University Hospital, Dept . of Neurology where the Central Coordination of the European Huntington’s Disease Opening Words Network (EHDN) is situated . In 2004 he was instrumental in founding EHDN and served as chairman of the Executive 12: 10h Committee until 2014 . EHDN serves as a platform for professionals, people affected by Huntington’s disease (HD), and their EHDN past, present and future relatives to facilitate working together throughout Europe and Jean-Marc Burgunder (Bern, Switzerland) conducts large prospective natural history studies in HD . He received his Doctoral Degree from the Albert-Ludwigs-University, “The European Huntington’s Disease Network has been created Freiburg . He was trained at the Royal Victoria Hospital, Queen’s in 2004 with the aim to advance reseach, conduct clinical trials University, Belfast, at the Kantonsspital, Basel and worked as and improve clinical care for patients with the disease and post-Doc at MGH, Harvard Medical School, Boston . their family . EHDN started as a small group with a core study, Registry, and constantly grew thank to the strong involvment of 14:20h members and the support by CHDI . After the globalisation of the observational study, now called Enroll-HD, EHDN has reshaped 20 Years’ Experience with Genetic Testing and its activities still working on the same aims . EHDN tasks are still Counselling for Huntington Disease in Portugal at hand and the network will continue its activities in close collab- Jorge Sequeiros (Porto, Portugal) oration with the patients’ organisations .” “Genetic testing for HD begun to be provided in 1998, at IBMC, Jean-Marc Burgunder has graduated in Medicine at the Faculty of following the IHA/WFN Guidelines and a genetic counselling Medicine in Bern, Switzerland, and trained in internal medicine, protocol already in use for Machado-Joseph disease . As a refer- neurology and neuroscience in Switzerland and in Bethesda, USA . ence lab for HD, we acquired some data on the number of pa- He is a Professor of Experimental Neurology at the University in tients/families in Portugal, as well as on population frequency of Bern . He is now, Chair of the EHDN Executive Committee, Co- intermediate and low-penetrance alleles . The genetic counselling Chair of the Scientific Panel on Neurogenetics of EAN, Chair of experience with HD helped building our research on psychosocial the European Reference Network on Rare Neurological disorders genetics, improving our protocol and clinical practice, as well as Advisory board . He is also director of the NeuroZentrum Siloah in contributing to the revised international guidelines proposed by Gümligen (Bern) . the EHDN . In the meantime, having begun as a research effort, our lab became fully licensed and accredited (ISO 15189) .” 12:50h Jorge Sequeiros obtained his MD from the Fac . Medicine, Univ . EHDN and Registry/Enroll-HD studies in Porto (1975) and a PhD in Genetics from ICBAS, Univ . Porto Portugal (1990) . He was post-doctoral Fellow in Medical Genetics (1982- Leonor Correia Guedes (Lisbon, Portugal) 1985) at Johns Hopkins Hosp ,. Baltimore . He is Director of the MSc on Genetic Counselling, ICBAS, Univ . Porto and research “How Portuguese patients and families collaborate in global HD group leader of UnIGENe and Director of the Centre for Predic- research and how the European Huntington’s disease network tive and Preventive Genetics (www .cgpp .eu) for clinical and labo- collaborates in clinical care and research in HD in Portugal .“ ratory genetic services at IBMC . He has held numerous positions including founder and first-President (1999-2009) of the College Portuguese Coordinator of the European Huntington’s disease of Medical Genetics, at the Portuguese Medical Association . He Network; Member of the EHDN Scientific and Bioethical advisory has been a member of EHDN (then Euro-HD) since its beginning board; Neurologist at Hospital de Santa Maria, Lisbon, Portugal; in 2003, and organised the 1st meeting of Portuguese-speaking Professor of Neurology, Medical School of the University of study sites (Porto, 2004) . He has been part of the EHDN working Lisbon, Portugal . groups since their first meetings.

13:20h–13:40h 14:50h

Coffee-Break Closing Words GENERAL INFORMATION PAGE 36 / 37

Official Networking Programme & other activities Saturday 16 June

CCL Auditorium I 18:30h

Opening & Welcome Reception Opening Lecture: Welcoming addresses by “Should we concern about ethical limits in neurogenetics?” Joaquim Ferreira, Local Chairperson Alexandre Quintanilha, Porto, Portugal Günther Deuschl, EAN President Musical performance: Honorary Membership Awards Original Fado Guitar Performance by Marta Pereira da Costa Mark Hallett, Bethesda, USA Alistair Compston, Cambridge, UK All participants and exhibitors are invited to the Opening and the Welcome reception afterwards . This year the reception Announcement: will be outside on the plaza in front of the CCL . We are happy Paul Boon, Chair EAN Programme Committee to serve food and cold drinks . Please wear your badge . GENERAL INFORMATION

Official Networking Programme & other activities

13:00-14:30h Jera Kruja, Room Copenhagen Tirana, Albania

Challenges for Women in Neurology Dr Jera Kruja, Professor of Neu- rology, is head of the University Service of Neurology, Faculty of Chairperson: Medicine, University of Medicine Elena Moro (Grenoble, France) and UHC Mother Teresa in Tirana, Albania . She has been The aim of the event is to help identify and overcome the president of the Albanian Society challenges that women can find during their academic and of Neurology and for more than hospital career development in neurology . This event is 20 years the delegate of this chapter and an active member of mainly directed to female neurology residents and female scientific panels of the European Federation of Neurological neurologists at the beginning of their career . Societies (EFNS) and afterward to the European Academy of Neurology. Prof. Kruja was also a member of the Scientific You are invited to bring your lunch to this session . Committee of EAN . Since 2014 she is a member of Teaching Course Committee of the World Federation of Neurology Catherine Lubetzki, (WFN) . She is a Lancet Commissioner for LMIC . Further- Paris, France more, she was a trainer of European Academy of Epilepsy . From 2010-2013 she was the National Health Contact Point, Catherine Lubetzki is Professor European Commission, CORDIS Fp7 programme and she of Neurology at Pierre and Marie was the first Rector of the University of Medicine of Tirana, Curie University and head of Albania . Prof . Kruja is a member of numerous national and the department of neurology international editing boards and speaker in many interna- in Salpêtrière Hospital, Paris, tional meetings . France . She is and/or has been involved in several committees Claudia Trenkwalder, and funding boards, including Kassel, Germany ECTRIMS executive committee and the scientific committee of ARSEP (French multiple sclerosis association for re- Claudia Trenkwalder, MD, search) . Her clinical activity is mainly dedicated to the man- started her clinical education agement of multiple sclerosis patients through the Salpêtrière in neurology and movement multiple sclerosis clinic and clinical research center . She disorders at the University leads a research group in the Brain and Spinal cord Institute Hospital of the Ludwig-Maximil- (ICM), located within the Salpêtrière campus . The research ian-University in Munich in 1988 topic is focused on the cellular and molecular mechanisms and was head of the “Movement involved in central nervous system myelination and remy- Disorders and Sleep” research elination, using different in vitro models as well as in vivo group at the Max- Planck Institute of Psychiatry in Munich approaches and post-mortem analysis . The general aim of the from 1993-2000, before moving to the Department of Clinical research projects is to understand why some multiple sclero- Neurophysiology at the University of Goettingen as Associate sis lesions remyelinate whereas others do not . This with the Professor . She is Medical Director of the Elena Klinik, in perspective of developing, through activation of promoting Kassel, the largest neurological hospital for Parkinson and cues, or suppression of inhibitory pathways, strategies aimed Movement Disorders in Germany, since 2003 . In 2012, she at stimulating endogenous remyelination, hence preventing became Full Professor of Neurology as a Foundation Chair axonal damage and limiting disability progression in Multiple at University Medical Center in Goettingen . Her research Sclerosis patients . interests are early symptoms and therapy in Parkinson disease, movement disorders in sleep such as Rem Sleep Behavior Disorder and Restless Legs Syndrome . She has published more than 365 peer reviewed papers and supports female careers in many ways including mentoring programs at the university site . She has been active in the International Parkinson and Movement Disorder society (IPMDS) for many years and is currently President-Elect of IPMDS, but was also Founding Member of the World Association of Sleep Medicine (WASM), and President of WASM from 2011-13 and active member of many national and international scientific societies GENERAL INFORMATION PAGE 38 / 39

Sunday 17 June

20 .15h

Music Recital at CCL, Auditorium II

A musical Journey from Hamburg to Paris, Vienna, New York and Petrograd with compositions by Georg Philipp Telemann (1681 – 1767), Frederic Chopin (1809 – 1849), Johannes Brahms (1833 – 1897), Gabriel Fauré (1845 – 1924), Antonin Dvorak (1841 – 1904), Dmitri Shostakovich (1906 – 1975) .

This chamber music recital is the third one organised and scheduled at the time of an EAN congress by the neurologists Klaus V . Toyka, Würzburg, and Hannah Cock, London, and pianist Beate Toyka, co-organised by the Faculty Neurology Department of the Lisbon University Hospital .

Participants of the congress are cordially invited to spend an Hannah Cock, Flute Klaus V . Toyka, Violin Beate Toyka, Piano hour of relaxed listening . The tickets are € 15 (€ 10 reduced fee) . GENERAL INFORMATION

Networking Programme & other activities Monday 18 June

13:00h 20 .00-22 .30h

History of Neuroscience Visit to ”Meet your Neurology Network“ the Egas Moniz Museum Museu Nacional de Arte Antiga, Lisbon

The participants of the History of Neuroscience Visit will The meet and greet event will take place in the Museu Nacional be picked up by bus at 13 .00 on Monday, June 18 . All parti de Arte Antiga . Created in 1884 and housed in the Palácio Alvor cipants will arrive at the museum between 13 .15 and 13 .20 . for almost 130 years, the MNAA-Museu Nacional de Arte Antiga Between 14 .45 and 15 .00 the bus will take the participants has had its current title for more than a century . It is the home back to the CCL . to the most important Portuguese public collection of art, rang- ing from paintings to sculpture, and gold and silverware, as well The Museum Egas Moniz is located at the Department of as decorative arts from Europe, Africa and the Far East . Neurology - Hospital Santa Maria (6th floor) in Lisbon. The Hospital Santa Maria is the largest hospital in Portugal, in- Since its foundation, it has been housed at the palace built in the augurated in 1953, it received the heritage of the Department late 17th century at the behest of the first Count of Alvor, after of Neurology of the old School Hospital of Santa Marta where his return from India, where he had served as Viceroy . The Egas Moniz developed his activity as investigator, Head of palace remained in the hands of the family until the mid-18th Department and Chair of Neurology until his retirement in century, when it became the property of a brother of the 1945 . Marquis of Pombal, Paulo de Carvalho, before becoming the As a tribute to the founder of the first department of Neuro residence of a rich diamond logy and Neurosurgery in Portugal and his pioneer work in trader, Dutch consul in Portu- angiography and psychosurgery, an area of the department gal, Daniel Gildemeester, who was dedicated to preserve and display the original instru- sponsored major improvement ments created by him to perform the first angiograms and work to the building’s interior surgical interventions in psychiatric patients, together with spaces . a photo collection, books written by him, and diplomas from numerous international scientific societies. Being a typical example of the Portuguese civil architecture A very important part of the of that period, the palace has a exhibition is a sequence of x rays long façade running parallel to performed during the process to the street . The building has a obtain the first angiograms in highly simple design with the humans and another sequence only decoration being its displaying the use of angiography ornamental baroque doorways . in various pathologies from different types of tumors to The entrance fee is € 25 several vascular abnormalities . (reduced fee € 20) and includes free snacks and drinks, the The original furniture of his entrance to the museum and office was brought from the free guiding through selected areas . old hospital and is also displayed reconstructing its Spartan ambiance . Between 20 00-21. 00h,. 6 guided tours will be made avialable .

The visit is divided in two groups: It is easy to reach from the Congress center by trams number • A visit to the library of the Department (coffee will be served) 714 or 727 (station Rua da Junqueira next to the CCL to Rua • A slide presentation about the life and work of Egas Moniz Presidente Arriaga) or within a 25-minute walk along the river . • A visit to the Museum Location: R . das Janelas Verdes, 1249-017 Lisboa, Portugal website: http://www .museudearteantiga pt/. GENERAL INFORMATION GENERAL INFORMATION

Session Overview Saturday 16 June - Room 0.01 Room 3-Day 3-Day Satellite Session 10:00 - 10:30 Celgene The importance of real world evidence genera tion in Multiple Sclerosis €

€

Room CbW Room CbW 2 CbW 08:30 - 10:00 EAN/EAPC: End-of-life care for neurological patients 14:45 - 16:15 Cases of drophead, camptocormia and axial weakness and related treatment CbW 1 € €

Room HoC Room HoC 1 HoC 2 HoC 14:15 - 16:15 Motor Unit Number Index (MUNIX) and phrenic nerve conduction 16:45 - 18:45 Nerve studies – Level 3studies – Level conduction studies and nerve echography – 1Level

Room Room 16:45 - 18:15 Neuro- OS OS 08:30 -10:00 Ability to drive in neurological disorders 14:45 - 16:15 Movement disorders 1 Copenhagen immunology FW 4 € €

III Auditorium Auditorium cont . TC 2 TC TC 2 TC 08:30 -10:00 Brain health in multiple sclerosis: 14:45 - 18:15 How to proceed with a suspected myopathy? a catalyst for new approach to management 2– Level FW 1 - ePoster sessions12:30-13:15 - ePresentation Sessions13:30-14:15

Room Oslo Room 16:45 - 18:15 Neurogenetics OS SpS 3 08:30 - 10:00 Etiological investiga 14:45 - 16:15 EAN / EFAS: Autonomic dysfunction as early markers in rare and neuro tion of disease: case-control studies degenerative diseases CdS 1 CdS

) break @ exhibition Hall 2 and Foyer A (lunch served from 12:30-13:30 Lunch Room Room Lisbon 16:45 - 18:00 Peripheral nerve disorders 1 OS OS 14:45 - 16:15 Neurological Manifestation 08:30 -10:00 The importance of brain network re-organisation in old age and for successful rehabilitation after stroke of Systemic diseases FW 3 12:30-14:45 12:30-14:45 € €

Room Room Exhibition opening hours Amsterdam cont . 08:30 - 10:00 25 Years of TC 3 TC TC 3 TC 14:45 - 18:15 The diagnoses – old andof ALS new approaches 2 – Level European Journal of Neurology SpS 12 € € Welcome Reception @ CCL plaza 20:00-21:30 Welcome Reception @ CCL

09:30-17:00 09:30-17:00

VIII Auditorium Auditorium 10:30 - 12:30 EAN / EAPC: Palliative care and neurology cont . TC 5 TC SYMP 4 SYMP SAT 5 TC 13:00 - 14:30 Biomarin: 14:45 - 18:15 Acute Turning the tide in misdiagnosis in Myasthenic Syndromes: Increasing the index of suspicion for auto-immune neuromuscular disorders emergencies in neuro muscular 2 disease – Level

Forum Talks | ALNYLAM PHARMACEUTICALS - Acute Hepatic Porphyrias | Scientific Theatre (Exhibition Hall 1) PHARMACEUTICALS Forum Talks | ALNYLAM 16:30-16:45 € € Coffee break @ exhibition Halls 1, 2, 3 and Foyer A Coffee break @ exhibition Halls 1, 10:00-10:30

V Auditorium Auditorium 10:30 - 12:30 EAN / ESO: Cerebral small vessel disease - recent advances and clinical implications 13:00 - 14:30 Zambon: 14:45 - 18:15 Neuroimaging and early 08:30 - 10:00 Biomarkers of neuromuscular disorders cont . TC 4 TC SYMP 3 SYMP SAT 4 TC What’s New in the Management of Quality Life in Parkinson’s Disease? detection of neurological diseases 2 – Level FW 2

Forum Talks | MERCK – Multiple Sclerosis | Scientific Theatre (Exhibition Hall 1) Forum Talks | MERCK – Multiple Sclerosis Scientific 10:15-10:30 II Auditorium Auditorium 16:45 - 18:15 EAN and European involvement in Rare Neurologic Diseases SpS 4 -

Room Berlin Room 08:30 - 10:00 Familial amyloid polyneuropathy: phenotype, genetics, 10:30 - 12:30 EAN / ECTRIMS: Therapeutic challenges in progressive MS 14:45 - 16:15 Digital outcome assessment 16:45 - 18:15 Multiple sclero SYMP 9 SYMP Topical SYMP OS treatment sis and related diseases 1 FW 5

VI Auditorium Auditorium 10:30 - 12:30 Diagnosing 13:00 - 14:30 Roche: theRedefining management of relapsing multiple 14:45 - 16:15 Update in 16:45 - 18:15 EAN Brain SYMP 2 SYMP SAT IaS 2 IaS 9 08:30 - 10:00 EAN / ILAE- New ILAECEA: ofclassification the epilepsies: applicability of new concepts and terminology in clinical practice genetic epilepsies sclerosis & primary progressive multiple sclerosis chronic headache disorders Challenge IaS 1

€ €

Coffee break @ exhibition (Halls 1, 2, 3 and Foyer A) Coffee break @ exhibition (Halls 1, I

Auditorium 16:15-16:45 16:15-16:45 therapies SYMP 1 SYMP 10:30 - 12:30 EAN / MDS-ES: Tauopathies: Pathophysiology, clinical features and experimental SAT When migraine is refractory: New approaches to shape the future of patient care 1 TC 14:45 - 18:15 EAN / MDS-ES: Dystonia – how to recognise and 1 treat – Level 1 TC cont . PLEN 18:30 -20:00 Opening 13:00 - 14:30 Lilly: GENERAL INFORMATION PAGE 42 / 43

Room 0.01 Room patients 3-Day 3-Day Satellite Session 09:30 - 10:00 BrainCelgene: volume loss: From heal thy individuals to Multiple Sclerosis € € €

Room CbW Room 08:00 - 09:30 The process of multiple 15:00 - 16:30 Difficult CbW 4 CbW CbW 5 CbW 16:45 - 18:15 Neurogenetics goes therapy sclerosis diagnosis decisions in treatment of myasthenia gravis CbW 3

€ € Room HoC Room 16:45 - 18:45 Ultrasound in 08:00 - 09:30 Tilt-table testing in neurology and clinical neurophysiology 2 – Level HoC 5 HoC vascular diagnosis 1– Level HoC 3

Room Room 16:45 - 18:15 Neuro-oncology T OS 08:00 - 09:30 Abstract, poster and presentation tips for success at international meetings 15:00 - 16:30 Tournament for neurologists in Training – basic Copenhagen Networking 13:00 - 14:30 Challenges for women in neurology CdS 2 CdS - € € -

III

Auditorium Auditorium cont . TC 10 TC Overflow 10:00 - 12:00 Presidential Symposium SAT TC 10 TC 15:00 - 18:15 Current treat immunology ments in neuro 1 logy – Level New insights in treatment and ofprevention vascular cognitive impairment 18:30 -20:00 Takeda: 08:00 - 09:30 EAN Corres ponding Members of the Mediterranean Area – Clinical Neuro- SpS 7 € € -

Room Oslo Room cont . 15:00 - 18:15 The neurological bedside exami TC 19 TC TC 19 TC nation – the art of identifying pathology – 1Level SpS 6 08:00 - 09:30 Resident and Research Fellow Section learn about clinical work and research

ePoster Sessions & ePresentation Sessions

Room Room Lisbon 12:30-13:15 12:30-13:15 16:45 - 18:15 Epilepsy OS 08:00 - 09:30 in spaceLost – clinical and neurobiological aspects of 15:00 - 16:30 Cerebrovascular diseases 1 OS topographagnosia FW 10 FW 13:30-14:15 13:30-14:15

€ € - -

ific Theatre (Exhibition Hall 1) Forum Talks | BIOGEN - Progressive supranuclear palsy Scient ific 16:15-16:30

Room Room Exhibition opening hours Amsterdam cont . 15:00 - 18:15 Clinical neuro TC 7 TC 08:00 - 09:30 Impact of technology in neuro- TC 7 TC rehabilitation physiology in neuro-rehabili 2tation – Level FW 8 € € ) from 12:00-13:00 break @ exhibition Hall 2 and Foyer A (lunch served Lunch

09:30-17:00 09:30-17:00 VIII Auditorium Auditorium cont . 15:00 - 18:15 New insights in the management of patients with ischaemic stroke or TIA – Level 2 08:00 - 09:30 geneticNovel intechniques neurological practice – time for responsible clinical and research 13:00 - 14:30 Biogen: TC 9 TC SAT TC 9 TC implementation Bringing hope for adults with Spinal Muscular Atrophy FW 9 12:00-15:00 12:00-15:00

Coffee break @ exhibition Halls 1, 2, 3 and Foyer A Coffee break @ exhibition Halls 1, 09:30-10:00

V Auditorium Auditorium 17:15 - 18:15 Miscellaneous 1 SpS 10 SAT 08:00 - 09:30 Neurological disorders of 15:00 - 16:30 Clinical Grand Rounds famous composers SAT 13:00 - 14:30 Novartis: Management of Seizures in Pediatric Patients with Tuberous Sclerosis Complex 18:30 -20:00 Alnylam: Connecting the Dots – Diagnosing and Identifying hATTR Amyloidosis OS SpS 5

Forum Talks | MERCK – Multiple Sclerosis Scientific Theatre ( Exhibition Hall 1) 09:45-10:00 € € - Forum Talk | ALNYLAM PHARMACEUTICALS - Acute Hepatic Porphyrias | Scientific Theatre (Exhibition Hall 1) PHARMACEUTICALS - Acute Hepatic Porphyrias | Scientific Forum Talk | ALNYLAM

II Auditorium Auditorium 10:00 - 12:00 Presidential Symposium 15:00 - 18:15 Tips and tricks in diagnosing headache 08:00 - 09:30 Epilepsy surgery hasin 2018: anything chan cont . Overflow 8 TC TC 8 TC ged in the last decades? disorders – 1 Level FW 7 09:30-09:45 € € Coffee break @ exhibition Halls 1, 2, 3 and Foyer A Coffee break @ exhibition Halls 1, Room Berlin Room 15:00 - 18:15 Update on MS treatment – 2Level 08:00 - 09:30 EAN / MDS-ES: Management of Parkinson’s disease in non-routine circumstances TC 6 TC TC 6 TC cont . FW 6 - - 16:15-16:45

Auditorium Auditorium 13:45 - 14:45 Bial: 15:00 - 16:30 How to diagnose acute vertigo and acute double vision 18:30 -20:00 SAT SAT IaS 4 SAT 08:00 - 09:30 EAN/ESO: Treatment decisions in some difficult scenarios of acute ischemic stroke derstanding of the MS disease continuum: a decade of change Management of Parkinson’s fromdisease: science to clinical wisdom Merck: Foundation and Innovation in Multiple Sclerosis treatment – avoiding conti nuous immuno suppression 12:15 - 13:15 OurNovartis: evolving un IaS 3

Auditorium PS 10:00 - 12:00 Presidential Symposium SAT SAT 13:45 - 14:45 Genzyme: Sanofi Demand more from life with Multiple Sclerosis #WomeninMS SpS 1 15:00 - 17:00 MDS-ES: European Basal Ganglia Club SAT 18:30 -20:00 It’sNovartis: time to Act on HowMigraine: can we manage the unmet needs? 12:15 - 13:15 Abbvie: Optimising care in Advanced Parkinson’s Why,disease: and how when, GENERAL INFORMATION

Session Overview Monday 18 June

Room 0.01 Room 3-Day 3-Day Satellite Session 09:30 - 10:00 Celgene Drug sequencing through platform and oral Whattherapies: should be done? €

€ Room CbW Room CbW 6 causing epilepsy CbW 7 CbW 08:00 - 09:30 Antibodies 15:00 - 16:30 Rare headache syndromes: idiopathic or symptomatic? € € € Room HoC Room HoC 6 HoC 7 HoC 08:00 - 09:30 Interpreting MRI in practice – 2Level HoC 4 HoC 15:00 - 16:30 Neuro-otology – 2 Level 16:45 - 18:45 Basic EMG – needle EMG and transcranial magnetic stimulation as an electro-diagnostic 2tool – Level

Room Room Copenhagen SpS 9 08:00 - 09:30 EAN / EBC The ValueEFNA: of Treatment of brain(VoT) disorders OS 15:00 - 16:15 Ageing and dementia 16:45 - 18:15 Sleep disorders OS ePoster Sessions & ePresentation Sessions

12:30-13:15 12:30-13:15 Room Oslo Room 13:30-14:15 13:30-14:15

FW 16 FW medicine in stroke 08:00 - 09:30 Precision 15:00 - 16:30 Tournament for neurologists in training - clinical 16:45 - 18:15 Multiple sclerosis and related disorders 2 T OS - € €

Room Lisbon Room SpS 8 Neurology – fromLessons Portuguese clinical neurosciences 14 TC 2gnosis– Level cont . 08:00 - 09:30 History of TC 14 TC 15:00 - 18:15 How to approach a patient with fromneuropathy: symptoms to dia

Room Room Amsterdam FW 15 FW Controversy 1 Controversy neurology + neuropsychology 08:00 - 09:30 Guillain-Barré NewSyndrome: developments in immunology, electrophysiology and treatment 15:00 - 16:30 Steroids in neuroinfections & Seizures and epileptiform discharges OS 16:45 - 18:15 Cognitive

€ € Exhibition opening hours 20:30-22:30 Networking Event

VIII ) from 12:00-13:00 break @ exhibition Hall 2 and Foyer A (lunch served Lunch Auditorium Auditorium FW 14 FW SAT based medicine and beyond in neuropsychiatric complications of Parkinson’s diseases 08:00 - 09:30 EAN / MDS-ES: Evidence- 13:00 - 14:30 The roleTeva: of CGRP in themigraine: latest clinical evidence and its implications in the new era of biologics TC 13 TC 13 TC 15:00 - 18:15 New concepts in critical care of stroke patients – 3Level cont . 09:30-17:00 09:30-17:00 € €

12:00-15:00 12:00-15:00 Coffee break @ exhibition Halls 1, 2, 3 and Foyer A Coffee break @ exhibition Halls 1, 16:15-16:45 Coffee break @ exhibition Halls 1, 2, 3 and Foyer A Coffee break @ exhibition Halls 1, 09:30-10:00 Auditorium V Auditorium FW 13 FW TC 12 TC 12 TC encephalitis in the Intensive Care Unit (ICU) SAT 13:00 - 14:30 Sanofi Genzyme: tales ofLatest the unexpected: Illuminating the path to earlier diagnosis in muscle diseases 15:00 - 18:15 EAN / ILAE- HowCEA: to approach EEG and avoid inover-reading 1epilepsy – Level 08:00 - 09:30 Autoimmune cont .

€ €

Forum Talks | MERCK – Multiple Sclerosis Scientific Theatre ( Exhibition Hall 1)09:45-10:00 Forum Talks | BIOGEN – Alzheimer’s disease | Scientific Theatre (Exhibition Hall 1) disease | Scientific 09:30-09:45 Forum Talks | BIOGEN – Alzheimer’s II Auditorium Auditorium FW 12 FW TC 11 TC 11 TC Parkinson’s 2disease – Level Overflow 10:00 - 12:00 Molecular and genetic therapies for neurogenetic disorders 08:00 - 09:30 Neurogenetic avenues and new directions on risk factors in dementia 15:00 - 18:15 EAN / MDS-ES: Evidence-based medicine in the treatment disabling motor and non-motor trouble in cont . - Room Berlin Room FW 11 FW SYMP 6 SYMP OS vention – hype or hope? 08:00 - 09:30 CGRP inhibition for migraine pre 15:00 - 17:00 Neuro Coma: modulation, imaging and neurobiology 17:15 - 18:30 Motor neurone diseases

VI Auditorium Auditorium IaS 5 SAT SAT IaS 6 OS 08:00 - 09:30 Diagnostic pitfalls in neuromuscular disease The journey continues … New Evidence for Pharmacological Treatment in Post-Stroke Recovery 15:00 - 16:30 Not every twitch or movement is a seizure in the neurological ICU 12:15 - 13:15 The newBiogen: EAN / ECTRIMS Multiple Sclerosis guidelines . 13:45 - 14:45 Everpharma: 16:45 - 18:15 Cerebrovascular diseases 2

Auditorium PS 10:00 - 12:00 Molecular and genetic therapies for neurogenetic disorders SAT 12:15 - 13:15 AmyloidAkcea: transthyretin (ATTR) amyloidosis: One disease, many symptoms SAT 13:45 - 14:45 Celgene: The ideal real world in Multiple Sclerosis care – a permanent clinical trial? 5 SYMP 15:00 - 17:00 The spectrum of dementias OS 17:15 - 18:15 Peripheral nerve disorders 2 GENERAL INFORMATION PAGE 44 / 45

3DS 3-Day Satellite Session FW Focused Workshop PLEN Plenary Symposium TC Teaching Course Overarching Theme CdS Career development Session HoC Hands-on Course SAT Satellite Symposium T Tournament € Chargeable CbW Case-based Workshop IaS Interactive Session SpS Special Session CONT Controversy OS Oral Session SYMP Symposium NET Networking Tuesday 19 June € € Room CbW CbW 8 CbW 9 13:00 - 14:30 Challenging cases of infections the nervous system 08:30 - 10:00 Imaging selection of stroke patients for treatmentspecific interventions

Room Separate registration fees apply for: Copenhagen OS disorders 2 08:30 - 10:00 Movement Teaching Courses = 50€ / 30€ reduced fee € € Hands-on Courses = 50€ / 30€ reduced fee

Case-based Workshops = 50€ / 30€ reduced fee

Auditorium III Auditorium TC 18 TC 18 OS medicine – Level 1medicine – Level 13:00 - 16:30 Basics of sleep cont. neuromuscular junction diseases 08:30 - 10:00 Muscle and 10:30 - 12:30 Highlights Overflow Room Oslo OS 08:30 - 09:45 Miscellaneous 2

Room Lisbon SpS 11 migration and neurological disorders 08:30 - 10:00 Population, € €

Room Exhibition opening hours Amsterdam TC 17 TC 17 OS 13:00 - 16:30 Advanced neuro-sonology 3– Level cont. 08:30 - 10:00 Headache and pain

09:30-13:30 Lunch break @ exhibition Hall 2 and Foyer A (lunch served from 12:30-13:30 break @ exhibition Hall 2 and Foyer A (lunch served Lunch ) 14:30-15:00VI + ePoster Area Coffee break near Auditorium Coffee break @ exhibition Halls 1, 2, 3 and Foyer A 10:00-10:30 Coffee break @ exhibition Halls 1, Auditorium VIII Auditorium Controversy 2 Controversy the diagnosis of Alzheimer’s disease & in the treatment of Multiple Sclerosis 13:00 - 14:30 Controversies in 08:30 - 10:00 Drug development and clinical trials in neurology CdS 3 12:30-13:30 € €

II Auditorium TC 16 TC 16 disorders – Level 2disorders – Level cont. 10:30 - 12:30 Highlights 13:00 - 16:30 Autoantibodies in neurological Overflow Room Berlin 08:30 - 10:00 Is it a vasculitis or not? IaS 8 € €

Auditorium VI Auditorium TC 15 TC 15 cont. 13:00 - 16:30 The “difficult to treat” headache 3patient – Level molecular characterisation and personalised therapies in brain tumors 08:00 - 10:00 Advances in SYMP 8 SYMP

Auditorium PS 10:30 - 12:30 Highlights and Breaking News IaS 7 13:00 - 14:30 EAN / MDS-ES: Mixed movement what dodisorders: we see and how do we approach? 08:00 - 10:00 A new look in neuropathogenesis of multiple sclerosis SYMP 7 SYMP FINAL PROGRAMME SCIENTIFIC PROGRAMME PAGE 46 / 47

Scientific Programme

4th Congress of the European Academy of Neurology

June 16 – 19 FINAL PROGRAMME SCIENTIFIC PROGRAMME PAGE 48 / 49

Saturday 16 June 2018 SCIENTIFIC PROGRAMME

08:30 – 10:00 08:30 – 10:00 08:30 – 10:00 Room CbW Room Oslo Auditorium VI

Case-based Workshop 1: EAN/ Career development Session 1: Interactive Session 1: EAN/ EAPC: End-of-life care for Etiological investigation of ILAE-CEA: Classification of neurological patients disease: case-control studies the epilepsies: old wine in new skins?

Chairperson: Chairperson: David Oliver (Canterbury, UK) Maura Pugliatti (Ferrara, Italy) Chairperson: Tim J von Oertzen (Linz, Austria) • Ventilation and gastrostomy in ALS at • Problems with the investigation of the end of life disease etiology • Classifications of seizure types Idris Baker (Swansea, UK ) Pierre-Marie Preux (Limoges, France) Tim J von Oertzen (Linz, Austria)

• Coping with patient/ family/ team • Structure and pitfalls of the case- • Terminology of seizure types distress at the end of life control studies Philippe Ryvlin (Lausanne, Switzerland) Peter Zepper (Salzburg, Austria) Maura Pugliatti (Ferrara, Italy) • Classification of epilepsies • Difficult discussions at the end of life • Statistical methods in case-control Eugen Trinka (Salzburg, Austria) Orla Hardiman (Dublin, Ireland) studies Derrick Bennett (Oxford, UK) Educational content: Educational content: A new concept of classification of epilepsies, As a patient with progressive neurological Educational content: seizure types and terminology were recently disease deteriorates and comes to the end Case-control studies represent the common- published by the ILAE. This session will dis- of life, there are increasing issues to be est study design for the investigation of the cuss the transition of the new classification discussed: etiology of a disease. Although case-control into clinical practice. The talks will summa- • Awareness of the issues regarding the studies can be easily run and are the only rise the main idea and structure of the new decisions as to continue or withdraw way to investigate rare diseases, they are classification, the discussion will focus on the treatment, such as ventilation or affected by a number of confounders that clinical applicability and its challenges. gastrostomy feeding must be controlled at the planning and • Awareness of the need for discussions analysis stage. The participation to this Please download the app “EAN Congress” to with patient and family about the disease course will consent the participants to learn actively participate in this Session and vote. deterioration and helping them to plan the indications, basic structure and pitfalls ahead of this study design. Some basic statistical • Awareness that the discussion within principles will be offered for the conduction teams can be difficult, as members cope and interpretation of case-control studies. with the issues differently, potentially leading to conflict • Awareness and ideas as to the possible ways of lead discussions about end of life, including the discussion of what to expect at the end of life, the fears that patients and families may have, preparations for the care at the end of life, consideration of hastened death

All these areas will be considered with opportunities for discussion of these difficult issues – practically and ethically.

Limited to 60 participants. Please register separately – additional fees will apply. SCIENTIFIC PROGRAMME PAGE 50 / 51

Saturday 16 June 08.30 – 10.00

08:30 – 10:00 08:30 – 10:00 08:30 – 10:00 Auditorium III Auditorium V Room Lisbon

Focused Workshop 1: Brain Focused Workshop 3: The health in Multiple Sclerosis: a Focused Workshop 2: importance of brain network catalyst for a new approach to Biomarkers of neuromuscular reorganisation in old age and management disorders for successful rehabilitation after stroke

Chairperson: Chairperson: Gavin Giovannoni (London, UK) Corrado Angelini (Venice, Italy) Chairperson: Paolo Maria Rossini (Rome, Italy) • Treating-2-target: the case for maximi- • Micro-RNA in muscular dystrophies sing brain health in MS Corrado Angelini (Venice, Italy) • Methods of directly interacting with Gavin Giovannoni (London, UK) brain function • Inflammatory neuropathies and Walter Paulus (Göttingen, Germany) • The economic cost of MS in Europe antibodies Gisela Kobelt (Mulhouse, France) Luis A Querol Gutierrez (Barcelona, Spain) • The importance of shifting our models of the effects of NIBS from producing • Translating recommendations for • Mitochondrial disorders and pure excitation or inhibition of target improving MS care into improved out- biomarkers structures to considering the wider comes Rita Horváth (Newcastle, UK) network effects Jeremy Hobart (Plymouth, UK) John C. Rothwell (London, UK)

Scientific content: • Connectivity disturbances in stroke Scientific content: The scientific content of the focused work- as revealed by integrated multimodal Treating to target is an approach that has been shop is intended to highlight the biomarkers neuroimaging by fMRI, EEG and TMS- successfully adopted in several therapeutic areas; in neuromuscular disorders, neuropathies EEG owing to recent advances in treatment, this is now and mitochondrial diseases, since the Paolo Maria Rossini (Rome, Italy) also a realistic goal for the clinical management follow-up of these disorders could be better of Multiple Sclerosis (MS). Early diagnosis and performed by clinicians if they follow not treatment of MS could improve outcomes for only by clinical examination but also by spe- Scientific content: patients. MS Brain Health is thus promoting a cific molecular biomarkers in future clinical Non-invasive brain stimulation (NIBS) is strategy to maximise lifelong brain health by trials to treat these disorders. available to many neurology and psychiatry minimising delays in the care pathway. The focus departments nowadays but its use for inter- of MS management is indeed shifting towards action with brain circuitry in many neurolog- early diagnosis and intervention; this has been as- ical and psychiatric conditions is not much sociated with changes in the drivers of the costs of more than empirical. The course will focus care. We present the results of a large European on discussing the effects of brain stimulation study, which assesses differences in the burden of and especially viewing these effects on a wide illness between countries. Understanding these network, not just focusing on a single effect between-country differences is crucial in order to on a certain brain site or function. This will evaluate the potential economic impact of future be specially focused on stroke and the infor- changes in MS care. To change existing practice, mation obtained by using electrophysiologi- however, it is necessary to define measures cal and neuroimaging techniques together. relating to ‘early’ diagnosis and treatment, so as to provide a benchmark that MS service providers can use for comparison. A modified Delphi process that involved experts from over 20 countries was conducted to define standards for the timing of key steps in the MS care pathway. The results of the process and these new consensus standards will be presented at the workshop. Participants in the workshop will be invited to put forward and discuss suggestions for implementing and measuring these standards in clinical practice. SCIENTIFIC PROGRAMME

08:30 – 10:00 08:30 – 10:00 08:30 – 10:00 Room Copenhagen Room Berlin Room Amsterdam

Special Session 12: 25 Years Focused Workshop 4: Ability to Focused Workshop 5: Familial of European Journal of drive in neurological disorders amyloid polyneuropathy: Neurology – History, future phenotype, genetics, and how to prepare your paper treatment for publication Chairperson: Johannes Mathis (Bern, Switzerland) Chairperson: Chairperson: Teresa Coelho (Porto, Portugal) Anthony Schapira (London, UK) • Fitness to drive in sleepy patients Johannes Mathis (Bern, Switzerland) • 60 years of transthyretin familial • History: the Editor-in-Chief’s view amyloid polyneuropathy in Europe: Anthony Schapira (London, UK) • Fitness to drive after the first epidemiology, clinical presentation and epileptic seizure genetic basics • Future: the publisher’s view Tony Marson (Liverpool, UK) Teresa Coelho (Porto, Portugal) Silvana Losito

• Fitness to drive after stroke • The course and prognostic factors • “How to prepare a scientific paper for Catarina Lundberg (Stockholm, Sweden) Laura Obici (Pavia, Italy) publication” Pertti Saloheimo (Espoo, Finland) • Recent advances in therapy Scientific content: Isabel Conçeicão (Lisbon, Portugal) Permission to drive is of great importance in Scientific Content: all patients, but because of accident risk due In this session, special attention to 25 years to disease this stands in conflict with public Scientific Content: of the European Journal of Neurology (EJN) safety. Physicians will be more and more Familial Amyloid Polyneuropathy first will be given. The editor-in-chief will give responsible, not only to diagnose and treat described in Portugal by Andrade in 1952, is an insight into how we review and handle patients, but also to achieve driving rehabili- no longer just a rare neuropathy. Nowadays papers, the publisher will outline how things tation, to consult patients on their individual ATTR amyloidosis is recognised as a complex have changed over 25 years and what the driving risks including the legal situation systemic disease, distributed worldwide. future of journal publishing holds. Particular and to decide if fitness to drive cannot be It can be related to the presence of TTR knowledge on how to prepare your scientific attested. mutations or simply to the aging process. paper for publication will be shared by one of A large genotype and phenotype variability the EJN’s associate-editors. is increasingly recognised but it’s always a severe, progressive and ultimately fatal disease. Misdiagnosis is a major problem. Several disease-modifying therapies are presently available, and others are under development. They have changed signifi- cantly the quality of life and survival of many patients. The presenters of this focused workshop work in three European Reference Centres for ATTR amyloidosis and will present data on genetic aspects, epidemiology, clinical presentation, progression, prognostic factors and recent advances in therapy. SCIENTIFIC PROGRAMME PAGE 52 / 53

Saturday 16 June 10.30 – 12.30

10:30 – 12:30 10:30 – 12:30 10:30 – 12:30 Auditorium I Auditorium VI Auditorium V

Symposium 3: EAN/ESO: Symposium 1: EAN/MDS-ES: Symposium 2: Diagnosing Cerebral small vessel disease Tauopathies: pathophysiology, genetic epilepsies - recent advances and clinical clinical features and experi- implications mental therapies Chairpersons: Reetta K. Kälviäinen (Kuopio, Finland) Chairpersons: Chairpersons: Hannah Cock (London, UK) José Ferro (Lisbon, Portugal) Carlo Colosimo (Terni, Italy) Hugh Markus (London, UK) Isabelle Le Ber (Paris, France) • Is epilepsy a genetic disease? Simon D. Shorvon (London, UK) • “Occult” SVD on an MRI scan: what • Tau protein in normal and pathological does it mean and what should I do? brain • Molecular diagnosis in genetic Stéphanie Debette (Paris, France) Tiago F. Outeiro (Goettingen, Germany) epilepsies: why we need to test Sarah Weckhuysen (Antwerpen, Belgium) • New insights into what causes • The spectrum of frontotemporal SVD- and treatment implications dementias • New therapeutic strategies in Hugh Markus (London, UK) Isabelle Le Ber (Paris, France) development for the genetic epilepsies José M. Serratosa (Madrid, Spain) • Cognitive impairment in • Progressive supranuclear palsy and SVD- mechanisms and management corticobasal degeneration: one disease • Whole exome sequencing (WES) Frank-Erik de Leeuw (Nijmegen, or two Reetta K. Kälviäinen (Kuopio, Finland) The Netherlands) Carlo Colosimo (Terni, Italy)

• Emerging disease-modifying treat- Scientific content: Scientific content: ments for tauopathies Epilepsy is a common neurological disease, Cerebral Small Vessel Disease (SVD) causes a Guenter U. Hoeglinger (Munich, and there might be a genetic basis in almost quarter of all strokes, being directly respon- Germany) half of the people with epilepsy. The diag- sible for lacunar stroke and also contributing nosis of genetic epilepsies makes the patient to intracerebral haemorrhage. It is also the assured of the reasons of his/her seizures and most common cause of vascular cognitive im- Scientific content: avoids unnecessary, expensive, and invasive pairment, and increasing evidence suggests Clinical features and diagnosis strategy investigations. Last decade has shown tre- it may increase the risk that someone with would be presented in the first part of each mendous growth in gene sequencing technol- Alzheimer’s pathology presents with clinical lecture (didactic) and potential therapeutic ogies, which have made genetic tests available dementia during life. Despite its importance new strategies could be presented (including at the bedside. Whole exome sequencing is there is much we do not understand about treatments that have been proposed and now being routinely used in the clinical set- it clinically and there are limited treatment have no effects) in the second part. ting for making a genetic diagnosis. Genetic options. This symposium will update attend- testing not only makes the diagnosis but ees on a number of important advances in also has an effect on the management of the the field. It will start with new data on what patients, for example, the role of aggravating incidental findings of SVD e.g. white matter sodium channels blockers in SCN1A-Dravet hyperintensities and microbleeds, which are syndrome patients and usefulness of ketogen- often found incidentally on MRI scans mean ic diet therapy in SLC2A1-generalised epilepsy in terms of patient risk. This is followed by patients. The purpose of this symposium is to new insights into what causes SVD and what give an overview in this direction and encour- implications these may have for treatment. age the clinicians to start considering genetic The symposium concludes with an update on testing as an important investigation along what causes cognitive decline in this patient with EEG and magnetic resonance imaging group. for better understanding and management of epilepsy in their patients. However, we will also discuss the important potential social implications of the genetic findings, which should not be forgotten. FINAL PROGRAMME

Saturday 16 June 10.30 – 16.15

10:30 – 12:30 10:30 – 12:30 14:15 – 16:15 Room Berlin Auditorium VIII Room Berlin

Symposium 9: EAN/ECTRIMS: Symposium 4: EAN/EAPC: Therapeutic challenges in Palliative care and neurology CME Topical Symposium: progressive Multiple Sclerosis Digital outcome assessment

Chairpersons: Chairpersons: Phil Larkin (Dublin, Ireland) Chairpersons: Per Soelberg Sørensen Paul Boon (Ghent, Belgium) Ludwig Kappos (Basel, Switzerland) (Copenhagen, Denmark) Jochen Klucken (Erlangen, Germany) David Miller (London, UK) • Palliative care from a neurologist’s perspective: the evidence • Digital outcome assessment in Multiple • Pathological concepts of David Oliver (Canterbury, UK) Sclerosis progressive MS Ludwig Kappos (Basel, Switzerland) Christine Stadelmann • Guidelines in progress across Europe (Göttingen, Germany) Raymond Voltz (Cologne, Germany) • Digital outcome assessment in epilepsy Sandor Beniczky (Dianalund, Denmark) • Understanding progression: the • What can a neurologist learn from contribution of clinical trials and palliative care specialists? • Digital outcome assessment in natural history studies Simone Veronese (Turin, Italy) Parkinson’s disease Jaume Sastre-Garriga (Barcelona, Spain) Jochen Klucken (Erlangen, Germany)

• Present and future treatment options Scientific content: in progressive MS Results of recent research on the effective- Scientific content: Tobias Derfuss (Basel, Switzerland) ness of palliative care in neurology/new Besides patient-reported outcomes objective evidence-based guidelines developed. outcome measures reflective of new diagnostic • Who and how to treat progressive MS and therapeutic techniques are becoming Giancarlo Comi (Milan, Italy) increasingly important in neurological conditions. In this session digital outcome measures in MS, epilepsy and Parkinson’s Scientific content: disease will be discussed in detail. This is The pathological features of progressive particularly relevant to innovation driven MS and insight into the factors that drive clinical practice. progression of disability based on pathophy siological concepts (mitochondrial failure, This symposium is supported by an ectopic expression of ion channels, virtual educational grant from Roche. hypoxia, compartmentalized inflammation, microglial activation) will be summarised in the first talk. In the second talk, the clinical definition of progressive MS, epidemiology of progressive MS, time course and quality of disability development in progressive MS, contributing factors for progression (small vessel disease, neurodegeneration, environmental factors, e.g. smoking, infections) will be described. Then clinical trials on progressive MS, concept of immunomodulation versus neuropro- tection/remyelination will be presented. In the last talk, the practical aspects of treatment of progressive MS will be highlighted: which patients might profit most, how to monitor treatment, when to stop treatment. FINAL PROGRAMME

PAGE 56 / 57

Saturday 16 June 14.15 – 16.15

14:15 – 16:15 entific attention over the past few years and 14:45 – 16:15 Room HoC are at the forefront of ALS research. Their Room CbW potential application in future clinical trials Hands-on Course 1: Motor Unit fuel the interest about these techniques. Number Index (MUNIX) and This course will focus on practical issues. Case-based Workshop 2: phrenic nerve conduction Participants will understand the applicability Cases of drophead, studies - Level 3 and limitations of these methods. Partici- camptocormia and axial pants will apply the methods at each other. weakness and related MUNIX will be performed on APB, ADM, treatment Chairperson: FDI, Biceps, TA, EDB. After the course Markus Weber (St. Gallen, Switzerland) attendees will be able to make high quality and reliable MUNIX measurements and Chairperson: • Introduction: MUNIX - a progression CMAP recordings of the diaphragm. John Vissing (Copenhagen, Denmark) marker of motor neuron loss Participants will be ready to apply these Markus Weber (St. Gallen, Switzerland) techniques in their centres, in particular in • Drophead syndrome future clinical trials in ALS. Roberto Massa (Rome, Italy) • Introduction: Phrenic nerve conduction studies Limited to 60 participants. Please register • Camptocormia Mamede Alves de Carvalho separately – additional fees will apply. Heinz Reichmann (Dresden, Germany) (Lisbon, Portugal) This course is supported by NATUS Medical • Axial weakness • Device 1 – MUNIX – UL muscles – Inc. John Vissing (Copenhagen, Denmark) 20 minutes Markus Weber (St. Gallen, Switzerland) Educational content: • Device 2 – MUNIX – Biceps – The workshop is directed towards the 20 minutes diagnostic utility of recognising different Christoph Neuwirth causes and mechanisms of “drop head”, (St. Gallen, Switzerland) camptocormia and axial weakness related to a differential diagnosis in neuromuscular • Device 3 – MUNIX – LL muscles – disorders and other neurological conditions. 20 minutes Treatment or management should be part of Sanjeev Nandedkar the presentation. (Hopewell Junction, USA) Limited to 60 participants. Please register • Device 4 - phrenic nerve conduction – separately – additional fees will apply. 20 minutes Mamede Alves de Carvalho (Lisbon, Portugal)

Educational content: Objective markers of disease progression in ALS clinical trials are urgently needed. Weakness in ALS is mostly dependent on lower motor neuron loss. Force evaluation depends on patient cooperation and fatigue. This is also true for respiratory tests; in addition, bulbar patients do not perform well due to weak facial muscles. Quantification of motor unit loss by means of MUNIX has the great advantage that this measure directly reflects the underlying pathology. Likewise, phrenic nerve conduction studies will not only objectively reveal diaphragmatic function but also provides prognostic information. Both methods have gained a lot of sci- SCIENTIFIC PROGRAMME

14:45 – 16:15 with establishing the correct diagnosis and 14:45 – 16:15 Auditorium VI creating a multimodal treatment plan to im- Room Oslo prove function and well-being. With proper Interactive Session 2: Update comprehensive treatment, the condition in chronic headache disorders improves in most patients. Special Session 3: EAN/EFAS: The aim of the course is familiarising neuro Autonomic dysfunction as logists in training how to recognize chronic early markers in rare and Chairperson: headache disorders one from another and to neurodegenerative diseases Anish Bahra (London, UK) develop strategies to approach the problem.

• Chronic migraine Please download the app “EAN Congress” to Chairperson: Julio Pascual (Santander, Spain) actively participate in this Session and vote. Gregor Wenning (Innsbruck, Austria)

• Medication overuse headache • Preclinical target discovery in MSA: Rigmor Jensen (Glostrup, Denmark) pitfalls and how can we avoid them Gregor Wenning (Innsbruck, Austria) • Chronic daily headache Anish Bahra (London, UK) • Biomarkers in MSA, a prerequisite for disease modification Alessandra Fanciulli (Innsbruck, Austria) Educational content: Participants will learn how to diagnose • Can autonomic dysfunction different- chronic headache disorders according to the iate early neurodegenerative diseases IHS classification and how to apply eventual including dementia, Parkinson and further investigations and treatment strat- MSA? egies. Although chronic migraine is a com- Walter Struhal (Tulln, Austria) mon disorder that severely impacts patient functioning and quality of life, it is usually • Autonomic dysfunction in hereditary underdiagnosed, and treatment responses sensory and autonomic neuropathies often remain poor even after diagnosis. In and Fabry‘s disease addition, effective treatment options are Max Hilz (Erlangen, Germany) limited due to the rarity of randomised controlled trials involving such patients.In the present course pharmacological, non-phar- Session Content: macological, treatment options for chronic Central and peripheral autonomic structures migraine will be discussed. are compromised early in a number of Medication overuse headache is a common neurodegenerative diseases. Autonomic and disabling headache disorder. It has a dysfunction is of considerable interest to be prevalence of about 1-2 % in the general employed as early biomarkers. Knowledge on population. The International Classification the evaluation of autonomic nervous system of Headache Disorders 3rd edition (beta however is not widely taught due to a lack version) has defined MOH as a chronic of autonomic experts in Europe. This SPS headache disorder with clearcut diagnositic discusses available early autonomic biomark- criteria Chronic daily headache is a challeng- ers on three manageable entities: dementia ing condition to treat and it is often accom- patients, Fabry’s disease and synucleinopa- panied by significant comorbidities, such as thies. Multiple system atrophy (MSA) is an chronic fatigue, depression, anxiety and in- adult-onset, fatal neurodegenerative disease somnia, which further complicate treatment. presenting with progressive autonomic fail- Unrealistic expectations of treatment goals ure, parkinsonian, cerebellar and pyramidal can lead to patient frustration and, as a re- features in various combinations. Up to date sult, decrease treatment adherence. Patients only symptomatic therapy is available. often desire headache-free status, but this Several considerations may account for the outcome is not realistic for many patients. By therapeutic failure of many current trials: contrast, an effective treatment goal starts currently available MSA preclinical testbeds may not reflect the complexity of human MSA pathology; preclinical interventional SCIENTIFIC PROGRAMME PAGE 58 / 59

Saturday 16 June 14.45 – 18.15

protocols may be substantially different from 14:45 – 18:15 14:45 – 18:15 human ones; a putative neuroprotective Auditorium I Auditorium III compound might be effective in early, or pre-clinical, disease stages only. Teaching Course 1: EAN/ Teaching Course 2: How to In the present session, the speakers will MDS-ES: Dystonia - how to proceed with a suspected focus on the role of oligodendroglial dysfunc- recognise and treat - Level 1 myopathy? - Level 2 tion, synuclein aggregation and mitochondrial failure in the pathogenesis of MSA and their role in testbed modelling, as well as Chairperson: Chairperson: pre-clinical target discovery. Early clinical, Marie Vidailhet (Paris, France) Antonio Toscano (Messina, Italy) autonomic, imaging and wet MSA-biomarkers and predictors of progression. Pitfalls • Inherited familial forms of dystonia • How to proceed with elevation of of concluded RCTs and solutions how to Christine Klein (Lübeck, Germany) serum CK overcome them in ongoing RCTs. Juan J Vilchez (Valencia, Spain) The audience will learn on evaluation and in- • Generalised dystonia terpretation of autonomic results and fitting Marie Vidailhet (Paris, France) • Bioenergetic failure in muscle disorders those data into diagnosis and management of Antonio Toscano (Messina, Italy) early neurodegenerative disease. • Focal dystoniae Alberto Albanese (Milan, Italy) • Clinical relevance of autoantibodies in MDs clinical practice • Functional dystonias and fixed Benedikt Schoser (Munich, Germany) dystonias Kailash Bhatia (London, UK) • How to deal with myotonic disorders Guillaume Bassez (Paris, France) Educational content: The phenomenology and classification Educational content: of dystonia will be presented. For each Myopathies are a heterogeneous group sub-type of dystonia, clinical features, of rare disorders where skeletal muscle is diagnosis strategy and illustrative cases will primarily compromised. These disorders be detailed. The value of genetic testing and are relatively rare and may show a wide the nomenclature of genetic forms will be range of symptoms at infancy, childhood or discussed. A general overview of treatments, adulthood. More recently, increased aware- then a case-based discussion on each ness, detailed characterisation of the clinical particular treatment and indication (limits spectrum and improved diagnostic workup and adverse effects) will be done (including have made it easier to recognize these special focus on specific forms such as the clinical entities although this is still chal- Dopa-responsive dystonia group. Differential lenging either in infantile or in adult cases. diagnosis and look-alike will be discussed. Innovative diagnostic techniques such as use Current concepts on pathophysiology will be of new released autoantibodies, biochemical briefly exposed. The sub-group of functional approaches or molecular genetic methods dystonias and fixed dystonia, diagnosis crite- as NGS (Next Generation Sequencing) or ria, care and perspective will be specifically whole exome/genome sequencing have been discussed. considered to better evaluate either known or emerging clinical myopathic entities This teaching course is aimed to update the evaluation of these disorders, taking into consideration the main pathogenic mechanisms of muscle dysfunction determined by genetic, bioenergetic and dis-immune causes, also to reach an early diagnosis, mainly in cases where a specific therapy is available. SCIENTIFIC PROGRAMME

14:45 – 18:15 techniques can evaluate upper motor neuron 14:45 – 18:15 Room Amsterdam involvement as well as disease progression. Auditorium V Their value in the diagnosis and follow-up of patients will be explored. Teaching Course 4: Teaching Course 3: The c) In clinical routine, neuroimaging is mostly Neuroimaging and early diagnoses of ALS – old and used to exclude other pathologies that could detection of neurological new approaches - Level 2 mimic specific symptoms and signs of diseases - Level 2 patients with ALS. However, a growing body of evidence suggests that neuroimaging tech- Chairperson: niques can also contribute to the diagnosis Chairperson: Philip Van Damme (Leuven, Belgium) of ALS by revealing specific and progressive Federica Agosta (Milan, Italy) changes in the brain and spinal cord. In • How to diagnose ALS? Clinical aspects addition, some imaging techniques can shed • Radiologically isolated syndromes and staging of disease light on the underlying disease mechanisms, Nicola de Stefano (Siena, Italy) Philip Van Damme (Leuven, Belgium) which may become important to track the effect of treatment interventions. A review • Genetic motor neuron diseases • Neurophysiological measurements of of the value and prospects of neuroimaging Peter Bede (Dublin, Ireland) ALS diagnosis and progression biomarkers will be given. Susanne Petri (Hannover, Germany) d) A simple laboratory test for ALS is lacking, • Preclinical Alzheimer’s disease and but over the last years a lot of progress has frontotemporal dementia • Neuroimaging biomarkers been made to identify and validate diagnostic Federica Agosta (Milan, Italy) Martin R. Turner (Oxford, UK) biomarkers for ALS in blood and CSF. Such markers can not only aid in diagnosis, but • Preclinical stages of Parkinson’s • Blood and CSF biomarkers may also contain prognostic information. disease Vincenzo Silani (Milan, Italy) Moreover, some of them reflect underlying Klaus Seppi (Innsbruck, Austria) disease mechanisms, important to follow in early phase clinical trials. An update on the Educational content: current state of blood and CSF biomarkers Educational content: In this teaching course, an overview of the for ALS will be given. Advanced neuroimaging techniques are of clinical presentation and diagnosis of ALS special interest for their potential to char- will be given. The classification of ALS, which acterise the signature of demyelinating and is based on clinical features and genetics will neurodegenerative conditions and aid both be explained, as well as the contribution of the diagnostic process and the monitoring of novel neurophysiological measurements to disease progression. This TC will overview ALS diagnosis and progression. In addition, recent research on the study of the preclini recent advances in neuroimaging and fluid cal stages of demyelinating/neurodegener- biomarkers - reflecting various aspects of the ative diseases as well as genotype-specific disease - will be discussed. changes in asymptomatic gene mutation a) The diagnosis of ALS largely remains a carriers. Characterising brain structural and clinical diagnosis, relying on correct clinical functional abnormalities in these subjects judgement of the presenting symptoms using neuroimaging may help anticipating and signs of the patients. The diagnostic the diagnosis and perhaps prevent the devas- algorithm of ALS will be discussed. ALS is a tating impact of these conditions. This aspect heterogeneous disorder and several clinical will become crucial when disease-modifying subtypes of ALS exist, which have different (personalised) therapies will be established. rates of progression. The first staging systems of ALS are emerging and will be discussed. b) Neurophysiological measurements remain the most important test in the diagnostic algorithm of ALS, as they can confirm the presence of lower motor neuron involvement and allows for precise assessment of the extent of lower motor neuron degeneration. In addition, several novel neurophysiological SCIENTIFIC PROGRAMME PAGE 60 / 61

Saturday 16 June 16.45 – 18.45

14:45 – 18:15 16:45 – 18:15 16:45 – 18:15 Auditorium VIII Auditorium II Auditorium VI

Teaching Course 5: Acute Special Session 4: EAN and Interactive Session 9: EAN emergencies in neuromuscular European involvement in BrainChallenge – Quiz Show disease - Level 2 Rare Neurologic Diseases (European Reference Networks and other activities) Moderators: Chairperson: Angelo Antonini (Padua, Italy) Maxwell Damian (Cambridge, UK) Marie Vidailhet (Paris, France) Chairperson: • Evaluation and differential diagnosis of Antonio Federico • Local Team acute neuromuscular weakness Zohar Argov (Jerusalem, Israel) • Introduction: EAN‘s activity on Rare • International Team Neurologic Diseases • Vasculitis of the peripheral nervous Antonio Federico (Siena, Italy) system The aim of the session is to promote a Alexander Vrancken • Epicare: the European Reference Net- meaningful and interactive learning experi- (Utrecht, The Netherlands) work for Rare Epilepsies ence based on clinical study cases designed Reetta Kälviäinen (Kuopio, Finland) for both senior and junior neurologists from • Emergencies in myasthenia, botulism all over the world. The cases will not only and myasthenic syndromes • NMD-ERN: the European Reference show how prompt and accurate diagnosis can Maxwell Damian (Cambridge, UK) Network for Neuromuscular Diseases be achieved despite the complexity of neu- Teresinha Evangelista (Newcastle, UK) rology, but will also draw attention to rarely • Emergencies in advanced genetic recognised conditions. muscle disease • RND-ERN: the European Reference Marianne de Visser Network for Rare Neurologic Diseases A team of local neurologists is competing (Amsterdam, The Netherlands) Holm Graessner (Tuebingen, Germany) with a team of international neurologists - each team consists of 4 senior and 2 junior • General discussion neurologists. Educational content: The diagnosis and management of Neu- Please download the app “EAN Congress” to romuscular emergencies is difficult, and Scientific content: actively participate in this Session and vote. requires very significant specialist expertise. The session will be focused on the presenta- This session provides teaching from leading tion of the European Reference Networks experts in the different facets of neuromus- (ERNs) on Rare Diseases, a recent organi- cular disorders that may present as emergen- zation by the European Union, that created cies, emphasising the rarer conditions that 24 ERNs dedicated to the rare diseases are often initially misdiagnosed. related to different specific rare disorders. The ERNs, networking centres at least from 8 EU countries, will improve the care and the research for rare disorders. After 1 year of activity, we will discuss the activities of the ERNs related to the main neurologic rare diseases: Epilepsy, Rare Neurologic Diseases, and Neuromuscular disorders. We will also present the EAN activities in this field. SCIENTIFIC PROGRAMME

Saturday 16 June 14.45 – 18.45

16:45 – 18:45 Educational content: nerve lesions. It is becoming increasingly used Room HoC Educational content: Nerve conduction studies in many centers to assess nerve compression are possibly the first and easiest approach and entrapment syndromes. Where nerve con- Hands-on Course 2: Nerve of the neurologist intending to practice duction studies may fall short, echography can conduction studies and nerve neurophysiology. In some countries, nerve reach further and the other way around. The echography - Level 1 conduction studies are performed by techni- speaker will present the basis of testing, the cians. However, a few techniques require good ways to recognise the structures under the ul- technical skills and interpretation abilities trasound probe and the methods of analysis, as Chairperson: according to the clinical context. This course is well as clinical cases illustrating the increasing Simon Podnar (Ljubljana, Slovenia) intended to revise all motor and sensory nerve importance of ultrasound in the assessment of conduction techniques utilised in human clini- peripheral nerve lesions. • Nerve conduction studies cal neurophysiology, in order to avoid mistakes Simon Podnar (Ljubljana, Slovenia) and errors in the interpretation of signals. Limited to 60 participants. Please register Long latency responses such as the F-wave will separately – additional fees will apply. • Nerve and muscle echography also be part of this course. Luca Padua (Rome, Italy) Nerve and muscle echography is an important This course is supported by NATUS Medical complement of the diagnosis of peripheral Inc. SCIENTIFIC PROGRAMME PAGE 62 / 63 SCIENTIFIC PROGRAMME

Saturday 16 June Oral sessions 14.45 – 16.15

14.45 – 16.15 15.15 | O101 14.45 – 16.15 Room Lisbon EXPLORE: a prospective, multinational Room Copenhagen natural history study of patients with Neurological manifestations acute hepatic porphyria with recurrent Movement disorders 1 of systemic diseases attacks L. Gouya1, J. Bloomer2, M. Balwani3, Chairperson: Chairpersons: D. Rees4, D. Bissell5, H. Bonkovsky6, Evzen Růička (Prague, Czech Republic) Theodor Landis (Lausanne, Switzerland) P. Ventura7, E. Sardh8, P. Harper8, Viktoria Papp (Aarhus, Denmark) R. Desnick3, S. Rock10, Q. Dinh9, A. Chan9, 14.45 | O109 W. Querbes9, C. Penz10, A. Simon9, Clinical predictors of screen-defined 14.45 | O105 K. Anderson10, J.-C. Deybach1 dementia in early Parkinson‘s disease Phase 1/2, randomised, placebo 1Paris, France, 2Birmingham, USA, 3New York, USA, F. Baig1, M. Lawton2, M. Rolinski2, controlled and open-label extension stu- 4London, UK, 5San Francisco, USA, 6Winston-Salem, C. Ruffmann1, T. Barber1, J.C. Klein1, C. Lo1, dies of givosiran an investigational RNA USA, 7Emilia-Romagna, Italy, 8Solna, Sweden, 9Cam- Y. Ben-Shlomo2, M. Hu1 interference (RNAi) therapeutic, bridge, USA, 10Galveston, USA 1Oxford, 2Bristol, UK in patients with acute intermittent porphyria 15.00 | O108 E. Sardh1, J. Phillips2, P. Harper3, 15.30 | O103 Skin nerve phosphorylated α-synuclein M. Balwani4, P. Stein5, D. Rees5, J. Bloomer6, Impact of Patisiran, an investigational deposits in Parkinson’s disease with D. Bissell7, R.J. Desnick4, C. Parker2, RNAi therapeutic, on nutritional status in orthostatic hypotension H. Bonkovsky8, N. Al-Tawil1, S. Rock9, patients with hereditary V. Donadio1, A. Incensi1, F. Del Sorbo2, Q. Dinh9, C. Penz9, A. Chan9, W. Querbes9, Transthyretin-Mediated Amyloidosis G. Rizzo1, R. Infante1, C.L. Scaglione1, A. Simon9, K. Anderson10 (TMA) N. Modugno3, E. Fileccia1, A. Elia2, 1Solna, Sweden, 2Salt Lake City, USA, 3Solona, Sweden, L. Obici1, T. Coelho2, D. Adams3, F. Cencini1, R. Liguori1 4New York, USA, 5London, UK, A. Gonzalez-Duarte4, W. O‘riordan5, 1Bologna, 2Milan, 3Isernia, Italy 6Birmingham, USA, 7San Francisco, USA, C.-C. Yang6, T. Yamashita7, A. Kristen8, 8Winston-Salem, USA, 9Cambridge, USA, I. Tournev9, H. Schmidt10, J. Berk11, 10Galveston, USA K.-P. Lin6, P. Gandhi12, M. Sweetser12, 15.15 | O111 J. Chen12, S. Goyal12, J. Gollob12, O. Suhr13 Brain Lewy body density is associated 1Pavia, Italy, 2Porto, Portugal, 3Le Kremlin-Bicêtre, with a lower prevalence of artherosclero- 15.00 | O104 France, 4Mexico D.F., Mexico, 5Lamesa, USA, 6Taipei, tic cardiovascular disease risk factors in Impact of prior TTR stabilizer use in Taiwan, Chinese Taipei, 7Kumamoto, Japan, 8Heidel- patients with Parkinson’s disease patients with hereditary transthyretin- berg, Germany, 9Sofia, Bulgaria, 10Münster, Germany, E. Driver-Dunckley1, N. Zhang1, C. Adler1, mediated amyloidosis in the APOLLO 11Boston, USA, 12Cambridge, USA, 13Umeå, Sweden G. Serrano2, L. Sue2, H. Shill3, S. Mehta1, phase-3 study of patisiran C. Belden2, E. Zamrini2, K. Davis4, T. Beach2 T. Coelho1, D. Adams2, A. Gonzalez-Duarte3, 1Scottsdale, 2Sun City, 3Phoenix, 4Sun city, USA W. O‘riordan4, C.-C. Yang5, T. Yamashita6, 15.45 | O102 A. Kristen7, I. Tournev8, H. Schmidt9, Clinical characterisation of Wilson’s J. Berk10, K.-P. Lin5, P. Gandhi11, disease patients: a retrospective study at 15.30 | O107 M. Sweetser11, J. Chen11, S. Goyal11, a tertiary-care centre in Lisbon Glucose dysregulation in advanced J. Gollob11, O. Suhr12 J. Rosa, A. Sousa, P. Brás, M. Machado, Parkinson’s disease: too much glucose 1Porto, Portugal, 2Le Kremlin-Bicêtre, France, 3Mexico M. Dias, M. Manita or not enough insulin? D.F., Mexico, 4Lamesa, USA, 5Taipei, Taiwan, Chinese Lisbon, Portugal A. Marques, F. Dutheil, E. Durand, I. Rieu, Taipei, 6Kumamoto, Japan, 7Heidelberg, Germany, A. Mulliez, M.L. Fantini, Y. Boirie, F. Durif 8Sofia, Bulgaria, 9Münster, Germany, 10Boston, USA, Clermont-Ferrand, France 11Cambridge, USA, 12Umeå, Sweden SCIENTIFIC PROGRAMME PAGE 64 / 65

Saturday 16 June 15.45 – 18.15

15.45 | O110 16.45 – 18.15 17.30 | O118 Temporal evolution of biomarkers in Room Berlin Characterising dynamic functional isolated REM sleep behavior disorder and network connectivity in the main clinical early Parkinson’s disease MS and related disorders 1 phenotypes of Multiple Sclerosis M.-L. Muntean1, B. Mollenhauer2, M. Hidalgo de la Cruz, M.A. Rocca, J. Zimmermann3, N. Focke2, T. Wicke1, Chairpersons: P. Valsasina, B. Colombo, F. Esposito, J. Ebentheuer1, M. Schaumburg1, E. Lang1, Hans-Peter Hartung (Düsseldorf, Germany) G. Comi, M. Filippi W. Oertel4, C. Trenkwalder1, F. Sixel-Döring1 Bernard Uitdehaag Milan, Italy 1Kassel, 2Göttingen, 3Berlin, 4Marburg, Germany (Maarssen, The Netherlands)

16.45 | O116 17.45 | O114 16.00 | O112 Effects of Fingolimod on MRI outcomes in Long-term prognosis of disease evolution Multimodal MRI markers modifications patients with paediatric-onset Multiple and evidence for sustained Fingolimod in Multiple System Atrophy (MSA): Sclerosis: results from the Phase-3 treatment effect by plasma a longitudinal study PARADIGMS study neurofilament light in RRMS patients P. Péran1, M. Galitzy1, W. Meissner2, D.L. Arnold1, B. Banwell2, A. Bar-or2, J. Kuhle1, J.A. Cohen2, H. Kropshofer1, O. Rascol1, A. Pavy-Le Traon1 A. Ghezzi3, B. Greenberg4, E. Waubant5, R. Meinert3, C. Barro1, M. Merschhemke1, 1Toulouse, France, 2Bordeaux, France G. Giovannoni6, J. Wolinsky7, J. Gärtner8, D. Häring1, D. Leppert1, D. Tomic1, L. Kappos1 K. Rostasy9, L. Krupp10, M. Tardieu11, 1Basel, Switzerland, 2Cleveland, USA, 3Freiburg, W. Brück8, T. Stites12, G.L. Pearce13, Germany M. Merschhemke14, T. Chitnis15 1Qubec, Canada, 2Philadelphia, USA, 3Gallarte, Italy, 4Dallas, USA, 5San Francisco, USA, 6London, UK, 18.00 | O115 7Houston, USA, 8Göttingen, Germany, 9Recklinghausen, Alemtuzumab provides durable clinical Germany, 10New York, USA, 11Paris, France, 12East Ha- efficacy in patients with active RRMS in nover, USA, 13Bloomington, USA, 14Basel, Switzerland, the absence of continuous treatment: 15Boston, USA 7-year follow-up of CARE-MS I (TOPAZ Study) B. van Wijmeersch1, P. Vermersch2, 17.00 | O117 A. Boyko3, J. de Seze4, H.-P. Hartung5, Characterising the Slowly Evolving E. Kubala Havrdova6, J. Said Inshasi7, Lesions (SELs) in a cohort of secondary P. McCombe8, X. Montalban9, C. Pozzili10, progressive Multiple Sclerosis patients M. Melanson11, N. Daizadeh11, C. Rodriguez11, A. Calvi, F. Prados, C. Tur, F. de Angelis, K. Selmaj12, N. John, A. Doshi, J. Stutters, D. Macmanus, O.B.O.T.C.-M.I.C. and Topaz Investigators11 S. Ourselin, O. Ciccarelli, J. Chataway, 1Hasselt, Belgium, 2Lille, France, 3Moscow, Russian Fe- F. Barkhof deration, 4Strasbourg, France, 5Düsseldorf, Germany, London, UK 6Prague, Czech Republic, 7Dubai, United Arab Emirates, 8Brisbane, Queensland, Australia, 9Barcelona, Spain, 10Rome, Italy, 11Cambridge, USA, 12Lodz, Poland 17.15 | O113 Spinal cord area is a stronger predictor of physical disability than brain volume in secondary progressive Multiple Sclerosis F. de Angelis1, J. Stutters1, A. Eshaghi1, A. Garcia1, F. Prados1, D. Plantone1, A. Doshi1, N.A. John1, A. Calvi1, D. Macmanus1, S. Ourselin1, S. Pavitt2, G. Giovannoni1, R. Parker3, C.J. Weir3, N. Stallard4, C.P. Hawkins5, B. Sharrack6, P. Connick3, S. Chandran3, C.A. Gandini Wheeler-Kingshott1, F. Barkhof1, J. Chataway1 1London, 2Leeds, 3Edinburgh, 4Coventry, 5Keele, 6Sheffield, UK SCIENTIFIC PROGRAMME

Saturday 16 June Oral sessions 16.45 – 18.15

16.45 – 18.00 17.30 | O121 16.45 – 18.15 Room Lisbon Charcot-Marie-Tooth disease type 4B Room Oslo with myelin outfoldings (CMT4B): Peripheral nerve disorders 1 a multicentre retrospective study D. Pareyson1, T. Stojkovic2, Neurogenetics Chairpersons: S. Leonard-Louis2, M.M. Reilly3, M. Laurà3, Christian Krarup (Copenhagen, Denmark) R. Horvath4, G. Ricci4, Y. Parman5, Chairpersons: Peter van den Bergh (Brussels, Belgium) E. Battaloglu5, M. Tazir6, M. Bellatache6, Thomas Klopstock (Munich, Germany) N. Bonello-Palot7, S. Sacconi8, Jean-Mark Burgunder (Bern, Switzerland) 16.45 | O120 R. Guimarães-Costa2, S. Attarian7, Corneal confocal microscopy and skin P. Latour9, A. Megarbane2, A. Schenone10, 16.45 | O124 biopsy in the evaluation of diabetic small G. Ursino10, M. Sabatelli11, M. Luigetti11, Estimated lifetime prevalences of fiber neuropathy L. Santoro12, F. Manganelli12, A. Quattrone13, autosomal mitochondrial disorders based J. Bednarik, A. Rajdova, I. Kovalova, P. Valentino13, T. Murakami14, SS. Scherer15, on allele frequencies of pathogenic M. Horakova, S. Divisova, J. Raputová, L. Dankwa15, ME. Shy16, CJ. Bacon16, variants in exome databases E. Vlckova DN. Herrmann17, C. Pisciotta1, S. Previtali1, J. Tan, M. Wagner, S. Stenton, T.-M. Strom, Brno, Czech Republic A. Bolino1 H. Prokisch, T. Klopstock 1Milan, 10Genoa, 11Rome, 12Naples, 13Catanzaro, Italy; Munich, Germany 2Paris, 7Marseille, 8Nice, 9Lyon, France; 3London, 17.00 | O119 4Newcastle, UK; 5Istanbul, Turkey; 6Algiers, Algeria; 17.00 | O126 Axonal function predicts response to 14Kurashiki, Japan; 15Philadelphia, 16Iowa City, 17Ro- Phenotypic and neuroimaging subcutaneous immunoglobulin in chronic chester, USA. expression of NKX6-2 mutations lead to inflammatory demyelinating a new distinct disease with spastic ataxia polyneuropathy: the PATH study and hypomyelination V. Bril1, N. van Geloven2, H.-P. Hartung3, 17.45 | O123 V. Chelban1, M. Alsagob2, K. Kloth3, G. Sobue4, J.-P. Lawo5, O. Mielke5, Long-term efficacy and safety of A. Chirita-Emandi4, J. Vandrovcova1, B.L. Durn6, I.S. Merkies7 Inotersen in patients with hereditary S. Efthymiou1, T. Bierhals3, N. Kaya2, 1Toronto, Canada, 2Leiden, Netherlands, 3Düsseldorf, transthyretin (hATTR) amyloidosis N.W. Wood1, H. Houlden1 Germany, 4Nagoya, Japan, 5Marburg, Germany, 6King treated in the open-label extension of 1London, UK, 2Riyadh, Saudi Arabia, 3Hamburg, Ger- of Prussia, USA, 7Maastricht, Netherlands the phase-3 study NEURO-TTR many, 4Timisoara, Romania V. Planté-Bordeneuve1, T. Brannagan2, A. Wang3, T. Coelho4, M. Waddington Cruz5, 17.15 | O122 M. Polydefkis6, P. Dyck7, M. Scheinberg8, 17.15 | O125 Cryoglobulinaemia-associated peripheral J. Berk9, F. Barroso10, D. Adams11, UFM1 founder mutation in the Roma neuropathies: clinical characteristics and C. Whelan12, G. Merlini13, B. Drachman14, population causes severe variant of prognosis from 20 years experience of S. Heitner15, I. Conceicao16, H. Schmidt17, Hypomyelination with Atrophy of the neuromuscular clinic G. Vita18, J. Campistol19, J. Gamez19, Basal ganglia and Cerebellum (H-ABC) M. Mazzoli, A. Ariatti, M.T. Mascia, P. Gorevic2, B. Monia20, M. Benson21, E.M. Hamilton1, E. Bertini2, L. Kalaydjieva3, F. Valzania, P. Nichelli, G. Galassi M. Gertz7 B. Morar3, D. Dojčáková4, D. Diodato2, Modena, Italy 1Creteil, France, 2New York, USA, 3Orange, USA, 4Porto, N. Wolf1, Q. Waisfisz1, T.E. Abbink1, Portugal, 5Rio de Janeiro, Brazil, 6Baltimore, USA, M.S. van der Knaap1 7Rochester, USA, 8Sao Paolo, Brazil, 9Boston, USA, 1Amsterdam, Netherlands, 2Rome, Italy, 3Perth, 10Buenos Aires, Argentina, 11Le Kremlin-Bicêtre, France, Australia, 4Presov, Slovakia 12London, UK, 13Pavia, Italy, 14Philadelphia, USA, 15Port- land, USA, 16Lisbon, Portugal, 17Münster, Germany, 18Messina, Italy, 19Barcelona, Spain, 20Carlsbad, USA, 21Indianapolis, USA SCIENTIFIC PROGRAMME PAGE 66 / 67

Saturday 16 June 16.45 – 18.15

17.30 | O129 16.45 – 18.15 17.45 | O133 A randomised trial of deferiprone for Room Copenhagen Syndrome and outcome of antibody- pantothenate Kinase-associated negative limbic encephalitis Neurodegeneration (PKAN) Neuroimmunology F. Graus1, D. Escudero1, L. Oleaga1, J. Bruna1, T. Klopstock1, F. Tricta2, C. Fradette2, A. Villarejo-Galende2, J. Ballabriga3, M. Spino2, B. Büchner1, I. Karin1, Chairpersons: M.I. Barceló3, F. Gilo2, S. Popkirov4, L. Neumayr3, C. Aguilar3, F. Zhao2, Maarten Titulaer P. Stourac5, J. Dalmau1 T. Kmiec4, N. Nardocci5, G. Zorzi5, H. Steele6, (Rotterdam, The Netherlands) 1Barcelona, 2Madrid, 3Palma de Mallorca, Spain, R. Horváth6, P. Chinnery7, P. Hogarth8, Radu Tanasescu, (Nottingham, UK) 4Bochum, Germany, 5Brno, Czech Republic S.J. Hayflick8, A. Blamire6, E. Vichinsky3 1Munich, Germany, 2Toronto, Canada, 3Oakland, USA, 16.45 | O134 4Warsaw, Poland, 5Milan, Italy, 6Newcastle upon Tyne, Aquaporin-4 autoantibodies from 18.00 | O130 7Cambridge, UK, 8Portland, USA Neuromyelitis Optica Spectrum Disorder: Neurofilament Light chain (NfL) serum patients cause complement- concentration reflects disease severity 17.45 | O128 independent spinal cord pathologies in patients with MOG-Ab associated Next Generation Sequencing results in and motor deficits in mice disorders an Italian cohort of hereditary optic K.H. Chan, L.W. Yick S. Mariotto1, A. Gajofatto1, E. Sechi2, neuropathy patients Hong Kong, Hong Kong (SAR of China) R. Capra3, C.R. Mancinelli3, K. Schanda4, C. La Morgia1, F. Tagliavini1, L. Caporali1, D. Alberti1, R. Bombardi5, L. Zuliani6, M. Carbonelli1, L. Di Vito1, P. Barboni1, M. Zoccarato7, M.D. Benedetti1, R. Tanel8, M.L. Cascavilla2, A. Carta3, A. Rufa4, 17.00 | O132 F. Rossi9, A. Pavone10, L. Grazian6, G. Sechi2, S. Bianchi Marzoli2, F. Mari5, M. Mancuso6, Evaluation of treatment response R. Delogu2, D. Urso2, F. Janes11, V. Fetoni12, M.A. Donati5, A.M. de Negri7, F. Sadun7, in adults with relapsing MOG- V. Manfioli13, G. Cantalupo1, M. Reindl4, M.L. Valentino1, R. Liguori1, V. Carelli1 Ab associated S. Monaco1, S. Ferrari1 1Bologna, 2Milan, 3Parma, 4Sienna, 5Florence, 6Pisa, A. Cobo-Calvo1, M. Sepulveda2, 1Verona, 2Sassari, 3Montichiari, Italy, 4Innsbruck, 7Rome, Italy T. Armangué2, A. Ruiz1, E. Maillart3, Austria, 5Vicenza, 6Treviso, 7Padua, 8Trent, 9Legnago, B. Audoin4, H. Zephir5, D. Biotti6, J. Ciron6, 10Catania, 11Udine, 12Milan, 13Rovigo, Italy F. Durand Dubief1, N. Collongues7, 18.00 | O127 X. Ayrignac8, E. Thouvenot9, The natural history of mitochondrial A. Montcuquet10, F. Rollot1, N. Solà Valls2, stroke-like episodes: observational S. Llufriu2, Y. Blanco2, S. Vukusic1, A. Saiz2, cohort study from the UK R. Marignier1 Y.S. Ng1, A. Schaefer1, R. Pitceathly2, 1Lyons, France, 2Barcelona, Spain, 3Paris, 4Marseilles, V. Nesbitt3, J. Hall1, M. Farrugia4, 5Lille, 6Toulouse, 7Strasbourg, 8Montpellier, 9Nîmes, M. Roberts5, J. Poulton3, M. Hanna2, 10Limoges, France R.W. Taylor1, D. Turnbull1, R. McFarland1, G. Gorman1 1Newcastle, 2London, 3Oxford, 4Glasgow, 5Salford, UK 17.15 | O135 Thrombotic and non-thrombotic neurological manifestations in Primary Antiphospholipid Syndrome C. Cunha1, J. Serodio2, I. Moreira1, A. Bettencourt1, E. Santos1, R. Samões1, G. Carvalheiras1, S. Cavaco1, A. Martins Silva1 1Porto, 2Viana do Castelo, Portugal

17.30 | O131 Mimics of Autoimmune Encephalitis J. de Vries, R. Neuteboom, M.W. Vernooij, R. Verdijk, P.A. Sillevis Smitt, M.J. Titulaer Rotterdam, The Netherlands FINAL PROGRAMME SCIENTIFIC PROGRAMME PAGE 68 / 69

Sunday 17 June 2018 SCIENTIFIC PROGRAMME

Sunday 17 June Sessions 08.00 – 09.30

08:00 – 09:30 08:00 – 09:30 specialised MS Clinics, that patients must be Room Copenhagen Room CbW closely monitored and often re-studied and that request for a second opinion may be Career Development Session 2: Case-based Workshop 3: important. Abstract, poster and presen- The process of MS diagnosis tation tips for success at inter- Limited to 60 participants. This course is national meetings sold out. Chairperson: Maria José Sá Chairperson: (Porto, Portugal) 08:00 – 09:30 Claudia Sommer (Würzburg, Germany) Room HoC • New diagnostic criteria • How to prepare & submit your abstract Wallace Brownlee (London, UK) Hands-on Course 3: Marianne Dieterich (Munich, Germany) Tilt-table testing in neurology • Most frequent misdiagnosis and clinical neurophysiology - • Preparing your poster or slides Franz Fazekas (Graz, Austria) Level 2 Aksel Siva (Istanbul, Turkey) • Patterns of decision making in • Delivering your poster or oral demyelinating diseases Chairperson: presentation Maria José Sá (Porto, Portugal) Gert van Dijk (Leiden, The Netherlands) Claudia Sommer (Würzburg, Germany) • Cardiovascular autonomic nervous Educational content: system: basic concepts Educational content: Wallace Brownlee will inform on participants Isabel Rocha (Lisbon, Portugal) Practical advice on every step from abstract the knowledge provided by the international preparation to delivering your poster or oral consensus groups of MS experts with a criti- • Autonomic function testing in neuro platform presentation will be provided by cal analysis of the evolution of MS diagnostic genic orthostatic hypotension experts from the Education and Program criteria, discussing the main pitfalls in the Alessandra Fanciulli (Innsbruck, Austria) committees of the EAN, with ample opportu- 2010’s criteria and measures to improve MS nity to ask questions and seek advice. diagnostic accuracy. • Tilt-table patterns in transient loss of Franz Fazekas will get the audience acquaint- consciousness (TLOC): reflex syncope, Target audience: ed with particular imaging aspects that may orthostatic hypotension and Neurologists at any level who are relatively be atypical for MS and lead to diagnostic psychogenic TLOC inexperienced in submitting work for errors (vascular and non-vascular diseases), Gert van Dijk (Leiden, The Netherlands) presentation at international congresses, or showing examples of most frequent misdi- experienced in their native country, but may agnosis prior to MS, and also aspects that be less competitive/successful on an interna- may be of help to overcome diagnostic delay Endorsed by European Federation of tional stage. in MS. Autonomic Societies (EFAS) Maria José Sá will inform how on the need of a structured and disciplined clinical Educational content: reasoning that must be followed since the Syncope is responsible for 3% of hospital suspect of MS, in a step by step way: iden- admissions; its economic burden of syncope tify the classical clinical features (typical is huge. A considerable part of these high neurological syndrome, relapsing-remitting costs is spent on tests that are not indicated. pattern of complaints), perform a neurolog- Till now few neurologists have taken an ical examination and request complemen- interest in syncope and tilt-table testing tary exams looking for evidence of MS and (TTT). However, reflex syncope and epilepsy exclusion of MS mimickers (MRI, CSF, VEP, often feature in one another’s differential OCT, analytic workup) and when to suspect diagnosis; they require a similar emphasis MS misdiagnosis (non-responders to MS on history taking and deductive reasoning. therapies, superimposed atypical symptoms, A TTT is useful for diagnosis and treatment, unusual MRI findings). not just for reflex syncope but also for various other syndromes including orthostatic It will be proposed a step by step approach hypotension, postural orthostatic tachycardia to overcome MS misdiagnosis: awareness syndrome and psychogenic pseudo-synco- that misdiagnosis do exist also in highly pe. Autonomic function testing can provide SCIENTIFIC PROGRAMME PAGE 70 / 71

Sunday 17 June 08.00 – 09.30

additional detail in the differentiation of 08:00 – 09:30 08:00 – 09:30 various autonomic neuropathies. In this Room Berlin Auditorium II course, we will review the basic concepts of cardiovascular physiology. Focused Workshop 7: Epilepsy Focused Workshop 6: EAN/ surgery in 2018: Has anything Limited to 60 participants. Please register MDS-ES: Management of changed in the last decades? separately – additional fees will apply. Parkinson‘s disease in non-routine circumstances Chairperson: 08:00 – 09:30 Mar Carreño (Barcelona, Spain) Auditorium VI Chairperson: Philippe G. Damier (Nantes, France) • Update on the concept of drug Interactive Session 3: EAN/ resistance. When should pediatric and ESO: Treatment decisions in • Fasting during Ramadan adult patients be referred for epilepsy some difficult scenarios of Philippe G. Damier (Nantes, France) surgery? acute ischaemic stroke Edouard Hirsch (Strasbourg, France) • Travelling abroad Even Růička (Prague, Czech Republic) • Common and not so common surgically Chairperson: remediable syndromes Patrik Michel (Lausanne, Switzerland) • Undergoing a surgical procedure Christoph Baumgartner (Vienna, Austria) Heinz Reichmann (Dresden, Germany) • Ischaemic stroke in a patient with high • Epilepsy surgery in patients without bleeding risk • Can people with PD drive? obvious MRI lesions: are we overusing Patrik Michel (Lausanne, Switzerland) Joaquim Ferreira (Lisbon, Portugal) intracranial electrodes? José Serratosa (Madrid, Spain) • Ischaemic stroke upon awakening Carla Ferreira (Braga, Portugal) Scientific content: Dopamine replacement therapy is highly Scientific content: • Ischaemic stroke in a disabled person effective to reduce Parkinson’s disease To review the current indications to perform Janika Kõrv (Tartu, Estonia) symptoms and helps many patients to have a epilepsy surgery in children and adults; fair quality of life. Patients may have to face review the clinical features and clinical some non-routine circumstances for which outcomes of common and not so common Educational content: the treatment needs to be adjusted. surgically treatable epilepsy syndromes, to In this course participants learn the con- The workshop aims to provide practical review the role of ample resections to treat siderations, options and management steps advice to manage such circumstances: Ram- epilepsy and to review the current approach for using i.v. thrombolysis, mechanical adan fasting, travelling abroad, undergoing a using invasive electrodes to patients with thrombectomy and other treatments in some surgical procedure or driving. How to adapt a drug resistant epilepsy and no obvious lesion difficult settings of acute ischaemic stroke. transient treatment reduction or withdrawal, on the MRI. how to change drug administration schedule, Please download the app “EAN Congress” to how to take into consideration treatment actively participate in this Session and vote. or treatment decrease side effects? What is adjustable? What is not? Clinicians should gain some hints and know ledge helping them in their daily practice. SCIENTIFIC PROGRAMME

Sunday 17 June Sessions 08.00 – 09.30

08:00 – 09:30 08:00 – 09:30 08:00 – 09:30 Room Amsterdam Auditorium VIII Room Lisbon

Focused Workshop 10: Focused Workshop 8: Impact Focused Workshop 9: Lost in space - clinical and of technology in neuro- Novel genetic techniques neurobiological aspects of rehabilitation in neurological practice - topographagnosia time for responsible clinical and research implementation Chairperson: Chairperson: Volker Dietz (Zurich, Switzerland) Wolfgang Heide (Celle, Germany) Chairperson: • Rehabilitation of hand function Thomas Gasser (Tübingen, Germany) • The map cannot be explored - disor- post-stroke: application of research ders of spatial exploration in neglect based technology • What should the general neurologist (perceptive topographagnosia) Volker Dietz (Zurich, Switzerland) know about Next Generation Sequen- Masud Husain (Oxford, UK) cing (NGS)? • Robotic support for cognitive therapy of Henry Houlden (London, UK) • The map is distorted - disorders of the hand function perceptual analysis of space Olivier Lambercy (Zurich, Switzerland) • Interpretation of NGS test: neurological (apperceptive topographagnosia) disease and beyond Wolfgang Heide (Celle, Germany) • Robotic technology in the rehabilitation Thomas Gasser (Tübingen, Germany) of gait after a stroke and spinal cord • The map is lost - disorders of spatial injury • The use of genetic information in the memory (associative topographagnosia Klaus Jahn (Munich, Germany) context of clinical trials and topographical amnesia) Cristina Sampaio (Lisbon, Portugal) Jan Laczó (Prague, Czech Republic)

Scientific content: The FW aims to present the actual advan- Scientific Content: Scientific content: tages and the limitations of technology to The development of genetic research, made Topographagnosia is a form of agnosia in- improve performance of locomotor and hand possible mainly by unprecedented techno- volving an inability to find one’s way around function after a stroke or spinal cord injury. logical advances over the past few years, (“lost in space”), read maps, draw plans, or A specific goal will be to discuss the devices has transformed many areas of neurology. perform similar functions, often associated that are based on research achievements and New classification systems based on genetic with damage to the right parietal or temporal are shown to be effective in the application defects have in many cases replaced the old lobe. The term stands for different clinical in neurorehabilitation centres. Especially clinico-pathologic order. Clinical genetic disorders of spatial orientation that accord- aspects of individually adapted rehabilitation testing has become a routine procedure in ing to De Renzi (1982) and Landis (1991) of limb function by technology will be preclinical neurology, and the first studies are can be divided into 3 groups: 1. disorders of sented. Another goal will be to discuss the designed that use genetic variants to stratify spatial exploration (perceptive topographag- actual activities to strengthen home training disease groups. nosia), 2. disorders of perceptual analysis of using simple technology with a focus on In this workshop, we will give an overview of space (apperceptive topographagnosia) and functional requirements of daily life activ- existing and emerging technologies and their 3. disorders of spatial memory and spatial ities. A special focus will be to discuss the applications in clinical practice and research. navigation (associative topographagnosia & present weaknesses/limitations of robot-sup- topographical amnesia). They are the basis ported neurorehabilitation. of the 3 lectures of this workshop, where experts in each of these fields will demonstrate the significance of these old clinical terms in the light of recent findings of modern cognitive neurology, neuroimaging and neurorehabilitation in patients with focal or neurodegenerative cortical damage. SCIENTIFIC PROGRAMME PAGE 72 / 73

Sunday 17 June 08.00 – 09.30

08:00 – 09:30 08:00 – 09:30 08:00 – 09:30 Auditorium V Room Oslo Auditorium III

Special Session 5: Special Session 6: Resident Special Session 7: Neurological disorders and Research Fellow Section EAN Corresponding Members of famous composers round table discussion: learn of the Mediterranean Area – about clinical work and Clinical Neuro-immunology research (clinical and labora- Chairperson: tory) around Europe Tomislav Breitenfeld (Zagreb, Croatia) Chairperson: Jean-Michel Vallat (Limoger, France) • Maurice Ravel‘s fatal neurological Chairperson: illness RRFS Representatives • NMO Devic‘s disease Vida Demarin (Zagreb, Croatia) Adnan Awada (Beirut, Lebanon) • Table 1 • Joseph Haydn – a case of subcortical José M Ferro (Lisbon, Portugal) • Neurological complications of vascular encephalopathy Behçet‘s disease Hansjörg Bäzner (Stuttgart, Germany) • Table 2 Maria Benabdeljlil (Rabat, Morocco) Klaus Toyka (Würzburg, Germany) • Stroke in famous composers • Auto-immune encephalitis Tomislav Breitenfeld (Zagreb, Croatia) • Table 3 Maarten Titulaer Hannah Cock (London, UK) (Rotterdam, The Netherlands) • Breaking barriers in neuro-musicology: Beethoven’s deafness, Schumann’s • Table 4 • Neurological complications of Lupus madness, Porter’s pain, Gershwin’s Eva Havrdova (Prague, Czech Republic) and anti-phospholipid antibodies uncinate seizures Jean-Michel Vallat (Limoges, France) Phillip L. Pearl (Boston, USA) Session Content: Main aims: Session Content: Session content: - Learn about academic career and research The wide spectrum of auto-immune Central Nerv- This Special session will present a series of opportunities around Europe ous System diseases (CNS) is more and more well biopathographies and short portraits of famous - Get expert advices on laboratory and recognised but is still underestimated for several composers describing their biography, talent, clinical research reasons. Clinical symptoms and signs are diverse creation and medical history. All presented - Meet experts from different parts of and can be observed in non-dysimmune CNS famous composers suffered from different Europe and improve the professional disorders. These last years, numerous and various neurological disorders. The presentations European network antibodies associated to some of these diseases will explain influence of those disorders on - Get to know opinion leaders’ careers have been discovered; nevertheless, the laboratory composer’s creativity and try to interpret his- and how they got there work-up for such antibodies is currently only torical materials in terms of modern medicine. available in a few laboratories, so that it may be Audience will be allowed (and animated) to The participants will directly sit down with difficult to confirm the diagnosis. For most of these comment and discuss the interaction between each Professor from different parts of Europe diseases, the treatment should not be delayed as neurological disorders and composer’s abil- (North, West, Central and East) and with the dysimmune process needs to be arrested at an ity to create art. While trying to explain the different fields of interest (such as stroke, early stage to avoid severe sequellae. Some of these complex relationship between neurological epilepsy, Multiple Sclerosis). dysimmune entities are encountered worldwide disorders and creativity through pathographies The participants will circulate and have the and a few others, like Behçet’s syndrome, are more of famous composers, organisers intend to unique opportunity to discuss questions frequent in Mediterranean countries. The objective present a new, really interesting and “some- such as career or research projects in detail. of this session is to stress the main CNS clinical thing else from other topics” session. This will offer the opportunity to ask more and imaging characteristics of such patients and We believe that it will turn into a memorable detailed and individualised questions. We to discuss the role of associated antibodies in gathering of people who share the same pas- aim to give interested residents an overview auto-immune encephalitis, Behçet’s disease, neu- sion, genuine love and enthusiasm for both, of different ways of developing a research or romyelitis optica (Devic’s syndrome) and systemic neurology and music. After all, Lisbon with its clinical career. lupus erythematosus. Clinical phenotypes together glorious cultural, musical and medical history with their typical paraclinical measures, putative seems to be an ideal site for a special session disease mechanisms, and therapeutic options in “Neurological disorders of famous composers”. this emerging class of inflammatory CNS disorders will be presented.

SCIENTIFIC PROGRAMME PAGE 74 / 75

Sunday 17 June 10.00 – 12.00

10:00 – 12:00 Prof. Philip Scheltens Auditorium I Prof. Dr. Philip Scheltens studied at the VU University Amsterdam, Neth- erlands, gaining his MD in 1984, and Plenary Symposium 2: PhD (Magnetic Resonance Imaging Presidential Symposium: Named Lectures in Alzheimer’s disease) in 1993. Since 2000 he is Professor of Cognitive Neu- rology and Director of the Alzheimer Chairpersons: Center at the VU University Medical Günther Deuschl (Kiel, Germany) Center in Amsterdam. His main Manuel Correia (Porto, Portugal) clinical and research interests are Alzheimer’s disease, vascular dementia, frontotemporal dementia, • Camillo Golgi Lecture – magnetic resonance imaging, PET imaging and fluid biomarkers. He The Immune Pathogenesis of Multiple Sclerosis: is active in the field of biomarkers and clinical trials and has been Degeneration, inflammation and gut microbiota – an the national PI for many studies, including phase 1-3 multicenter unholy alliance clinical trials. He founded and directs the Alzheimer Center since Hartmut Wekerle (Munich, Germany) 2000, from which over 55 PhD theses have appeared since then. In 2013, he co-founded the Dutch national plan against dementia • Edouard Brown-Séquard Lecture – (Deltaplan Dementie) and serves as vice-chair of the board since The evolution of Alzheimer’s disease and dementia then. He has authored over 850 peer reviewed publications and his Philip Scheltens H-factor is currently 103. In 2011, he was elected as member of the (Amsterdam, The Netherlands) Royal Dutch Academy of Arts and Sciences (KNAW) and serves as Secretary General since 2015. In 2016 he was awarded the European • Moritz Romberg Lecture – Grand Prix for Alzheimer’s Research. Migraine mechanisms and new drug targets Jes Olesen (Glostrup, Denmark) Prof. Jes Olesen is Professor of Neurology, dr.med. (Copenhagen, Denmark), dr. Prof. Hartmut Wekerle hon.c. (Rome, Italy), dr. hon.c. Hartmut Wekerle was director and (Yekaterinburg, Russia), and fellow member of the Max Planck Institute of of the Royal College of Physicians Neurobiology. In 2012 he was awarded (FRCP). Born on 9.9.1941 in Hobro, a Hertie Senior Professorship, and he Denmark, Jes Olesen received his leads an Extended Emeritus Group. MD at the University of Copenhagen Hartmut Wekerle’s scientific research 1967. Further specialist education in focuses on the mechanisms initiating neurology at major teaching hospitals and driving Multiple Sclerosis and its in Copenhagen, the National Hospital, Queen Square, London, and experimental models, which imply au- the Cornell Medical Center, New York. Consultant neurologist at toimmune attack against the nervous Gentofte Hospital 1985-1993, Glostrup Hospital 1993- . He is the system. Wekerle’s work led to the identification of brain reactive founder Danish Headache Center 2001-Previous Associate Editor autoimmune T lymphocytes in the immune system. Most recently, of Cephalalgia and Pain. He was Editorial board member of several he identified the commensal bacterial gut flora as a factor triggering journals and President of several Organisations, such as the Danish the pathogenic potential of immune cells. He develops and uses Headache Society, Scandinavian Migraine Society, International new imaging approaches to detail the mechanisms of autoimmune Headache Society, Danish Stroke Association, Year of the Brain 1997 T-cell migration into the brain. Wekerle has received numerous campaign, European Federation of Neurological Societies (EFNS) awards, including the Jung Prize, Zülch Prize, Koetser Prize, Charcot and European Brain Council (EBC). Honorary member Australian, Award (MS International Federation), Grand Prix Louis D. (Institut German, Austrian and International headache societies and of the de France), and a Koselleck Award (DFG), Jacob-Henle-Medal Austrian, French, British, German and Polish Neurological Societies (University Medical Center, Goettingen). He holds an Honorary and of European Federation of Neurological Associations (EFNA) Professorship of the University of Munich and Honorary Doctorates and EAN (as former EFNS President). He received the Great Nordic of the Universities of Hamburg and Wuerzburg. He is a member of Research Prize of the Lundbeck Foundation and many other nation- the German Academy of Science (Leopoldina), Honorary Member al and international prizes. Citations: Google Scholar 50673 H-Fac- of the Société Française de Neurologie and Honorary Member of the tor: Google Scholar 113, i/10-index: Google Scholar 539. 525 articles Cuban Neuroscience Society. in refereed journals, 235 book chapters, 33 books. Has supervised 16 doctoral and 25 Ph.D. dissertations. SCIENTIFIC PROGRAMME

15:00 – 16:30 15:00 – 16:30 • Diplopia accompanied by vertigo. The Room CbW Auditorium VI aim is to explore those common brainstem syndromes which present with simultaneous Interactive Session 4: diplopia and vertigo. Typical presentations of Case-based Workshop 4: How to diagnose acute vertigo lower brainstem ischemia and demyelination Difficult decisions in treatment and acute double vision will be discussed. The speaker will expand on of myasthenia gravis the above two presenters’ material to explore the specific scenarios in which simultaneous Chairperson: diplopia and vertigo offer particular localisa- Chairperson: Michael Leo Strupp (Munich, Germany) tion value. Jan J.G.M. Verschuuren (Leiden, The Netherlands) • Acute vertigo Please download the app “EAN Congress” to Michael Leo Strupp (Munich, Germany) actively participate in this Session and vote. • Refractory MG treatment Nils Erik Gilhus (Bergen, Norway) • Acute diplopia Konrad P. Weber (Zurich, Switzerland) 15:00 – 17:00 • Thymectomy in MG Auditorium I Jan J.G.M. Verschuuren • Acute vertigo and diplopia (Leiden, The Netherlands) Caroline Tilikete (Lyon, France) Special Session 1: • Treatment in pregnancy EAN/MDS-ES: European Jacqueline A. Palace (Oxford, UK) Educational content: Basal Ganglia Club • Acute vertigo. The first question to be answered is whether this is central, i.e., Educational content: brainstem or cerebellar infarction, or periph- Chairperson: In this case-based workshop the participants eral, i.e., acute unilateral vestibulopathy/ Evzen Růička (Prague, Czech Republic) will learn in small working groups how to vestibular neuritis. This has major diagnostic diagnose and treat myasthenia gravis in and therapeutic consequences. By means of different stages of their condition. a careful patient history and a systematic • David Marsden Award Lecture – clinical examination one can make a correct Functional (psychogenic) Dystonia Limited to 60 participants. diagnosis with a sensitivity and specificity Mark Hallett (Bethesda, USA) This course is sold out! of more than 90%. Key clinical signs of a central lesion (“the big five”) are: skew de- • Video case presentations viation/vertical divergence, central fixation nystagmus (versus peripheral vestibular spontaneous nystagmus), gaze-evoked Session Content: nystagmus, saccadic smooth pursuit and Every year the European Basal Ganglia Club normal head-impulse test. Typical signs and features a prominent speaker to present a symptoms and their interpretation in terms C. David Marsden Award lecture. of a topographic anatomical diagnosis are In addition, selected video case studies will presented by the cases and discussed with be featured. Presenters of the video case the audience. studies will have been chosen through an • Acute diplopia. The goal of the session is application and selection process in colla to provide practicing neurologists with a boration with the International Parkinson framework for examining patients with acute and Movement Disorder Society – European diplopia. Based on a targeted history, the Section’s Education Committee. participants will be introduced to bedside examination skills with objective methods (e.g. cover test) and subjective methods (e.g. Maddox rod). Simple instrument-based methods, such as the Hess screen test, will be demonstrated to document strabismus. The examination skills will be presented in a case-based manner and discussed with the audience. SCIENTIFIC PROGRAMME PAGE 76 / 77

Sunday 17 June 15.00 – 18.15

15:00 – 16:30 15:00 – 18:15 15:00 – 18:15 Auditorium V Room Berlin Room Amsterdam

Teaching Course 6: Teaching Course 7: Special Session 10: Update on MS treatment - Clinical neurophysiology Clinical Grand Rounds Level 2 in neurorehabilitation - Level 2

Chairpersons: Chairperson: José Ferro (Lisbon, Portugal) Giancarlo Comi (Milan, Italy) Chairpersons: Miguel Coelho (Lisbon, Portugal) Josep Valls-Solé (Barcelona, Spain) • Treating relapsing remitting MS: Dafin Muresanu (Cluj Napoca, Romania) • Neuromuscular disorders what we have learned and what Mamede Carvalho (Lisbon, Portugal) we still need to know • Evoked potentials as biomarkers of Per Soelberg Sørensen neurologic dysfunction • Movement disorders (Copenhagen, Denmark) Peter Fuhr (Basel, Switzerland) Werner Poewe (Innsbruck, Austria) • Is there an option to treat progressive • Non-invasive brain stimulation for the • (Post) Stroke MS? improvement of motor function after Didier Leys (Lille, France) Giancarlo Comi (Milan, Italy) stroke Joseph Classen (Leipzig, Germany) Patients will be examined during the session • What is new on symptomatic treatment The clinician will first inform on the patient’s Alan Thompson (London, UK) • From immobility to spasticity. Neural history, focus on neurological examination, and non-neural components of move- work up a plan to confirm the diagnosis and • Strategies to enhance remyelination ment limitation etiology. Catherine Lubetzki (Paris, France) Josep Valls-Solé (Barcelona, Spain)

• Neurophysiological signals for brain Session Content: Educational content: computer interface The practice of Neurology has been trans- This course is designed for neurologists Donatella Mattia (Rome, Italy) formed and much improved by the use of a wishing to update their knowledge in the myriad of ancillary procedures, from neu- treatment of Multiple Sclerosis. The recent roimaging to antibody and genetic testing. availability of new treatments for relapsing Educational content: The current technology-based style of patient Multiple Sclerosis and the growing evidences Brain lesions involve changes in brain evaluation raises the question of the role of of the importance to personalise treatment activity, either because of adaptation, clinical skills in the diagnostic process. requires a careful evaluation of the tools compensation, plasticity or loss of function. In this session, highly experienced neurolo- that may assist the neurologist in treatment Neurorehabilitation intends to make benefi- gists will interview and examine real patients choice and in monitoring the response to cial use of such changes by promoting those with difficult or complex neurological condi- the intervention. The first treatment for that are adequate to give better function or tions. They will discuss the clinical diagnosis, progressive MS has been recently approved quality of live. Neurophysiology is the way request and review all available diagnostic by EMA with some restrictions. In parallel to understand how the basic mechanisms of tests and will end by formulating a final some positive perspectives have also been neurorehabilitation can work. In this course, diagnosis. opened for the treatment of secondary the speakers will deal with several aspects The session will highlight how clinical rea- progressive MS - how to implement these of how neurophysiology contributes to as- soning and skills are fundamental in guiding new options in clinical practice will be dis- sessment of clinical deficit, helps elucidating the neurological patient clinical pathway. cussed. New perspectives on remyelination pathophysiological mechanisms and provides have also quite recently appeared through useful guidance to treatment. The attendants Target audience: some proof of concept studies. Success and will be able to understand the value of bio- residents, practicing neurologists with failures in remyelination strategies and the markers of central nervous system function, interest in general neurology, movement dis- future developments will be extensively the bases for non-invasive stimulation treat- orders, stroke and neuromuscular disorders. explored. Relevant news are also available in ment, the physiology of changes from immo- symptomatic treatments and rehabilitation bility to spasticity and the role of remaining which are fundamental aspects in patient neurophysiological signals to assist in the use management. of computer-driven devices. SCIENTIFIC PROGRAMME

15:00 – 18:15 15:00 – 18:15 15:00 – 18:15 Auditorium II Auditorium VIII Auditorium III

Teaching Course 8: Teaching Course 9: Teaching Course 10: Tips and tricks in diagnosing New insights in the Current treatments in headache disorders - Level 1 management of patients neurology – Level 1 with ischaemic stroke or TIA - Level 2 Chairperson: Chairperson: Rigmor Hojland Jensen Nadine Attal (Glostrup, Denmark) Chairperson: (Boulogne-Billancourt, France) L. Jaap Kappelle • Taking a proper headache diagnosis (Utrecht, The Netherlands) • Current treatment possibilities in Rigmor Hojland Jensen dementia (Glostrup, Denmark) • Mechanical thrombectomy for acute Ana Verdelho (Lisbon, Portugal) ischaemic stroke • Introduction into the IHS classification Jesper Petersson (Malmö, Sweden) • Update on diagnosis and therapy of Gisela Terwindt (Leiden, The Netherlands) metabolic myopathies • Secondary prevention after stroke and Pascal Laforêt (Paris, France) • Neuroimaging in headache: atrial fibrillation why, when, how? Valeria Caso (Perugia, Italy) • Current treatment in Guillain-Barré Gioacchino Tedeschi (Naples, Italy) Syndrome and myasthenia gravis • Moyamoya syndrome Pieter A van Doorn • Neurophysiology and laboratory L. Jaap Kappelle (Rotterdam, The Netherlands) testing in headache (Utrecht, The Netherlands) Delphine Magis (Liège, Belgium) • Pain in neurology: what to treat • TIA and mimics and how Maria Tuna (Oxford, UK) Nadine Attal Educational content: (Boulogne-Billancourt, France) Participants will learn how to diagnose headache disorders according to the IHS classifi- Educational content: cation and how to apply further imaging and Without any doubt intra-arterial thrombec- Educational content: other investigations. tomy is the most spectacular breakthrough This Teaching Course on current treatments in the treatment of acute ischaemic stroke in various neurological disorders/diseases of the last decade. In this course both recent will give an update of current treatment and advances and chances for research with management strategies in dementias, muscle respect of this treatment will be discussed. disorders, two major autoimmune neuro- Atrial fibrillation is one of the most common muscular diseases, i.e. GBS and myasthenia causes of TIA in elderly patients. New oral gravis. Furthermore, not only neuropathic anticoagulants have been proven beneficial, pain, but pain associated with different types but there are still some uncertainties how of neurological diseases will be covered. The and when to use these new medications. lectures will not only refer to current state of Moyamoya disease should nowadays be the art therapies but also address secondary considered as an uncommon cause of TIA or and tertiary therapies and allow a glimpse ischaemic stroke in young patients. Clinical into potential future therapeutic options and features, diagnosis and management of this developments. intracranial vasculopathy will be the topic of the third presentation in this course. Finally, stroke neurologists know that a TIA can be a difficult diagnosis and that one of the most common causes of a TIA that does not respond to proper treatment is a wrong diagnosis. Therefore, mimics of TIA are important to recognise and will be discussed from a clinical point of view. SCIENTIFIC PROGRAMME PAGE 78 / 79

Sunday 17 June 15.00 – 18.45

15:00 – 18:15 16:45 – 18:15 16:45 – 18:45 Room Oslo Room CbW Room HoC

Teaching course 19: Hands-on Course 5: The neurological bedside Case-based Workshop 5: Ultrasound in vascular examination – the art of Neurogenetics goes therapy diagnosis - Level 1 identifying pathology - Level 1 Chairperson: Chairpersons: Ettore Salsano (Milan, Italy) Elsa Azevedo (Porto, Portugal) Chairperson: Natan Bornstein (Tel Aviv, Israel) Klaus V. Toyka (Würzburg, Germany) • A young female with sudden and recurrent abnormal movements • Basic principles in evaluation • Cranial nerves Iris Unterberger (Innsbruck, Austria) of carotid systems Jean Schoenen (Liège, Belgium) Natan Bornstein (Tel Aviv, Israel) • A young man with bilateral • Motor system including functional abnormalities of the basal ganglia • Evaluation of intracranial arteries motor disorders Yann Nadjar (Paris, France) by ultrasound Klaus V. Toyka (Würzburg, Germany) Elsa Azevedo (Porto, Portugal) • A strange case of psychotic behaviour • Reflexes & sensory system and intermittent ataxia • Assessment of the venous system Claudio Bassetti (Bern, Switzerland) Ettore Salsano (Milan, Italy) by ultrasound José Valdueza (Bad Segeberg, Germany) • Higher cortical functions and coma Joseph Classen (Leipzig, Germany) Educational content: Main goal of the workshop is to guide clini- Educational content: cians through the clinical reasoning process This course will give an overview about the Educational content: in diagnosing rare or very rare hereditary diagnostic abilities of extra and intracranial The TC is in part a repetition of the 2015 diseases (i.e., GLUT1 deficiency syndrome, ultrasound with special emphasis on stroke TC in Berlin with a largely extended video biotin-responsive encephalopathy, and and emergencies. Investigations with extra- demonstration of the examination tech- Hartnup disease) which are effectively and intracranial ultrasound will be demon- niques and its contextual interpretation, treatable. We will stress that the change in strated on healthy volunteers. and the examination of comatose patient. the treatment (beyond genetic counselling) Its content largely reflects the sections is possible also in very recently identified in- Limited to 60 participants. Please register of the EAN-e-book co-authored by Profs. herited neurologic diseases (Tarailo‑Graovac separately – additional fees will apply. Toyka, Classen, Schneider and Saur (see the et al., NEJM, 2016), thus justifying the need website of the EAN). The aim of the course of deep phenotyping and prompt access to is familiarising neurologists in training how advanced genetic studies to obtain the pre- to do the various tests at the bedside and in cise diagnosis. Each case will allow to revise the emergency room and how to interpret the causes of three uncommon neurologic/ findings in the context of other abnormalities neuroimaging syndromes, i.e., paroxysmal ultimately identifying pathology and making dyskinesias, bilateral abnormalities of basal a diagnosis. In addition, the course will ganglia and thalamus, and episodic ataxias, briefly address the principles of diagnosing and two of them will allow to briefly talk pseudo-neurological motor disorders by (1) about the differential diagnosis (sometime analysing motor patterns and (2) identifying difficult) of the functional/psychogenic incongruences of abnormal findings and disorders. (3) understanding the role of psychiatric confounders. Limited to 60 participants. Please register separately – additional fees will apply. In order to have access to the eBook and to download it directly from the website, you have to be an EAN member. SCIENTIFIC PROGRAMME

Sunday 17 June Oral sessions 15.00 – 16.45

15.00 – 16.30 16.15 | O201 15.45 | TBASIC04 Room Lisbon Short and long-term risks of stroke after A novel gene causing primary familial orthodox-definition transient ischaemic brain calcification: JAM2 Cerebrovascular diseases 1 attack versus disqualified monosympto- L.V. Schottlaender1, R. Abeti1, matic events: Oxford vascular study Z. Jaunmuktane1, M. Soutar1, J. McKinley2, Chairpersons: M.A. Tuna, P.M. Rothwell O. Swayne1, C. Bettencourt1, R. Forbes3, Jacques De Reuck (Ghent, Belgium) Oxford, UK P.J. Morrison2, D. Hughes1, A. Pittman1, Christian Enzinger (Graz, Austria) B. Kalmar1, M. de Grandis4, G.V. McDonnell2, S. Brandner1, M. Aurrand Lyons4, P. Giunti1, 15.00 | O204 15.00 – 16.30 H. Houlden1 Effect and safety of Tenecteplase in Room Room Copenhagen 1London, United Kingdom, 2Belfast, United Kingdom, stroke patients with atrial fibrillation 3Portadown, United Kingdom, 4Marseilles, France A.H. Aamodt1, E. Eriksen1, M. Kurz2, Tournament Basic L. Alteheld1, A. Fromm3, N. Logallo3, H. Naess3 Chairpersons: 16.00 | TBASIC05 1Oslo, 2Stavanger, 3Bergen, Norway Sofia Reimao (Lisbon, Portugal) Subcortical anatomy of the default mode Claudia Sommer (Würzburg, Germany) network: a functional and structural Pille Taba (Tartu, Estonia) connectivity study 15.15 | O202 P. Nascimento Alves1, C. Foulon2, L. Cerliani2, Idarucizumab in cerebral ischemia or 15.00 | TBASIC01 S. Karolis2, M. Thiebaut de Schotten2 intracranial hemorrhage under A missense mutation in the Low 1Lisbon, Portugal, 2Paris, France Dabigatran therapy in Germany – complexity domain of endogenous a nationwide case collection TDP43 induces gain of splicing function P. Kermer1, C. Eschenfelder2, H.-C. Diener3, and neurodegeneration in the mouse 16.15 | TBASIC06 M. Grond4 H. Oliveira1, P. Fratta2, T. Ricketts3, A passive transfer animal model of 1Sande, 2Ingelheim, 3Essen, 4Siegen, Germany P. Sivakumar2, K. Lo2, J. Humphrey2, CASPR2 antibodies S. Corrochano3, B. Kalmar2, V. Plagnol2, M.P. Giannoccaro1, D.A. Menassa1, W. Emmet2, A. Ule2, E. Buratti4, F. Baralle4, L. Jacobson1, E.P. Coutinho1, B. Lang1, 15.30 | O205 E. Pauws2, D. Housman5, E. Wang5, R. Liguori2, A. Vincent1 Characterisation of TRPM4-blocking N. Fawzi6, A. Isaacs2, P. Stanier2, 1Oxford, United Kingdom, 2Bologna, Italy antibody in ischaemic stroke M. Lythgoe2, Y. Gondo7, R. Fukumura7, K.Y. Loh, R.Z. Lee, C.P. Poore, P. Liao L. Greensmith2, E. Fisher2, Singapore, Singapore A. Acevedo-Arozena8 16.45 – 18.15 1Newcastle, United Kingdom, 2London, United King- Room Lisbon dom, 3Oxfordshire, United Kingdom, 4Trieste, Italy, 15.45 | O206 5Massachusetts, USA, 6Providence, USA, 7Tsukuba, Epilepsy Mechanical thrombectomy for acute Japan, 8La Laguna, Spain ischaemic stroke in the very old Chairpersons: A.S. Lopes de Sousa, M. Mariano, S. Galego, Tim von Oertzen (Linz, Austria) A. Fior, P. Ferreira, A. Paiva Nunes 15.15 | TBASIC02 Ivan Rektor (Brno, Czech Republic) Lisbon, Portugal Parkinson’s disease motor symptoms are linked to red nucleus volume and cerebellar metabolism 16.45 | O207 16.00 | O203 A. Bonnet1, R. Sanford2, A. Riou1, S. Drapier1, Will this child have epilepsy? Develop- Cerebral thrombi are heterogeneous and F. Le Jeune1, M. Vérin1, D.L. Collins2 ment and validation of a prediction model their composition correlates with the 1Rennes, France, 2Montreal, Canada to assess the risk of epilepsy after (a) density of the occluded vessel on CT scan paroxysmal event(s) A. Semerano, M. Pozzato, G. Gullotta, E. van Diessen1, H. Lamberink1, W. Otte1, D. Strambo, F. Simionato, F. Scomazzoni, 15.30 | TBASIC03 N. Doornebal2, O. Brouwer2, F. Jansen1, C. Righi, P. Panni, N. Anzalone, A. Falini, Salivary alpha-synuclein and tau in K. Braun1 F. Sanvito, C. Doglioni, G. Martino, G. Comi, Parkinson’s disease and progressive 1Utrecht, 2Groningen, Netherlands L. Roveri, M. Bacigaluppi supranuclear palsy Milan, Italy G. Vivacqua, S. Antonio, R. Mancinelli, A. Fabbrini, D. Belvisi, E. Bianchini, E. Gaudio, A. Berardelli Rome, Italy SCIENTIFIC PROGRAMME PAGE 80 / 81

Sunday 17 June 16.45 – 18.15

17.00 | O212 16.45 – 18.15 17.30 | O215 National surveillance of mortality in chil- Room Copenhagen Associations of anticoagulant use with dren with Epilepsy in the UK and Ireland outcome in newly diagnosed glioblastoma O. Abdel-Mannan, A. Sutcliffe Neuro-oncology E. Le Rhun1, E. Genbrugge2, R. Stupp3, London, UK O.L. Chinot4, L.B. Nabors5, T. Cloughesy6, Chairpersons: D.A. Reardon7, W. Wick8, T. Gorlia2, Wolfgang Grisold (Vienna, Austria) M. Weller9 17.15 | O211 Anette Storstein (Bergen, Norway) 1Lille, France, 2Brussels, Belgium, 3Chicago, USA, 4Mar- Laryngeal motor-evoked potentials as an seilles, France, 5Birmingham, 6Los Angeles, 7Boston, indicator of vagus nerve activation 16.45 | O216 USA, 8Heidelberg, Germany, 9Zurich, Switzerland C. Bouckaert, R. Raedt, S. Gadeyne, Stroke and „stroke-like” events after E. Carrette, S. Proesmans, F. Dewaele, brain radiotherapy: a large series with J. Delbeke, P. Boon, K. Vonck long-term follow-up 17.45 | O218 Ghent, Belgium G. Berzero1, A.L. Di Stefano2, F. Ducray3, Association between kynurenine M. Eoli4, A. Pichiecchio1, L.M. Farina1, metabolism in peripheral blood V. Cuccarini4, M.C. Brunelli5, L. Diamanti1, mononuclear cells and cognition in lung 17.30 | O209 S. Condette Auliac2, A. Salmaggi6, A. Silvani4, cancer patients undergoing Properties of epileptiform activity in the B. Giometto7, F. Bourdain2, A. Pace8, chemotherapy human hippocampus and temporal lobe A. Vidiri8, S. Bastianello1, M. Ceroni1, J. Rybacka-Mossakowska, D. Swiniuch, intraoperatively recorded: preliminary E. Marchioni1 J. Gazdulska, R. Ramlau, W. Kozubski, results 1Pavia, Italy, 2Suresnes, 3Lyons, France, 4Milan, 5Trevi- S. Michalak F. Farias Serratos1, C.V. Farias Serratos1, so, 6Lecco, 7Padua, 8Rome, Italy Poznan, Poland B.M. Farias Serratos2, K. Kawai3 1León, 2Querétaro, Mexico, 3Tokyo, Japan 17.00 | O213 18.00 | O217 Increased efficacy of carboplatin after Long-term follow-up of Optic Pathway 17.45 | O210 blood-brain barrier opening using low Gliomas in children with MiR-134 serum expression in Mesial intensity pulsed ultrasound in preclinical neuro fibromatosis type-1: Temporal Lobe Epilepsy (MTLE) patients models of glioblastoma an oncology hospital experience B. Leal, D. Rodrigues, C. Carvalho, A. Dréan, N. Lemaire, G. Bouchoux, M. Valente Fernandes, J. Passos, D. Garcez, R. Ferreira, J.M.M. Chaves, A. Bettencourt, L. Goldwirt, L. Goli, A. Bouzidi, C. Schmitt, M. Mafra, F. Campos, S. Nunes, D. Salgado J. Freitas, J.M.C.F. Lopes, M. Canney, J. Guehennec, M. Verreault, Lisbon, Portugal J.E.D.P. Ramalheira, A. Martins Da Silva, M. Sanson, J.-Y. Delattre, K. Mokhtari, P. P Costa, B. Martins Da Silva K. Beccaria, F. Sottilini, A. Carpentier, Porto, Portugal A. Idbaih Paris, France

18.00 | O208 Late onset epilepsy of unknown origin 17.15 | O214 and progression to dementia: two faces Clinico-radiological, molecular, of beta amyloid pathology therapeutic and prognostic features of M. Romoli1, P. Eusebi1, L. Farotti1, C. Liguori2, medulloblastoma of the adult: results C. Bedetti1, S. Siliquini1, N.B. Mercuri2, from an institutional series L. Parnetti1, P. Calabresi1, C. Costa1 F. Franchino, F. Roveta, C. Chiavazza, 1Perugia, 2Rome, Italy A. Pellerino, F. Bruno, F. Mo, I. Morra, C. Mantovani, R. Rudà Turin, Italy SCIENTIFIC PROGRAMME

Sunday 17 June Oral sessions 17.15 – 18.15

17.15 – 18.15 17.30 | O220 Auditorium V Brain-computer interface technology for upper limb rehabilitation after stroke: Miscellaneous 1 a translational effort F. Pichiorri, E. Colamarino, F. Cincotti, Chairpersons: D. Mattia Maxwell Damian (Cambridge, UK) Rome, Italy Gustave Moonen (Charneux-Herve, Belgium)

17.15 | O219 17.45 | O221 Predicting long-term neurological Clinical features and risk factors in outcome after cardiac arrest with serum Metronidazole-induced encephalopathy: Neurofilament Light chain a systematic review of 121 patients M. Moseby Knappe1, N. Mattsson1, C.G. Sørensen, W. Karlsson, F.M. Amin, N. Nielsen1, H. Zetterberg2, K. Blennow3, M. Lindelof J. Dankiewicz1, I. Dragancea1, Copenhagen, Denmark M.P.H. Friberg1, G. Lilja1, P.S. Insel1, C. Rylander2, E. Westhall1, J. Kjaergaard4, M.P. Wise5, C. Hassager6, M.A. Kuiper7, 18.00 | O222 P. Stammet8, M.C. Jaeger Wanscher6, Predicting factors for quality of life J. Wetterslev6, D. Erlinge1, J. Horn9, following Traumatic Brain Injury: T. Pellis10, T. Cronberg1 CROCFLAME catamnesis 1Lund, 2Gothenburg, 3Gothenburg/Mölndal, Sweden, K. Rauen1, L. Reichelt2, P. Probst2, 4Copenhagen, Denmark, 5Cardiff, UK, 6Copenhagen, B. Schäpers3, F. Müller3, K. Jahn3, N. Plesnila2 Denmark, 7Leeuwarden, Netherlands, 8Luxembourg, 1Zurich/Schlieren, Switzerland, 2Munich, Germany, Luxembourg, 9Amsterdam, Netherlands, 10Tricase, Italy 3Bad Aibling, Germany SCIENTIFIC PROGRAMME PAGE 82 / 83

Sunday 17 June 17.15 – 18.15 FINAL PROGRAMME SCIENTIFIC PROGRAMME PAGE 84 / 85

Monday 18 June 2018 SCIENTIFIC PROGRAMME

08:00 – 09:30 08:00 – 09:30 08:00 – 09:30 Room CbW Room HoC Auditorium VI

Case-based Workshop 6: Hands-on Course 6: Antibodies causing epilepsy Interpreting MRI Interactive Session 5: in practice - Level 2 Diagnostic pitfalls in neuromuscular disease Chairperson: Maarten J. Titulaer Chairperson: (Rotterdam, The Netherlands) Maria Assunta Rocca (Milan, Italy) Chairperson: Jochen Schäfer (Dresden, Germany) • Faciobrachial dystonic seizures and • White matter lesions other autoimmune seizure types Maria Assunta Rocca (Milan, Italy) • Bilateral finger extension weakness – Sarosh Irani (Oxford, UK) is it treatable? • Grey matter lesions Jochen Schäfer (Dresden, Germany) • What is the relevance of GAD65 Menno Schoonheim antibodies in epilepsy? (Amsterdam, The Netherlands) • A typical phenotype of proximal Helena Ariño (Barcelona, Spain) muscle weakness with an unusual • Brain atrophy genetic result • Antibodies in status epilepticus Gioacchino Tedeschi (Naples, Italy) Kristl Claeys (Leuven, Belgium) Maarten J. Titulaer (Rotterdam, The Netherlands) • A diagnostic conundrum - Educational content: various clinical manifestations, This 90-minute hands-on-course on MRI, same genetic defect Educational content: one of the key elements of diagnosis and Gabriele Siciliano (Pisa, Italy) There is an increasing of studies that link differential diagnosis in many neurological antibodies to epilepsy. However, it is cur- disease, is directed to specialist trainees rently unclear when to consider this cause and practitioners who already have a basic Educational content: for patients with epilepsy, and what pitfalls knowledge of neuroimaging. The course will In this interactive Session, differential can be expected. Three neurologists with have three stations with experts in the vari- diagnostic problems in neuromuscular expertise in both antibodies and epilepsy will ous aspects of imaging and the participants medicine will be discussed with the audience guide the attendants to this evolving new will rotate, to increase their possibility to using four cases to illustrate the diagnostic field of clinical neurology. The speakers will actively discuss practical issues. The attend- pathway and potential pitfalls in reaching a discuss the literature within this workshop ants will learn how to interpret imaging diagnosis. The cases will cover major fields of using different cases. The antibodies most features of white matter (WM) lesions in the neuromuscular medicine: channelopathies, frequently related to epilepsy are LGI1, GAD main WM diseases and will be trained in the muscular dystrophies, metabolic myopathies, and GABAbR, and these will be all discussed recognition of imaging red flags, useful for inflammatory myopathies. After presentation from different perspectives, and common the differential diagnosis of these conditions. of the cases the audience will be invited to issues of debate during diagnosis and They will become familiar with imaging offer diagnostic options by means of a smart- treatment will be covered within these case strategies to identify lesions of the grey mat- phone voting app; furthermore, questions presentations. ter (GM) and will directly apply guidelines will be asked and discussed regarding inves- for the assessment of these lesions. Finally, tigations and management of the patient. Limited to 60 participants. Please register they will have the chance to participate Emphasis will be laid upon demonstrating separately – additional fees will apply. to a session of practical quantification of ways how to approach a neuromuscular atrophy in healthy subjects and patients with patient with seemingly puzzling physical different neurological conditions and will be findings and how to consider and evaluate guided in the interpretation of physiological the neuromuscular differential diagnoses. and disease-related variations of brain atrophy measures. Please download the app “EAN Congress” to actively participate in this Session and vote. Limited to 60 participants. This course is soldout. SCIENTIFIC PROGRAMME PAGE 86 / 87

Monday 18 June 08.00 – 09.30

08:00 – 09:30 08:00 – 09:30 08:00 – 09:30 Room Berlin Auditorium II Auditorium V

Focused Workshop 11: Focused Workshop 13: CGRP inhibition for migraine Focused Workshop 12: Autoimmune encephalitis in prevention – hype or hope? Neurogenetic avenues the Intensive Care Unit (ICU) and new directions on risk factors in dementia? Chairperson: Chairperson: Michel Ferrari (Leiden, The Netherlands) Harald Prüss (Berlin, Germany) Chairperson: • Rationale of blocking CGRP Ana Isabel Verdelho (Lisbon, Portugal) • New concepts in etiology and Messoud Ashina (Copenhagen, Denmark) disease mechanisms in • The penetrance continuum of genetic autoimmune encephalitis • Clinical results variants in common causal and risk Harald Prüss (Berlin, Germany) Uwe Reuter (Berlin, Germany) genes in neurodegenerative dementia Christine Van Broeckhoven • “Established” and experimental • Clinical interpretation (Antwerp, Belgium) treatments of refractory Michel Ferrari (Leiden, The Netherlands) autoimmune encephalitis • Large data bases, big science? Stephan Rüegg (Basel, Switzerland) Pieter Jelle Visser Scientific content: (Maastricht, The Netherlands) • Epileptic seizures and status in Phase-2 trials have shown great promise autoimmune encephalitis of CGRP (Calcitonin gene-related peptide) • To exercise prevention Sophie Demeret (Paris, France) and CGRP receptor antibodies and small Ana Isabel Verdelho (Lisbon, Portugal) molecule antagonist in the prevention and acute treatment of migraine and cluster Scientific content: headache attacks. By 2018 most phase-3 Scientific content: In this Focused Workshop we will give lec- trials will have been completed. Efficacy and The objective of this session is to approach tures about the issue of severe autoimmune safety data will be presented and critically recent advances on the field of dementia and encephalitis, requiring neurointensive care. compared with those of existing migraine to make a critical appraisal of the real con- New concepts of etiology and pathophysiol- and cluster headache prophylactic (e.g. tribute of those advances in clinical practice. ogy as well as special aspects of treatment, topiramate, propranolol, verapamil) and also alternative methods in refractory cases acute (e.g. triptans) treatments. will be discussed. Prompt recognition of epileptic seizures or status epilepticus and Target audience: adequate treatment are essential as this can All clinical neurologists; basic science re- prevent permanent neurological damage. searcher with respect to pharmacology SCIENTIFIC PROGRAMME

08:00 – 09:30 area of major unmet need. This session will 08:00 – 09:30 Auditorium VIII review current treatments for depression, Room Oslo cognitive impairment, psychosis and impulse control disorder and will also consider future Focused Workshop 16: Focused Workshop 14: possible therapeutic approaches. Precision medicine in stroke EAN/MDS-ES: Evidence- based medicine and beyond in neuropsychiatric complications 08:00 – 09:30 Chairperson: of Parkinson‘s diseases Room Amsterdam José M Ferro (Lisbon, Portugal)

Focused Workshop 15: • Do we need precision medicine Chairperson: Guillain-Barré Syndrome: in stroke? David John Burn new developments in Daniel Bereczki (Budapest, Hungary) (Newcastle upon Tyne, UK) immunology, electrophysiology and treatment • Do we already have precision • Treatments of depression in medicine in stroke? Parkinson’s disease Catarina Fonseca (Lisbon, Portugal) Olivier Rascol (Toulouse, France) Chairperson: Peter Van den Bergh (Brussels, Belgium) • What to expect in the future? • Therapeutic approaches of cognitive Joan Montaner (Barcelona, Spain) decline and dementia • Understanding the auto-immune David John Burn attack (Newcastle upon Tyne, UK) Hugh J. Willison (Glasgow, UK) Scientific content: Precision medicine means a tailored ap- • Therapeutic approaches of • Unravelling the electrophysiological proach to the diagnosis and management of hallucinations and psychosis diagnostic challenges the individual patient. Its ultimate goal is to Murat Emre (Istanbul, Turkey) Peter Van den Bergh (Brussels, Belgium) provide individualised treatment for each patient, avoiding the incertitude and side-ef- • Prevention, detection and therapeutic • Novel treatment methods fects of current treatment strategies. Person- approaches of impulsivity disorders Pieter A. van Doorn alised medicine is already a reality in current Angelo Antonini (Padua, Italy) (Rotterdam, The Netherlands) practice in oncology, both for establishing individual prognosis, and more importantly to select chemotherapy and immunotherapy Scientific content: Scientific content: for each patient, based on a number of ge- This focused workshop will address several This focused workshop aims at presenting netic and biochemical biomarkers. For other key non-motor symptoms that frequently recent advances in the understanding of the fields of medicine the applications of pre- complicate the course of Parkinson’s or pathophysiology of Guillain-Barré syndrome. cision medicine in daily practice, although may even predate the motor features. In New insights in the immunopathology and promising, are still in its infancy. That is the part, these symptoms may be precipitat- electrophysiological abnormalities will case of stroke, whose current management ed or exacerbated by drugs used to treat be discussed. They are leading to novel only occasionally needs genetic information. motor impairments. But undoubtedly the treatment algorithms and to more specific However, this scenario is likely to be modi genesis of depression, cognitive impairment, treatments. fied soon, due to developments in biology, psychosis and impulse control disorder imaging, and informatics. Prof. Bereczki will relates to underlying neuropathological introduce the topic and will scrutinise if we and neurochemical changes in strategic need precision medicine beyond the clinical, brain areas. Treatments used to manage biochemical and imaging parameters that these challenging symptoms are generally we currently use to decide on treatments inadequate, despite their de facto logical and to provide prognostic information. Dr. focus on neurotransmitter placement and/or Fonseca will review recent progresses on the receptor stimulation. Furthermore, despite application of precision medicine to stroke, the availability of several agents in class, including a glimpse of ongoing studies. The such as antidepressants, the evidence basis last speaker, Prof Montaner, will address the to guide treatment of many of these symp- road to success of future developments in the toms is poor. Neuropsychiatric symptoms field, including expected advances in genom- associated with Parkinson’s are therefore an ics, serological biomarkers, novel biological data, imaging information and on the issues SCIENTIFIC PROGRAMME PAGE 88 / 89

Monday 18 June 08.00 – 09.30

raised by the analysis of large data collection presented abnormalities that could be of clinical Most of the current healthcare systems do of stroke patients both from clinical trials, significance. The bridging from diagnostic to not adequately respond to the need of pa- registries and administrative sets. therapeutic interventions was made in the last tients with brain disorders. They mainly re- decades of the XX Century with the first devices spond when a person is sick and have many able to perform intravascular interventions. deficiencies in the management of patients 08:00 – 09:30 Emergency intravascular procedures for clot with brain disorders who need long-term Room Lisbon removal, was the next step. These are only a few care and treatment. examples how human creativity can surpass We present the results from the Value of Special Session 8: imagination. Treatment (VoT) Project providing evidence History of Neurology: on the socio-economic impact of coordinated Lessons from Portuguese and patient-centered clinical interventions clinical neurosciences 08:00 – 09:30 which has been launched within the Euro- Room Copenhagen pean Brain Council. EAN was responsible for the neurological diseases and the scope Chairperson: of this project will be presented. EFNA will Victor Oliveira (Lisbon, Portugal) Special Session 9: face the issue from the person with BD per- EAN/EBC/EFNA: The Value spective through the description of a ‘patient • Functional neurosurgery: of Treatment (VoT) of brain journey’ from diagnosis to treatment, with leucotomy revisited disorders special focus on patient reported outcomes, Alim Benabid (Grenoble, France) highlight on the main needs of people with BD, and ultimately providing elements for • Would whole-exome sequencing Chairpersons: improving care pathways of people with BD. change the history of Wolfgang Oertel (Marburg, Germany) Machado Joseph disease? David Vodušek (Ljubljana, Slovenia) Patricia Maciel (Braga, Portugal) Maura Pugliatti (Ferrara, Italy)

• From pioneers to interventional • Brain disorders in Europe: unmet needs angiography Wolfgang Oertel (Marburg, Germany) Victor Oliveira (Lisbon, Portugal) • The value of early diagnosis and treatment. A patient journey Scientific Content: Joke Jaarsma The field of Neurosciences deals nowadays (Amsterdam, The Netherlands) with some challenges where one can track the connection with the early landmarks of • The Value of Treatment: Using Neurology. Some new discoveries or therapeutic economic modelling to assess costs applications revisit old attempts and, in some and outcomes associated with health sense, pursue them. Surgical interventions care interventions. in the brain were desperate attempts to help Michela Tinelli (London, UK) mental ill patients in the absence of any effi- cacious medication and without any foreseen • The value of health: improving way to entertain hope for a barely normal life. outcomes and care pathways Deep brain stimulation for different therapeutic Richard Dodel (Marburg, Germany) targets pursues the idea of surgical intervention in the brain to achieve therapeutic benefits. Well • The value of early treatment identified genetic diseases with precise abnor- Maura Pugliatti (Ferrara, Italy ) malities, allow us to entertain the hope of some sort of highly selective interventions to restore the normal sequence of amino-acids helping Session Content: people to benefit from them. The broad use of Brain disorders (mental and neurological angiography as it is performed at these early disorders) represent an enormous burden decades of the XXI century only hardly could be on both individuals and societies. The broad anticipated by Egas Moniz when he performed impact of brain disorders (BD) is threatening the first angiograms trying to identify intracra- the quality of life of millions of European nial tumours or even when, a few years later, citizens with important implications on he understood that the vessels, themselves, economic growth. SCIENTIFIC PROGRAMME

10:00 – 12:00 netic reactivation of endogenous genes. Others, 15:00 – 17:00 Auditorium I as (4) zinc-finger transcriptional repressors and Room Berlin (5) CRISPR/Cas9 constructs (“gene editing”), interact directly with DNA. Fine examples Symposium 6: Coma: Plenary Symposium 3: of these therapeutical strategies, in recessive neuromodulation, Molecular and genetic (spinal muscular atrophy and Friedreich ataxia) imaging and neurobiology therapies for neurogenetic and dominant neurological diseases (familial disorders amyloid neuropathy and Huntington disease), are being presented in this session. Chairpersons: Steven Laureys (Liège, Belgium) Chairpersons: Karin Diserens (Lausanne, Switzerland) Jorge Sequeiros (Porto, Portugal) 15:00 – 17:00 Jean-Marc Burgunder (Bern, Switzerland) Auditorium I • Mechanisms of impaired consciousness Daniel Kondziella (Copenhagen, Denmark) • Molecular and genetic therapies for Friedreich ataxia Symposium 5: • Where structural changes Massimo Pandolfo (Brussels, Belgium) The spectrum of dementias predict outcome Louis Puybasset (Paris, France) • Antisense oligonucleotide and gene replacement therapy in spinal Chairpersons: • Cognitive-motor dissociation: cave! muscular atrophy: a new therapeutic era Jonathan Schott (London, UK) Karin Diserens (Lausanne, Switzerland) for motor neuron diseases Evelien Lemstra Kevin Talbot (Oxford, UK) (Leiden, The Netherlands) • Neuromodulation: outlook into the future • Anti-amyloid and gene therapy in the • Alzheimer’s disease Steven Laureys (Liège, Belgium) treatment of familial amyloid Reinhold Schmidt (Graz, Austria) polyneuropathy Maria Joao Saraiva (Porto, Portugal) • Vascular dementia Scientific Content: José Ferro (Lisbon, Portugal) Clinical and paraclinical evaluation of • Gene-based therapy in neurological patients in coma and with chronic disorders disorders: what is in the pipeline? • Frontal lobe dementias of consciousness after brain injury has expe- Jean-Marc Burgunder (Bern, Switzerland) Jonathan Schott (London, UK) rienced an important development in these last years. This symposium aims at providing • Lewy body dementia the audience with updated information on Scientific Content: Evelien Lemstra several domains, which will cover current In recent years, novel therapeutical strategies (Leiden, The Netherlands) understanding of mechanisms subtend- and new approaches to old ones brought fresh ing disorders of consciousness, practice in hope for treatment of hereditary neurological post-cardiac arrest prognostication, newer diseases. We have been seeing the emergence Scientific Content: neuroimaging data, an updated version of of a variety of therapies, either aimed at a faulty The dementias are at the heart of neurology: evaluation of chronic patients and an outlook (missing or toxic) protein function, targeted at brain disorders with a significant impact on into neurostimulation. RNA expression (gene silencing) or at DNA itself society and a huge challenge for neurologists (gene therapy). Increased knowledge on disease in terms of diagnosis, treatment and care. Target Audience: progression, biomarkers and measurable out- Knowledge of the full spectrum of dementias Neurologists, neurointensivists, nurses in comes, as well as on pathogenic pathways and is needed for each neurologist because of the ICU, clinical neurophysiologists. networks, enabled more and better functional high prevalence. The symposium covers all and preclinical studies (in cell and animal mod- major diseases causing dementia and high- els). As a consequence, abundant clinical trials lights all aspects of the diseases, given by have been conducted or are now under way. New the best specialists within the EU Neurology pharmaceutical molecules and novel genetic community therapies have been developed for systemic or intrathecal delivery. Some, like (1) antisense oligonucleotides and (2) RNA interference compounds, interfere with messenger RNA, to reduce its expression, while (3) small molecules are designed to alter RNA splicing or for epige- SCIENTIFIC PROGRAMME PAGE 90 / 91

Monday 18 June 15.00 – 16.30

15:00 – 16:30 15:00 – 16:30 15:00 – 16:30 Room CbW Room Amsterdam Room HoC

Controversy 1: Hands-on Course 7: Case-based Workshop 7: Steroids in neuroinfections & Neuro-otology - Rare headache syndromes: Seizures and eleptiform Level 2 idiopathic or symptomatic? discharges

Chairperson: Chairperson: Chairpersons: Eleftherios Papathanasiou Peter Sandor (Baden, Switzerland) Israel Steiner (Petach Tikvah, Israel) (Nicosia, Cyprus) Iris Unterberger (Innsbruck, Austria) • Exercise and sexual headache types • Benign paroxysmal positional vertigo: Stefan Evers (Münster, Germany) • Steroids in Acute and chronic provocation and liberation maneuvers Bacterial Meningitis - PRO Michael Strupp (Munich Germany) • Thunderclap headache types Diederik van de Beek Thomas Brandt (Munich, Germany) Raquel Gil-Gouveia (Lisbon, Portugal) (Amsterdam, The Netherlands) • Vestibular evoked myogenic potentials • Chronic daily persistent headache • Steroids in Acute and chronic Eleftherios Papathanasiou Peter Sandor (Baden, Switzerland) Bacterial Meningitis - CON (Nicosia, Cyprus) Erich Schmutzhard (Innsbruck, Austria) Dominik Straumann (Zurich, Switzerland) Educational content: • Seizures and epileptiform discharges In this workshop, participants can learn worsen clinical outcome and should • Video impulse test to identify rare other idiopathic headache be aggressively treated Konrad P. Weber (Zurich, Switzerland) disorders (group 4 of IHS classification) and Nicolas Gaspard (Brussels, Belgium) to differentiate from similar symptomatic • Neuro-otological bedside tests headache disorders • Seizures and epileptiform discharges Adolfo Bronstein (London, UK) do not impact clinical outcome and Marianne Dieterich (Munich, Germany) Limited to 60 participants. Please register should not be aggressively treated separately – additional fees will apply. Vincent Alvarez (Lausanne, Switzerland) Educational content: This course encompasses the major bedside Educational content: and auxiliary tests for evaluating patients Part1: with vestibular signs and symptoms. A room Steroid therapy in neurological infections rotating scheme has been designed with and seizures impact and management four stations, spending twenty minutes at in comatose patients are a controversial each, with practical demonstrations. The topic. The debate will focus on its use in benign paroxysmal positional vertigo (BPPV) bacterial and viral infections of the nerv- and neuro-otological bedside test stations ous system will involve the neuro-otological clinical examination and the treatment of BPPV with Part 2: the different manoeuvers for each separate To know the consequences of seizures on canal BPPV. The vestibular evoked myogenic brain and clinical outcome of acutely ill potential station will use a common evoked patients and to know how to approach potential system available in all neurophys- subclinical seizures in the ICU and to un- iological laboratories. The head impulse derstand the pros and cons of aggressive station will demonstrate head mounted anti-seizures treatment video systems commercially available for eye movement documentation.

Limited to 60 participants. Please register separately – additional fees will apply. SCIENTIFIC PROGRAMME

15:00 – 16:30 15:00 – 18:15 PD patients, will be discussed, along with Auditorium VI Auditorium II evidence on how best to approach treatment. After successfully completing this course the Interactive Session 6: participants should be able to: Not every twitch or Teaching Course 11: 1) identify and approach clinically important movement is a seizure in EAN/MDS-ES: Evidence- motor and non-motor determinants of qual- the neurological ICU based medicine in the ity of life in a patient with PD from early to treatment disabling motor advanced disease and non-motor trouble in 2) understand evidence-based treatments to Chairperson: Parkinson‘s disease - Level 2 approach gait problems and falls, as well as Raimund Helbok (Innsbruck, Austria) autonomic dysfunction and sleep problems in a patient with PD • Not every twitch is a seizure - Chairperson: 3) make clinical decisions that take into the view of an epileptologist Maria Stamelou (Athens, Greece) account the scientific evidence and patient Andrea Rossetti (Lausanne, Switzerland) preferences on an individualised level. • Falls and gait disorders • Movement disorders associated with Even Růička (Prague, Czech Republic) hypoxic encephalopathy and brain death • Bladder disturbances and Raimund Helbok (Innsbruck, Austria) sexual disorders Maria Stamelou (Athens, Greece) • Encephalitis and movement disorders Pille Taba (Tartu, Estonia) • Hypotension and dysautonomia .Gregor K. Wenning (Innsbruck, Austria)

Educational content: • Nocturnal and sleep problems in PD Seizures are commonly observed in the Claudia Trenkwalder (Kassel, Germany) setting of acutely brain injured patients. Differentiation of epileptic seizures from non-epileptic seizures is challenging for the Educational content: clinician and may be facilitated by the use Parkinson’s disease is heterogeneous in clin- of continuous EEG monitoring. Moreover, ical presentation and evolution of motor and especially in patients with autoimmune non-motor symptoms. The pharmacological encephalitis, hypoxic brain injury and brain and non-pharmacological treatment of the death, typical and sometimes bizarre move- individual patient is challenging in particular ment disorders are observed. Clinical cases in advanced stages of the disease. This will be presented with videos of patients and teaching course aims to provide the basis for supported by additional monitoring tools independently and individually apply current (i.e. EEG). Each section will include a brief evidence based treatments for disabling discussion of the underlying disease. motor and non-motor features in patients with Parkinson’s disease, in clinical practice. Please download the app “EAN Congress” to More specifically, the first talk will focus on actively participate in this Session and vote. evidence-based pharmacological and rehabilitation approaches to deal with, probably the most important determinants of quality of life and prognosis in terms of motor symptoms, e.g., the falls and gait-disorders. The following talks will focus on evidence based treatments of important non-motor symptoms of PD, specifically urinary and sexual problems, as well as autonomic dysfunction, as expressed among other with orthostatic or post-prandial hypotension. Lastly, sleep related issues that may be prevalent in Parkinson’s disease and may influence the quality of sleep, and thus, quality of life in SCIENTIFIC PROGRAMME PAGE 92 / 93

Monday 18 June 15.00 – 18.15

15:00 – 18:15 15:00 – 18:15 15:00 – 18:15 Auditorium V Auditorium VIII Room Lisbon

Teaching Course 12: Teaching Course 13: EAN/ILAE-CEA: How to New concepts in critical care Teaching Course 14: approach EEG and avoid of stroke patients - Level 3 How to approach a patient overreading in epilepsy - with neuropathy: from Level 1 symptoms to diagnosis Chairperson: - Level 2 Stefan Schwab (Erlangen, Germany) Chairperson: Soheyl Noachtar (Munich, Germany) • Ischemic stroke: periinterventional Chairperson: management for acute Eduardo Nobile-Orazio (Milan, Italy) • Systematic approach to neurointerventions EEG abnormalities Bart van der Worp • Sensory Motor neuropathy Soheyl Noachtar (Munich, Germany) (Utrecht, The Netherlands) Michael Lunn (London, UK)

• How to localise EEG potentials • Intracerebral hemorrhage (ICH) • Motor neuropathy Sándor Beniczky (Dianalund, Denmark) in patients with anticoagulation: Eduardo Nobile-Orazio (Milan, Italy) New therapeutic options? • What are epileptiform discharges & Stefan Schwab (Erlangen, Germany) • Sensory Neuropathy what do they mean clinically? Claudia Sommer (Würzburg, Germany) Francisco Sales (Coimbra, Portugal) • Subarachnoid hemorrhage (SAH): How do we treat delayed ischemic • Focal and asymmetric neuropathy • What is spiky but not neurological deficit (DIND) Jean-Marc Léger (Paris, France) epileptiform discharges? Erich Schmutzhard (Innsbruck, Austria) Matthew C. Walker (London, UK) • Spontaneous intracerebral Endorsed by the Peripheral Nerve hemorrhage (ICH): The issue of Society (PNS) Educational content: perihemmorhagic edema EEG is a strong tool in the diagnosis of Dimitre Staykov (Eisenstadt, Austria) epilepsy. Yet, it is a subjective method Educational content: with inherent short comings, when it is not This introductory course is mainly directed approached systematically. This course will Educational content: at specialist trainees or practitioners wishing first give a systematic approach to reading Discussion of new therapeutic concepts in to update and further develop their knowl- the EEG and typical pitfalls. Then, the local- the management of patients with acute cer- edge in the diagnosis of neuropathy. The isation of EEG discharges will be discussed ebrovascular disease treated on the NCCU. speakers will address how to approach a pa- with its use for differential diagnosis and Especially the peri-interventional manage- tient according to their clinical presentation typical pitfalls, when localisation is not done ment of patients undergoing thrombectomy and how to focus the diagnostic investigation adequately. The last two lectures will give in ischemic stroke is debated and clear according to them. We will also try to sug- an overview of what constitutes an IED, how guidelines are missing. Another topic will gest a correct sequence of tests to be used to well EEG finds IEDs, what they mean clini- be laid on the management of patients achieve a correct diagnosis starting from the cally and lastly, which discharge differential with intracerebral haemorrhage and brain less expensive and traumatic ones. diagnoses exist and how to identify them. oedema therapy as well as special therapy of ICH under anticoagulation. Patients with subarachnoid haemorrhage often develop further complications after aneurysm repair. However, neurocritical care therapy is often complicated by vasospasm which can cause further ischemic events, possible treatment interventions will be discussed. SCIENTIFIC PROGRAMME

Monday 18 June 16.45 – 18.45

16:45 – 18:45 Educational content: and other spontaneous activity at rest, motor Room HoC Dysfunctions of the pyramidal tract may unit potentials (MUP) at weak effort, and the require assessment of central conduction time recruitment pattern at maximal voluntary Hands-on Course 4: and other central motor functions to complete effort. The examiner should be trained and Basic EMG - needle EMG the diagnostic workout. This is accomplished skilful enough to combine sound and vision and transcranial magnetic nowadays thanks to the use of transcranial for the identification of subtle abnormalities. stimulation as an magnetic stimulation (TMS). Apart from In this Hands-on-Course, the speaker will electrodiagnostic tool - the most common evaluation of central demonstrate how to perform a needle EMG Level 2 conduction time, TMS allows for the study exam, including positioning of the needle and of sensorimotor integration, cortical maps of searching for relevant information. There representation of muscles, excitability thresh- will also be demonstration of techniques to Chairperson: old, intracortical inhibition and many other quantitate the shape, duration and amplitude Letizia Leocani (Milan, Italy) features of the motor system. The course is of MUPs, which are useful in the assessment intended to familiarize the attendants with of degenerative neuromuscular disorders. The • Transcranial magnetic stimulation the magnetic stimulators and practice in attendants will actively participate in discussing as an electrodiagnostic tool themselves the evaluation of central motor the exams and interpretation in volunteers Letizia Leocani (Milan, Italy) functions. Needle electromyography (EMG) is an This course is supported by NATUS Medical • Needle EMG essential part of electro-diagnosis. Several Inc. and MagVentures. Christian Krarup different criteria are recorded to diagnose (Copenhagen, Denmark) neurogenic disorders or myopathy. These Limited to 60 participants. Please register include recording of denervation potentials separately – additional fees will apply.

ANZEIGE? SCIENTIFIC PROGRAMME PAGE 94 / 95

Monday 18 June 16.45 – 18.45 SCIENTIFIC PROGRAMME

Monday 18 June Oral sessions 15.00 – 16.30

15.00 – 16.15 15.45 | O303 15.00 – 16.30 Room Copenhagen EEG microstates - association with Room Oslo cognitive impairment and Alzheimer’s Ageing and dementia disease CSF biomarkers Tournament Clinical U. Smailovic1, T. Koenig2, T. Andersson1, Chairpersons: E. Jonsson Laukka1, G. Kalpouzos1, Chairpersons: Patrik Cras (Edegem, Belgium) B. Winblad1, V. Jelic1 Klaus V. Toyka (Würzburg, Germany) Bruno Dubois (Paris, France) 1Stockholm, Sweden, 2Berne, Switzerland Patricia Canhao (Lisbon, Portugal) Hanna Cock (London, UK) 15.00 | O304 Added value of multimodal structural 16.00 | O306 MRI to the clinical diagnosis of primary Metabolic correlates of reserve and 15.00 | TCLIN01 progressive aphasia variants resilience in MCI due to Alzheimer’s Assessment of diabetic medication in E. Canu1, F. Agosta1, F. Imperiale1, F. Caso1, Disease (AD) ~8,000 dementia patients with diabetes A. Fontana2, G. Magnani1, A. Falini1, M. Bauckneht1, A. Chincarini1, R. Piva1, mellitus. A study from the Swedish G. Comi1, M. Filippi1 D. Arnaldi1, N. Girtler1, F. Massa1, Dementia Registry 1Milan, 2San Giovanni Rotondo, Italy M. Pardini1, H. Efeturk1, M. Pagani2, J. Secnik1, E. Schwertner1, K. Johnell2, G. Sambuceti1, F. Nobili1, S.D. Morbelli1 J. Fastbom2, M. Alvarsson1, B. Winblad1, 1Genoa, 2Rome, Italy S. Garcia-Ptacek1, M. Eriksdotter1, D. Religa1 15.15 | O305 1Stockholm, Sweden, 2Stockhom, Sweden Enrichment of clinical trials in prodromal AD using ventricular volume to identify individuals at increased risk of rapid 15.15 | TCLIN02 disease progression Cerebrovascular events after surgery M. Marizzoni1, C. Ferrari1, L. Cavaliere1, versus conservative therapy for M. Didic2, G.L. Forloni3, J. Jovicich4, moyamoya disease: a meta-analysis J.L. Molinuevo Guix5, F. Nobili6, I. Smets, A. Wouters, R. Lemmens L. Parnetti7, P. Payoux8, F. Ribaldi1, Leuven, Belgium P.M. Rossini9, P. Schonknecht10, A. Soricelli11, M. Tsolaki12, P.J. Visser13, J. Wiltfang14, R. Bordet15, O. Blin2, G. Frisoni16 15.30 | TCLIN03 1Brescia, Italy, 2Marseilles, France, 3Milan, Italy, 4Trent, Pediatric and adult ms: a longitudinal multi- Italy, 5Barcelona, Spain, 6Genoa, Italy, 7Perugia, Italy, modal MRI study to explore the substrates 8Toulouse, France, 9Rome, Italy, 10Leipzig, Germany, of the different clinical courses 11Naples, Italy, 12Thessaloniki, Greece, 13Amsterdam, E. de Meo1, M.A. Rocca1, A. Meani1, Netherlands, 14Essen, Germany, 15Lille, France, L. Moiola1, B. Colombo1, M. Rodegher1, 16Geneva, Switzerland A. Ghezzi2, G. Comi1, A. Falini1, M. Filippi1 1Milan, Italy, 2Gallarate, Italy

15.30 | O302 ABBV-8E12, a humanised anti-Tau 15.45 | TCLIN04 monoclonal antibody for the treatment Safety and efficacy of percutaneous of Early Alzheimer’s disease and PSP: pulsed radiofrequency at the C1-C2 level in multiple dose, randomised, double-blind, chronic cluster headache: a retrospective placebo-controlled Phase-2 studies analysis of 21 cases N. Mendonca1, H. Florian2, D. Wang2, T. Kelderman, G. Vanschoenbeek, W. Robieson2, H. Soares2, J.B. Braunstein3, E. Crombez, K. Paemeleire D.M. Holtzman3, R.J. Bateman3, Ghent, Belgium B. Rendenbach-Mueller1, K. Budur2 1Ludwigshafen, Germany, 2North Chicago, USA, 3Saint Louis, USA SCIENTIFIC PROGRAMME PAGE 96 / 97

Monday 18 June 17.15 – 18.15

16.00 | TCLIN05 17.15 – 18.15 16.45 – 18.15 Has deep brain stimulation changed the Auditorium I Auditorium VI natural history of Parkinson’s disease? A case control longitudinal study Peripheral nerve disorders 2 Cerebrovascular diseases 2 P. Mahlknecht1, M. Peball1, M. Werkmann1, K. Mair1, M. Nocker1, W. Eisner1, C. Peralta2, Chairpersons: Chairpersons: S. Eschlböck1, G.K. Wenning1, P. Willeit1, Davide Pareyson (Milan, Italy) Valeria Caso (Perugia, Italy) K. Seppi1, W. Poewe1 Judith Molnar (Budapest, Hungary) José Ferro (Lissabon, Portugal) 1Innsbruck, Austria, 2Buenos Aires, Argentina 17.15 | O309 16.45 | O312 16.15 | TCLIN06 Validity and reliability of the Transthyretin Direct oral anticoagulants versus Vitamin Neuromyelitis optica spectrum disorder Amyloidosis Neuropathy Score (TTR- K antagonists after a recent ischaemic and rituximab: a multi-center analysis ANS): a new outcome measure designed stroke: a pooled individual patient data G. Novi1, M. Capobianco2, F. Gallo1, specifically for Familial Amyloid analysis G. Mataluni3, A. Signori1, A. Laroni1, Polyneuropathy (TTR-FAP) D.J. Seiffge1, M. Paciaroni2, D. Wilson3, P. Annovazzi4, F. Buttari5, S. Rossi6, C. Monteiro1, C. Rodrigues2, J. Fernandes2, M. Koga4, K. Macha5, M. Cappellari6, L. Zuliani7, F. Sica5, E. Cocco8, L. Benedetti1, M. Cardoso2, C. Alves2, A. Martins Da Silva2, S. Schaedelin1, C. Shakeshaft3, M. Takagi4, J. Frau9, S. Malucchi10, F. Sperli2, T. Coelho2 B. Bonetti6, B. Kallmünzer5, P. Bovi6, M.P. Sormani1 1La Jolla, USA, 2Porto, Portugal S. Schwab5, G. Tsivgoulis7, P. Lyrer1, 1Genoa, Italy, 2Orbassano, Italy, 3Rome, Italy, 4Galla- K. Toyoda4, D. Werring3, V. Caso8, rate (VA), Italy, 5Pozzilli, Italy, 6Milan, Italy, 7Treviso, S. Engelter1, G.M. de Marchis1 Italy, 8CAGLIARI, Italy, 9Cagliari, Italy, 10Orbassano 17.30 | O308 1Basel, Switzerland, 2Perugia, Italy, 3London, UK, (TO), Italy Mutations in MME cause autosomal 4Osaka, Japan, 5Erlangen, Germany, 6Verona, Italy, recessive late-onset CMT type-2 disease 7Athens, Greece, 8Perugia, Italy M. Frasquet Carrera1, A. Sánchez-Monteagudo1, 17.00 | O313 A.L. Pelayo-Negro2, T. Garcia-Sobrino3, Cerebrovascular lesions during normal J. Pardo Fernandez3, M. Misiego4, aging: a neuropathological study with J. Garcia-Garcia5, M.-J. Sobrido3, 7.0-tesla magnetic resonance imaging M.J. Chumillas1, J. Vázquez-Costa1, J.L. de Reuck, F. Auger, N. Durieux, C. Espinos1, V. Lupo1, T. Sevilla1 V. Deramecourt, C. Cordonnier, C. Maurage, 1Valencia, 2Santander, 3Santiago de Compostela, F. Pasquier, D. Leys, R. Bordet 4Torrelavega, 5Albacete, Spain Lille, France

17.45 | O307 17.15 | O314 Peripheral neuropathy in the context of Correlates of pontine small vessel systemic vasculitis and other autoimmu- disease: a post-mortem study ne diseases: the importance of etiologic R. Geraldes, M. Esiri, J. Palace, G. Deluca characterisation Oxford, UK R. Rodrigues1, M. Branco1, M. Lopes1, L. Fontao1, H. Scigliano1, R. Taipa2, M. Melo Pires2, C. Santos1 17.30 | O316 1Feira, 2Porto, Portugal Integrity of the circle of Willis as an important predictor of early catastrophic outcome after endovascular thrombec- 18.00 | O310 tomy in middle cerebral artery occlusion Statins and cryptogenic axonal polyneu- stroke ropathy: a literature review and case- A. Karamyan, C. Ramesmayer, control study M. Killer-Oberpfalzer, J. Mutzenbach, J. Warendorf1, A. Vrancken1, N. Visser1, K. Millesi, C. Hecker, S. Pikija N.C. Notermans2 Salzburg, Austria 1Utrecht, 2Huizen, Netherlands SCIENTIFIC PROGRAMME

Monday 18 June Oral sessions 17.15 – 18.30

17.45 | O311 17.15 – 18.30 18.15 | O321 Predicting intracerebral hemorrhage Room Berlin Amyotrophic Lateral Sclerosis (ALS) expansion with non-contrast CT: spatial epidemiology in the Mount Etna the BAT Score Motor neurone diseases region, Italy: further evidences for a A. Morotti1, D. Dowlatshahi2, G. Boulouis3, pathogenetic role of volcanogenic metals F. Al-Ajlan2, A. Demchuk4, R. Aviv5, L. Yu6, Chairpersons: R. Vasta1, C. Rascunà2, S. Lo Fermo2, K. Schwab6, J. Romero6, E. Gurol6, Alberth Ludolph (Ulm, Germany) P. Volanti3, F. Patti2, M. Ferrante2, A. Viswanathan6, C. Anderson6, Y. Chang6, Vitalie Lisnic (Chisinua, Moldova) M. Zappia2, F. Boumédiène4, A. Nicoletti2 S. Greenberg6, A. Qureshi7, J. Rosand6, 1Turin, 2Catania, 3Mistretta, Italy, 4Limoges, France J. Goldstein6 17.15 | O317 1Pavia, Italy, 2Ottawa, Canada, 3Lille, France, 4Calgary, AVXS-101 Phase-1 gene replacement Canada, 5Toronto, Canada, 6Boston, USA, 7Minneapolis, therapy clinical trial in SMA type-1: USA continued event free survival and achievement of developmental milestones S. Al-Zaidy1, R. Shell1, W. Arnold1, 18.00 | O315 L. Rodino-Klapac1, T. Prior1, L. Lowes1, Atrial fibrillation in cryptogenic stroke: L. Alfano1, K. Berry1, K. Church1, J. Kissel1, the Nordic Atrial Fibrillation and Stroke S. Nagendran2, J. L‘italien2, D. Sproule2, Study (NOR-FIB) C. Wells2, A. Burghes1, K. Foust2, K. Meyer1, A. Tancin Lambert1, X.Y. Kong2, S. Likhite1, B. Kaspar2, J.R. Mendell1 B. Ratajczak-Tretel1, B. Halvorsen2, 1Columbus, 2Bannockburn, USA D. Russell2, V. Bjerkeli2, M. Skjelland2, H. Næss3, E.C. Sandset2, H. Ihle-Hansen2, 17.30 | O319 S.B. Krogseth4, H. Ihle-Hansen5, RNA-sequencing and motif analysis of G. Hagberg5, K. Arntzen6, T.C. Truelsen7, Human Motor Neurons implicates selec- K.L. Ægidius8, C. Kruuse9, G. Eldøen10, tive role of SMN/SYNCRIP complex and S. Rafiq10, H. Lerstad2, M. Kurz11, J. Sømark12, Motif 7 in Spinal Muscular Atrophy E. Schordan13, D. Atar2, A.H. Aamodt2 I. Faravelli1, M. Nizzardo1, F. Rizzo1, 1Fredrikstad, 2Oslo, 3Bergen, 4Tønsberg, 5Bærum, 6Bodø, M. Taiana1, U. Pozzoli2, R. Del Bo1, Norway, 7Copenhagen, 8Bispebjerg, 9Herlev, Denmark, N. Bresolin1, G.P. Comi1, S. Corti1 10Molde, 11Stavanger, 12Lillehammer, Norway, 13Hunin- 1Milan, 2Bosisio Parini, Italy gue, France

17.45 | O318 Integrated miRNAs analysis of ALS iPSCs and iPSCs-derived motor neurons towards the development of a molecular therapy for ALS D. Gagliardi, M. Rizzuti, M. Nizzardo, V. Melzi, G. Filosa, L. Dioni, L. Calandriello, N. Bresolin, G.P. Comi, S. Barabino, S. Corti Milan, Italy

18.00 | O320 Structural connectivity alterations in Amyotrophic Lateral Sclerosis are modu- lated by the topology of the anatomical brain connectome E.G. Spinelli1, F. Agosta1, S. Basaia1, N. Riva1, Y. Falzone1, A. Chiò2, A. Falini1, G. Comi1, M. Filippi1 1Milan, 2Turin, Italy SCIENTIFIC PROGRAMME PAGE 98 / 99

Monday 18 June 16.45 – 18.15

16.45 – 18.15 17.45 | O323 16.45 – 18.15 Room Amsterdam Reduced dynamism of functional Room Oslo connectivity is associated with cognitive Cognitive neurology/ impairment in Multiple Sclerosis patients: MS and related disorders 2 neuropsychology a dynamic functional connectivity study in a multi-center setting Chairpersons: Chairperson: M.A. Rocca1, A. D‘ambrosio1, P. Valsasina1, Ludwig Kappos (Basel, Switzerland) Walter Paulus (Göttingen, Germany) A. Gallo2, N. de Stefano3, D. Pareto4, Antonella Macerollo (London, UK) F. Barkhof5, O. Ciccarelli6, C. Enzinger7, 16.45 | O326 G. Tedeschi2, M.L. Stromillo3, M.J. Arévalo4, 16.45 | O329 Assessment of auditory localisation in H. Hulst5, N. Muhlert8, M. Koini7, M. Filippi1 Multiple Sclerosis Impact Scale and brain patients with disorders of consciousness 1Milan, 2Naples, 3Sienna, Italy, 4Barcelona, Spain, volume are independent predictors of M. Carrière, H. Cassol, S. Wannez, 5Amsterdam, Netherlands, 6London, UK, 7Graz, Austria, cognitive impairment in Secondary A. Thibaut, C. Chatelle, G. Martens, 8Manchester, UK Progressive Multiple Sclerosis S. Laureys, O. Gosseries A. Doshi1, F. de Angelis1, N. Muhlert2, Liege, Belgium J. Stutters1, A. Eshaghi1, F. Prados1, 18.00 | O327 D. Plantone1, N. John1, A. Calvi3, Persistent allocentric navigation deficits D. Macmanus1, S. Ourselin1, S. Pavitt4, 17.00 | O325 indicate hippocampal damage in G. Giovannoni1, R. Parker5, C.J. Weir5, Transcranial Direct Current Stimula- Transient Global Amnesia N. Stallard6, C.P. Hawkins7, B. Sharrack8, tion (tDCS) over lateral parietal cortex A. Zwergal1, F. Schöberl1, S. Irving1, P. Connick5, S. Chandran5, facilitates object-location and face-word C. Pradhan1, S. Bardins1, C. Trapp1, C.A. Gandini Wheeler-Kingshott1, associative memory E. Schneider2, P. Bartenstein1, M. Dieterich1, O. Ciccarelli1, F. Barkhof6, J. Chataway1 J. Bjekić, M. Čolić, M. Živanović, T. Brandt1 1London, 2Manchester, UK, 3Milan, Italy, 4Leeds, 5Edin- S. Milanović, S. Filipovic 1Munich, Germany, 2Senftenberg, Germany burgh, 6Coventry, 7Keele, 8Sheffield, UK,9 Amsterdam, Belgrade, Serbia Netherlands

17.00 | O331 17.15 | O324 Phase-2 multicenter study results of Association between neuropsychiatric Ublituximab, a novel glycoengineered symptoms, cognitive functioning and AntiCD20 monoclonal Antibody (mAb), in structural brain changes in Clinically patients with Relapsing Multiple Sclerosis Isolated Syndrome (CIS) (RMS) E. Hynčicová, M. Vyhnalek, A. Kalina, E.J. Fox1, A. Lovett-Racke2, M. Inglese3, T. Nikolai, L. Martinkovic, J. Lisý, J. Hort, R. Shubin4, C. Twyman5, J. Eubanks3, E. Meluzinová, J. Laczó K. Mok3, W. Su3 Prague, Czech Republic 1Round Rock, 2Columbus, 3New York, 4Pasadena, 5Lexington, USA

17.30 | O322 Locus coeruleus atrophy assessed with 17.15 | O328 3T MRI in typical and atypical Alzheimer‘s Efficacy of Ozanimod versus Interferon disease and correlations to neuropsycho- beta-1a by DMT treatment experience and logical data EDSS categorisation from a multicenter, P. Olivieri1, J. Lagarde1, R. Valabrègue1, randomised, double-blind, M. Bottlaender2, S. Lehericy1, M. Sarazin1 phase-3 study of relapsing Multiple Sclerosis 1Paris, 2Orsay, France H.-P. Hartung1, J.A. Cohen2, G. Comi3, A. Bar-or4, K.W. Selmaj5, D.L. Arnold6, L. Steinman7, X. Montalban8, E.K. Havrdova9, J.K. Sheffield10, V. Huang10, B.A.C. Cree11, L. Kappos12 1Düsseldorf, Germany, 2Cleveland, USA, 3Milan, Italy, 4Philadelphia, USA, 5Lodz, Poland, 6Montreal, Cana- da, 7Stanford, USA, 8Toronto, Canada, 9Prague, Czech Republic, 10San Diego, USA, 11San Francisco, USA, 12Basel, Switzerland SCIENTIFIC PROGRAMME

Monday 18 June Oral sessions 16.45 – 18.15

17.30 | O333 16.45 – 18.15 17.45 | O339 A neurometabolic profile of SPMS: the Room Copenhagen Differential diagnosis in excessive relationship between brain metabolites daytime sleepiness based on sleep- and and clinical disability Sleep disorders vigilance tests: a preliminary analysis of N. John1, B. Solanky1, F. Deangelis1, the Bern sleep database J. Stutters1, F. Prados1, D. Plantone1, C. Tur1, Chairperson: J. Mathis, A. Mathis, D. Andres, W. Schmitt, A. Doshi1, A. Monteverdi2, D. Macmanus1, Ulf Kallweit (Hagen, Germany) C. Bassetti, D. Schreier S. Ourselin1, S. Pavitt3, G. Giovannoni1, Berne, Switzerland R. Parker4, C.J. Weir4, N. Stallard5, 16.45 | O337 C.P. Hawkins6, B. Sharrack7, P. Connick4, Actigraphy ultradiam and circadian S. Chandran4, C. Wheeler-Kingshott1, rhythmicity in disorders of consciousnes 18.00 | O336 F. Barkhof1, J. Chataway1 A. Camargo, S. Blandiaux, A. Piarulli, Effects of acute exposure to high altitude 1London, UK, 2Pavia, Italy, 3Leeds, 4Edinburgh, O. Gosseries, S. Laureys on RLS symptoms and PLMS: 5Coventry, 6Keele, 7Sheffield, UK Liege, Belgium a bilateral study A. Stefani1, H. Hackner1, T. Wildt1, N. Seelose1, E. Holzknecht1, H. Gatterer1, 17.45 | O330 17.00 | O334 M. Faulhaber1, M. Burtscher1, J. Ulfberg2, Siponimod affects disability progression Sleep microstructure in Parkinson’s di- B. Högl1 in SPMS patients independent of relapse sease: Cycling Alternating Pattern (CAP) 1Innsbruck, Austria, 2Hamnplan, Örebro, Sweden activity: results from the phase III as a sensitive marker of early NREM sleep EXPAND study instability. B. Cree1, R. Fox2, G. Giovannoni3, R. Cremascoli1, L. Priano2, M. Bigoni3, P. Vermersch4, A. Bar-or5, R. Gold6, G. Albani4, L. Sellitti5, E. Giacomotti3, D. Tomic7, B. Magnusson7, N. Rouyrre7, R. Picconi3, A. Mauro5 D. Piani Meier7, G. Karlsson7, F. Dahlke7, 1Pavia, 2Turin, 3Verbania, 4Piancavallo, 5Piancavallo di L. Kappos7 Oggebbio, Italy 1San Francisco, 2Cleveland, USA, 3London, UK, 4Lille, France, 5PA, USA, 6Bochum, Germany, 7Basel, Swit- zerland 17.15 | O338 Autoreactive T-cells in narcolepsy patients target multiple antigens of 18.00 | O332 hypocretin-producing neurons Measuring disease activity in Multiple D. Latorre1, U. Kallweit2, E. Armentani1, Sclerosis: do we need spinal cord MRI? J. Mathis3, A. Lanzavecchia1, R. Khatami4, S. Ruggieri, A. Logoteta, E. Tinelli, M. Manconi5, M. Tafti6, C. Bassetti3, L. de Giglio, L. Prosperini, C. Gasperini, F. Sallusto1 C. Pozzilli 1Bellinzona, Switzerland, 2Hagen, Germany, 3Berne, Rome, Italy 4Barmelweid, 5Lugano, 6Lausanne, Switzerland

17.30 | O335 Reliability of a standardised test to document cataplexy to identify hypocretin deficiency F. Pizza, S. Vandi, E. Antelmi, G. Plazzi Bologna, Italy SCIENTIFIC PROGRAMME PAGE 100 / 101

Monday 18 June 16.45 – 18.15 Monday 18 June Oral sessions 16.45 – 18.15 Monday 18 June 16.45 – 18.15 FINAL PROGRAMME SCIENTIFIC PROGRAMME PAGE 104 / 105

Tuesday 19 June 2018 SCIENTIFIC PROGRAMME

08:00 – 10:00 sitates non-invasive monitoring of treatment molecular subgroups of brain metastases Auditorium I success, and new MRI approaches to detect from melanoma, breast and non-small cell cortical lesions, damage to myelin sheath lung cancer. Symposium 7: A new look and axonal integrity. Also, the contribution S. Pfister will describe the new molecular in neuropathogenesis of of high-Tesla field imaging to differentiation classifications of medulloblastomas and Multiple Sclerosis of MS lesions will be covered. ependymomas, and the molecular pathways that are now druggable.

Chairpersons: 08:00 – 10:00 Ralf Gold (Bochum, Germany) Auditorium VI 08:30 – 10:00 Maria Troiano (Bari, Italy) Room Berlin Symposium 8: Advances in • Role of environmental factors for MS molecular characterisation Interactive Session 8: Ralf Gold (Bochum, Germany) and personalised therapies Is it a vasculitis or not? in brain tumors • Role of B-cells in different types of MS Xavier Montalban (Barcelona, Spain) Chairperson: Chairpersons: Peter Berlit (Essen, Germany) • Challenges for modern MS therapy Riccardo Soffietti (Torino, Italy) on back-ground of pathogenesis Stefan Oberndorfer (St. Pölten, Austria) • CNS- and PNS-manifestations of Luca Massacesi (Florence, Italy) possible angiitis (case presentations) • Targeting the immune cells or the glial Peter Berlit (Essen, Germany) • The contribution of MRI for better cells in glioblastoma: the new question understanding of MS Michael Weller (Zurich, Switzerland) Declan Chard (London, UK) Educational content: • Subependymal giant cell astrocytoma The clinical presentations include polyneu- (SEGA): a model of targeting tumor ropathy, spinal cord disease, brain tumour, Scientific content: growth and seizures epilepsy and stroke. The necessary investi- Progress in understanding the pathogenesis François Ducray (Lyon, France) gations (e.g. imaging, neurophysiology, CSF, of MS includes epidemiological studies, biopsy), possible differential diagnoses and influences of lifestyle and nutrition, develop- • Specific inhibitors of molecular management will be discussed. In a step-to- ment of novel MRI techniques and approval pathways in brain metastases: step approach during each case presentation, of new MS treatments. This is critically from improved response to several single best answer questions with up needed in view of the growing number of improved survival to 5 possible answers will be presented and autoimmune diseases of the central nervous Riccardo Soffietti (Turin, Italy) answered by the audience. At the end of the system in industrialised countries. session, attendees should know about the Our proposed symposium aims at giving an • New molecular subtypes of best approach to the diagnosis of vasculitis, integrated view of all these aspects. There medulloblastomas and important differential diagnoses, and the is now solid scientific data on the influence ependymomas: different management of systemic vasculitides and of salt intake, dietary fatty acids and obe- outcome and treatment options primary CNS-angiitis. sity, smoking, and UV light-exposure and Stefan Pfister (Heidelberg, Germany) their impact on the immune system. Novel Please download the app “EAN Congress” to immune players have entered the scenario: actively participate in this Session and vote. especially the function of B lymphocytes in Scientific content: relapsing and progressive MS, and in turn The Symposium will provide an overview and the therapeutic effects associated with B-cell update about the recent advances in molecu- depletion by monoclonal antibodies shed lar biology of different types of brain tumors, new light on this immune cell population. that have led to innovative treatments either In view of the growing armamentarium of in clinical trials or daily clinical practice. MS therapies we are better prepared to offer M. Weller will present the new avenues of individualised treatment in relapsing MS. research in terms of immunotherapies and The point is whether we start early enough to molecular treatments in glioblastoma. avoid chronification of the immune response F. Ducray will discuss the possibility to target and still can recognise key factors. In addi- both seizures and tumor growth in SEGAs. tion, novel risks of highly active immuno- R. Soffietti will report the improvement of therapies must be recognized. All this neces- prognosis following targeted therapies in SCIENTIFIC PROGRAMME PAGE 106 / 107

Tuesday 19 June 08.30 – 10.00

08:30 – 10:00 08:30 – 10:00 08:30 – 10:00 Room CbW Auditorium VIII Room Lisbon

Case-based Workshop 9: Career development Special Session 11: Imaging selection of stroke Session 3: Drug development Population, migration and patients for specific and clinical trials in neurology neurological disorders treatment interventions

Chairperson: Chairperson: Chairperson: Marie Trad (Paris, France) Antonio Federico (Siena, Italy) Christian Enzinger (Graz, Austria) • Introduction to drug development: • Migration as a reality of today • Concept: how to identify “salvageable” Early stage development Antonio Federico (Siena, Italy) brain tissue Isabelle Clavier (Paris, France) Jean-Claude Baron • Changing risk factor profile and (Cambridge, UK / Paris, France) • Implementing pivotal clinical trials migration. Health indicators - in Neurology who cares? • Morphologic criteria and perfusion Marie Trad (Paris, France) Serefnur Öztürk (Konya, Turkey) Christian Enzinger (Graz, Austria) • Interpreting clinical trials results • Neurologic infections in immigrants • Vessel occlusion and collaterals Kerry Gordon (Reading, UK) Mostafa El Alaoui Faris (Rabat, Morocco) Marc Ribo (Barcelona, Spain)

Educational content: Session content: Educational content: This session will focus on the process of drug To increase awareness for effects of migra- Following the format of this interactive development in Neurology. Its objectives tion on neuroepidemiology, generalisation of workshop, individual cases presented are: education for young neurologists’ career regional special neurological diseases, nega- by experts will be used to demonstrate development, train young clinical trial inves- tive effects on health care systems, specially evidence-based approaches to select stroke tigators on factors contributing to successful effected groups (women, children, elderly) patients faced in everyday care for specific implementation and execution of clinical treatment interventions, with a particular trials in neurology, as well as understand- focus on imaging criteria. This workshop ing study designs and clinical trials results should allow attendants to appreciate the interpretation. increasing knowledge-based concerning an extension of the time-window for interventions of selected patients fulfilling stringent criteria resting on information derived from neuroimaging, while also emphasizing to remain vigilant to deliver “standard” approaches to patients with stroke within accepted windows of treatment.

Limited to 60 participants. Please register separately – additional fees will apply. SCIENTIFIC PROGRAMME

10:30 – 12:30 13:00 – 14:30 13:00 – 14:30 Auditorium I Room CbW Auditorium VIII

Case-based Workshop 8: Controversy 2: Controversies Plenary Symposium: Challenging cases of in the diagnosis of Alzheimer‘s Highlights and Breaking News infections of the disease & in the treatment of nervous system Multiple Sclerosis

Chairpersons: Joaquim Ferreira (Lisbon, Portugal) Chairperson: Chairpersons: Günther Deuschl (Kiel, Germany) Israel Steiner (Petach Tikvah, Israel) Giancarlo Comi (Milan, Italy) Paul Boon (Ghent, Belgium) Jonathan M. Schott (London, UK) • Chronic meningitis • Neuromuscular and neurophysiology Diederik van de Beek (Amsterdam, • Induction is the key strategy in Mamede de Carvalho The Netherlands) MS treatment Eva Havrdova (Prague, Czech Republic) • Stroke • Chronic encephalitis Patricia Canhao Israel Steiner (Petach Tikvah, Israel) • Induction is not the key strategy in MS treatment • Headache • Space taking focal infection Aksel Siva (Istanbul, Turkey) Isabel Pavao Martins Bettina Pfausler (Innsbruck, Austria) • This house believes that all patients • Multiple Sclerosis diagnosed with young onset dementia João Cerqueira Educational content: should be offered genetic testing – PRO Chronic meningoencephalitis is defined as an James Rowe (Cambridge, UK) • Dementia and cognition inflammation of the brain parenchyma and Alexandre Mendonça meninges of subacute onset and persisting • This house believes that all patients evidence for an inflammatory process lasting diagnosed with young onset dementia • Movement disorders more than one month. Chronic meningitis should be offered genetic testing – Miguel Coelho and encephalitis can be due to infectious and AGAINST inflammatory causes. Diagnosis of the cause Massimo Musicco (Milan, Italy) of this condition is of paramount importance Breaking News from Lancet Neurology in order to provide effective therapy that in many cases can lead to full recovery. The Educational content: • Safety and efficacy of rasagiline as an wide range of different etiologies renders the Part 1: add-on therapy to riluzole in patients approach to patients with chronic encephalitis The main objective of the topic for con- with amyotrophic lateral sclerosis: particularly difficult. Taking an in-depth troversies in MS is how to decide which a randomised, double-blind, history combined with a complete physical treatment should be started in naïve MS parallel-group, placebo-controlled trial examination is mandatory in every patient. patients. The two opposing views on in- Albert Ludolph (Ulm, Germany) This should be followed by thorough analysis duction will be discussed by each speaker of the CSF, a systemic workup and in difficult and the rationale for the initiation of more • Cognitive behavioural therapy with and challenging cases also brain biopsy. This effective treatments. optional graded exercise therapy in course aims to present the current knowledge Part 2: severely fatigued patients with myotonic on etiology, neurological course of disease, Advances in genetics mean that it is now dystrophy type 1: a single-blind diagnostic and therapeutic management steps easy to screen for multiple mutations that randomised trial of patients presenting with clinical signs and can cause dementia. There is however Baziel van Engelen (Nijmengen, symptoms of chronic meningoencephalitis. marked variability in the uptake of ge- The Netherlands) netic testing across different centres and Limited to 60 participants. Please register between different countries, and opinion After the presentation of the Congress separately – additional fees will apply. is divided as to when and to whom these Highlights, the winners of the Tournament tests should be offered. A robust debate for neurologists in training will be will ensure that attendees are aware of the announced and receive their certificates. relevant issues including: which genetic tests are available, how genetic testing Good-bye words & Presentation EAN 2019 should be undertaken, the likelihood of Oslo SCIENTIFIC PROGRAMME PAGE 108 / 109

Tuesday 19 June 13.00 – 16.30

finding a genetic cause, and the potential behavioral impairment. The often-complex 13:00 – 16:30 benefits of establishing a definite diagnosis; heterogeneity of disease presentations and Auditorium VI as well as the potential disadvantages etiologies require clinical tools to recognise including the burden of knowledge on indi- and categorise the disorder to subsequently Teaching Course 15: viduals and family members who may find focus on diagnostic and treatment strategies. The “difficult to treat” themselves at risk, the costs, and the ethics headache patient - of testing for conditions for which there are Three experts in the field will present cases Level 3 currently no disease modifying treatments. with mixed movement disorders and discuss these patients interactively with the audience by using a digital (wireless) voting app. The Chairperson: 13:00 – 14:30 first part will be focused on hypokinetic Stefan Evers (Münster, Germany) Auditorium I movement disorders; mixed movement disorders plus parkinsonism and presented • Migraine treatment beyond guidelines by Dan Healy, from Dublin, Ireland. The Stefan Evers (Münster, Germany) Interactive Session 7: EAN/ second part focusses on mixed hyperkinetic MDS-ES: Mixed movement movement disorders with a focus on dysto- • Neuromodulation in clinical practice disorders: what do we see and nia: it will include cases with dystonia plus Jan Hoffmann (Hamburg, Germany) how do we approach chorea, plus paroxysmal disorders, and plus myoclonus. The hyperkinetic cases will be • Unconventional treatments of discussed by Mark Edwards, London, UK. cluster headache Chairperson: The final part is on movement disorders Peter J. Goadsby (London, UK) Marina de Koning-Tijssen plus ataxia and cases will be presented by (Groningen, The Netherlands) Marina de Koning-Tijssen, Groningen, the • Refractory trigeminal neuralgia Netherlands. The focus of the sessions is on Giorgio Cruccu (Rome, Italy) • Hypokinetic movement disorders; mixed phenotyping and to improve clinical diag- movement disorders plus parkinsonism nosis and management in mixed movement Dan Healy (Dublin, Ireland) disorders patients Educational content: Participants will be learning how to treat • Mixed Hyperkinetic movement Please download the app “EAN Congress” to patients not responding to treatment ac- disorders: dystonia plus chorea, actively participate in this Session and vote. cording to guidelines; including the use of dystonia plus paroxysmal disorders, unconventional treatments and not approved dystonia plus myoclonus evidence-based treatment. Mark Edwards (London, UK )

• Movement disorders plus ataxia Marina de Koning-Tijssen (Groningen, The Netherlands )

Educational content: This interactive session is focused on mixed movement disorders and how we do approach them in clinical practice. For clinicians en- countering a patient with a movement disorder there are three main practical questions: what do we see (phenotype), what is the cause (etiology) and what is the optimal treatment? Assessing the phenotype is a crucial first step. Many disorders have a ‘core’ movement disorder such as parkinsonism, chorea, dystonia or ataxia. However, many patients in addition to their ‘core’ movement disorder also reveal pronounced comorbid features, such as other concurrent movement disorders, spasticity, myopathy, neuropathy, epilepsy, cognitive or SCIENTIFIC PROGRAMME

13:00 – 16:30 13:00 – 16:30 provide structural information regarding the Auditorium II Room Amsterdam underlying etiology of optic nerve and transorbital diseases. In conclusion, the proposed Teaching Course 16: Teaching Course 17: teaching course will highlight the rapidly Autoantibodies in Advanced Neurosonology - expanding indications of neurosonology that neurological disorders - Level 3 increase its applicability on a wide spectrum Level 2 of neurological disorders. This course is organised on behalf of the ESNCH. Chairperson: Chairperson: Fabienne Perren (Geneva, Switzerland) Romana Höftberger (Vienna, Austria) 13:00 – 16:30 • Transcranial Doppler versus Auditorium III • What the neurologist needs to know transoesophagal echocardiography in choosing the right assay for for the detection of patent Teaching Course 18: autoantibody testing foramen ovale Basics of sleep medicine - Romana Höftberger (Vienna, Austria) Georgios Tsivgoulis (Athens, Greece) Level 1

• Demyelination: what is new in • Application and benefits of transorbital neuromyelitis spectrum disorder sonography in neurological disorders Chairperson: (NMOSD) and the value of myelin Christos Krogias (Bochum, Germany) Rolf Fronczek (Leiden, The Netherlands) oligodendrocyte glycoprotein (MOG) antibodies • High frequency versus low frequency • Normal sleep mechanisms & Jacqueline Palace (Oxford, UK) transcranial ultrasound for sono why do we sleep? thrombolysis Rolf Fronczek (Leiden, The Netherlands) • Autoimmune encephalitis Fabienne Perren (Geneva, Switzerland) Maarten J. Titulaer • Diagnostics & methods – (Rotterdam, The Netherlands) • Brain parenchymal sonography in sleep investigations and pitfalls movement disorder: a practical Ulf Kallweit (Hagen, Germany) • What’s new in myasthenia gravis? clinical tool or theoretical research Amelia Evoli (Rome, Italy) João Sargento Freitas • Primary sleep disorders – (Coimbra, Portugal) symptoms, diagnosis & treatment Poul Jørgen Jennum Educational content: (Copenhagen, Denmark) In this TC, the speakers will prove practical Educational content: relevant knowledge on autoantibody testing Low cost, avoidance of irradiation, and high • Sleep in neurological disorders in neurological disorders. They will discuss temporal resolution are inherent advantages Guiseppe Plazzi (Bologna, Italy) the clinical phenotypes, suggested treat- of ultrasound imaging that translate into ments and discuss the newest developments multiple clinical uses in many domains of in this rapidly advancing field of neurology. neurology. Educational content: They will provide tricks to recognise these This teaching course will aim to highlight Neurological sleep disorders are common. diseases and share pitfalls to avoid misdiag- clinical uses of ultrasound examination in More than 90% of these are either primary nosis. In addition, the attendant will learn cerebrovascular, neurodegenerative, and neurological disorders or secondary to other how these diseases can be relevant to other neuro-orbital diseases. In particular, modern neurological disorders. Hence, pathology of disciplines within clinical neurology and treatment and prevention of ischemic stroke the sleeping brain - sleep medicine - is a vital basic neurosciences. rely on prompt diagnosis. Ultrasonography part of neurology training. This teaching has found a place as a noninvasive screening course will cover the basics of sleep medicine test and bedside technique that provides esti- and sleep-wake-disorders in neurology. mates of the degree of patent foramen ovale. Improvement in image quality permits novel First, we will take a closer look at the sleep uses of ultrasonography in neurodegenera- questions from the previous EAN exam. tive and transorbital system disorders, providing clinically important information that - Dr. Fronczek will cover the basic mecha- is complementary to the clinical examination nisms of physiological sleep with a focus on and neuroimaging. Transcranial parenchy- neuroanatomy and sleep staging, and give an mal sonography may assist in the differential update about our current knowledge about diagnosis of movement disorders, while why we need to sleep. transorbital sonography ultrasound may SCIENTIFIC PROGRAMME PAGE 110 / 111

Tuesday 19 June 13.00 – 16.30

- Dr. Kallweit will give an overview about - Dr. Jennum will give a broad overview of - To conclude, Dr. Plazzi will discuss sleep the methods to diagnose sleep disorders the different neurological primary sleep dis- and wake problems secondary to other (questionnaires, polysomnography, multiple orders (pathophysiology, clinical symptoms, neurological disorders (M. Parkinson, M. sleep latency test (MSLT), maintenance of diagnosis & treatment + video’s), including Alzheimer, M. Huntington, paraneoplastic wakefulness test (MWT), actigraphy, vigi- REM parasomnias (primary REM-sleep be- disorders, Multiple Sclerosis/neuromyelitis lance tests and biomarkers). Furthermore, havior disorder, RBD), NREM parasomnias optica and traumatic brain injury). diagnostic pitfalls will be discussed, such as (pavor nocturnus, sleep walking), narcolepsy the most common mistakes, false-positive type 1 + 2, idiopathic hypersomnia, the After this, the sleep questions from the EAN MSLT’s and interpretation of the MWT. The Kleine Levin Syndrome, obstructive sleep exam will be revisited, to hopefully observe a evaluation of excessive daytime sleepiness apnea syndrome (OSAS)/central apneas, marked improvement in scores. versus fatigue and decreased vigilance will be restless legs syndrome and periodic limb covered. movements disorder. SCIENTIFIC PROGRAMME

Tuesday 19 June Oral sessions 08.30 – 10.00

08.30 – 10.00 09.30 | O401 08.30 – 09.45 Room Amsterdam Cluster Headache is more than the Room Oslo extreme pain attack: a prospective diary Headache and pain study of 500 Cluster Headache attacks Miscellaneous 2 A. Snoer1, N. Lund1, A. Hagedorn1, R. Jensen2, Chairpersons: M. Barloese2 Chairpersons: Raquel Santos Gil Gouveia (Lisbon, Portugal) 1Glostrup, 2Copenhagen, Denmark Erich Schmutzhard (Innsbruck, Austria) Elena Lebedeva (Yekaterinburg, Russia) Alexandre Bisdorff (Esch-sur-Alzette, Luxembourg) 08.30 | O405 09.45 | O404 Phase-3 study (SPARTAN) of Lasmiditan The long-term efficacy and safety of 08.30 | O408 compared to placebo for acute OnabotulinumtoxinA for the prevention of Early hemodynamic profile in tilt-induced treatment of migraine chronic migraine in patients with medica- vasovagal syncope L.A. Wietecha, B. Kuca, M.G. Case, tion overuse: results of the COMPEL study M. Ghariq1, D.P. Saal2, F.I. Kerkhof1, K.J. Selzler, S.K. Aurora S. Tepper1, M.-C. Wilson2, A. Orejudos3, R.H. Reijntjes1, R.D. Thijs1, J.G. van Dijk1 Indianapolis, USA A. Manack Adams3, A. Blumenfeld4 1Leiden, 2Rotterdam, Netherlands 1Hanover, 2Covington, 3Irvine, 4Carlsbad, USA

08.45 | O406 08.45 | O407 Field testing the diagnostic criteria for Reduced pupillary modulation in patients headache attributed to Transient with relapsing-remitting Multiple Scle- Ischaemic Attacks rosis is associated with longer disease E.R. Lebedeva1, N.M. Gurary1, J. Olesen2 duration and higher disease severity 1Yekaterinburg, Russian Federation, 2Copenhagen, R. Wang1, S. Roy1, C. de Rojas Leal1, M. Liu1, Denmark K. Hösl2, D.-H. Lee1, R.A. Linker1, M.J. Hilz1 1Erlangen, 2Nuremberg, Germany

09.00 | O403 Identifying natural subgroups of mig- 09.00 | O409 raine-based on profiles of comorbidities ‘JUMP’, an innovative trans-patholo- and concomitant conditions: results of gy transitional care program for young the Chronic Migraine Epidemiology and adults with chronic neurological disease Outcomes (CaMEO) study E. Mc Govern, B. Marine, E. Manzato, R. Lipton1, K. Fanning2, D. Buse1, F. Mochel, C. Guillonnet, B. Michel, V.T. Martin3, M. Reed2, A. Manack Adams4, E. Flamand-Roze, E. Maillart P.J. Goadsby5 Paris, France 1New York, 2Chapel Hill, 3Cincinnati, 4Irvine, USA, 5London, UK 09.15 | O410 Characterisation of a Listeria 09.15 | O402 monocytogenes meningitis mouse model Increased preictal beta-ERD-response of M. Koopmans, J. Lee, M. Brouwer, primary sensorimotor cortex during brief W.K. Man, M. Valls Seron, D. van de Beek hand movements with sensory Amsterdam, Netherlands stimulation in migraine M.S. Mykland1, M.H. Bjørk2, M. Stjern1, T. Sand1 09.30 | O411 1Trondheim, 2Bergen, Norway Cerebral lesion localisation in patients with acute pure vestibular and ocular motor strokes: results from the prospective EMVERT trial A. Zwergal, K. Möhwald, E. Salazar-Lopez, H. Hadzhikolev, T. Brandt, M. Dieterich, K. Jahn Munich, Germany SCIENTIFIC PROGRAMME PAGE 112 / 113

Tuesday 19 June 08.30 – 10.00

08.30 – 10.00 09.30 | O413 09.00 | O419 Auditorium III A phase 1/2 Golodirsen trial developed The Nocebo effect in Parkinson‘s disease by the SKIP-NMD consortium to iden- M. Leal Rato1, G. Duarte2, A. Ferreira2, Muscle and neuromuscular tify potential treatments for Duchenne T. Teodoro2, T. Mestre3, J. Costa2, J. Ferreira2 junction disease Muscular Dystrophy: study design and 1Amadora, 2Lisbon, Portugal, 3Ottawa, Canada patient characteristics Chairpersons: F. Muntoni1, V. Straub2, D. Frank3, Tiziana Mongini (Turin, Italy) A.M. Seferian4, G. Dickson5, M. Guglieri2, 09.15 | O418 Theodoros Kyriakides (Nicosia, Cyprus) J. Domingos1, L. Servais4, E. Mercuri6, Non-invasive intervention for motor S.-N. Study Group3 signs of Parkinson’s disease: the effect of 08.30 | O412 1London, 2Newcastle upon Tyne, UK, 3Cambridge, USA, vibratory stimuli Molecular mechanisms of mitochondrial 4Paris, France, 5Surrey, UK, 6Rome, Italy A. Macerollo1, D. Cletheroe2, DNA disease: pathological and genetic J. Vega Hernandez3, J. Moody2, G. Saul2, studies in patients with Mendelian N. Villar2, P. Korlipara1, T. Foltynie1, disorders of mtDNA maintenance 09.45 | O416 P. Limousin1, H. Zhang1, J. Kilner1 D. Lehmann1, A.E. Vincent2, H. Rosa2, Vacuolated PAS-positive lymphocytes as 1London, 2Cambridge, 3Manchester, UK M. Rocha2, S. Zierz3, R.W. Taylor2, screening tool and a possible therapeutic D.M. Turnbull2 biomarker in late-onset Pompe disease 1Ulm, Germany, 2Newcastle upon Tyne, UK, 3Halle, (LOPD) 09.30 | O422 Germany O. Musumeci1, D. Parisi1, S. Mondello1, Evaluation of gait and posture in essen- T. Brizzi1, V. Mosca1, A. Migliorato1, tial tremor before and after unilateral 08.45 | O414 A. Ciranni1, T. Mongini2, C. Rodolico1, Gamma Knife Thalamotomy Quantifying muscle amyloid content in G. Vita1, A. Toscano1 E. Boutin, J.-P. Azulay, A. Eusebio, inclusion body myositis using [18f] florbe- 1Messina, 2Turin, Italy R. Carron, J. Regis, T. Witjas, M. Vaugoyeau tapir positron emission tomography Marseilles, France J. Lilleker1, R. Hodgson2, M.E. Roberts1, K. Herholz2, J. Howard2, R. Hinz2, H. Chinoy2 08.30 – 10.00 1Salford, UK, 2Manchester, UK Room Copenhagen 09.45 | O423 Functional brain connectome architecture Movement disorders 2 in a large cohort of Parkinson’s disease 09.00 | O415 patients Cardiorespiratory function in Duchenne Chairpersons: S. Basaia1, F. Agosta1, H. Zahedmanesh1, Muscular Dystrophy in a UK large tertiary Pille Taba (Tartu, Estonia) T. Stojkovic2, V. Marković2, I. Stanković2, care centre: longitudinal progression and Joaquim Ferreira (Lisbon Portugal) I. Petrović2, E. Stefanova2, V.S. Kostic2, the role of steroid treatment M. Filippi1 J. Domingos1, C.G. Tay2, K. Maresh1, 08.30 | O420 1Milan, Italy, 2Belgrade, Serbia D. Ridout1, P. Munot1, A. Sarkozy1, S. Robb1, Generation and characterisation of R. Quinlivan1, M. Riley1, M. Burch1, iPSC-derived oligodendrocytes of pa- M. Fenton1, C. Wallis1, E. Chan1, F. Abel1, tients with Multiple System Atrophy A. Manzur1, F. Muntoni1 E. Abati, G. Monzio Compagnoni, 1London, UK, 2Malaya, Malaysia N. Bresolin, G.P. Comi, S. Corti, A. Di Fonzo Milan, Italy

09.15 | O417 Statin-induced myopathies: beyond im- 08.45 | O421 muno-mediated necrotising myopathies Spastic-ataxia in a Portuguese cohort of M.M.N. Muelas, Y. Pamblanco, I. Azorin, hereditary ataxias P. Marti, C. Gomis, F. Mayordomo, J. Damásio, I. Alonso, C. Barbot, R. Vílchez, L. Gomez, J. Poyatos, J.J. Vilchez A.F. Brandão, A. Sardoeira, S. Pina, Valencia, Spain P. Coutinho, J. Barros, J. Sequeiros Porto, Portugal SCIENTIFIC PROGRAMME

SCIENTIFIC PROGRAMME PAGE 114 / 115

Tuesday 19 June 08.30 – 10.00 FINAL PROGRAMME INDUSTRY SPONSORED PROGRAMME PAGE 116 / 117

Industry Sponsored

Programme

INDUSTRY SPONSORED PROGRAMME PAGE 118 / 119

Acknowledgements

We wish to express our gratitude to the following companies and organisations who contributed to the success at EAN 2018.

Premium Sponsors

Major Sponsors

Global Quality